MXPA98001643A

MXPA98001643A - Derivatives of 2, 3-dioxo-1,2,3,4-tetrahidro-quinoxalinilo novedo

Info

Publication number: MXPA98001643A
Application number: MXPA/A/1998/001643A
Authority: MX
Inventors: Biollaz Michel; Moretti Robert; Ofner Silvio; Acklin Pierre; Auberson Yves; Jacob Veenstra Siem; Allgeiger Hans
Original assignee: Acklin Pierre; Allgeier Hans; Auberson Yves; Biollaz Michel; Moretti Robert; Novartis Ag; Ofner Silvio; Jacob Veenstra Siem
Priority date: 1995-08-31
Filing date: 1998-02-27
Publication date: 1998-11-12

Abstract

The 2,3-dioxo-1,2,3,4-tetrahydroquinoxalinyl derivatives of the formula I: wherein: one of the radicals R 1 and R 2 is a group R 5 and the other is a group of the formula: -CH ( R6) -alk-R7 (Ia), -alk-CH (R6) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-N + (R8) (R9) -X -R7A (Id), -alk-OX-R7 (Ie) or -alk-SX-R7 (If), R3, R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano , or nitro, R6 is amino unsubstituted or lower alkylated and / or lower alkanoylated, R7 is hydrogen, an aliphatic, cycloaliphatic or heterocycloaliphatic radical, acyl derived from carbonic acid or a half ester or half carbon dioxide, cyano from sulfuric acid or of an aliphatic or aromatic sulfonic acid or a phosphoric acid or a phosphonic acid ester, amino that is unsubstituted or aliphatic or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl, or an aromatic or heteroaromatic radical, R8 is hydrogen, an aliphatic or araliphatic radical, or acyl derived from an aliphatic or araliphatic carboxylic acid or an aliphatic or araliphatic half ester of carbonic acid, or R7 and R8, together with X and the nitrogen atom linking R8 and X, form a mono- or unsubstituted or substituted diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7 , R8 and R9, together with X and the nitrogen atom linking R8, R9 and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through the quaternary nitrogen atom, where A is the union of a protonic acid, alk is lower alkylene, and x (except that, together with R7 and R8 and the nitrogen atom linking R8 and X or together with the nitrogen atom linking R8, R9 and X, being part of one of said ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, and the pharmaceutically acceptable salts thereof, can be used in the preparation of a medically for the treatment of pathological conditions that respond to blockade of AMPA, kainate, and / or the glycine binding sites of the NM receptor

Description

DERIVATIVES OF 2.3 -DIOXO-1.2,3, 4 -THERAHIDRO-OUINOXALINILO NOVEDOSOS The invention relates to the use of 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives of the formula I: wherein one of the radicals R ^ and R2 is a group R5 and the ctro is a group of the formula: -CH (R6) -alq-R7 (Ia), -alq-CH (R6) -R7 (Ib), -alq-N Rg (-X-R7 (Ic), -alq-N + (R8) (R9) -X-R7 A "(Id), -alq-0-X-R7 (le) or -aiq-SXR - (If), R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is unsubstituted amino or lower alkylated and / or lower alkanoylated, R7 is hydrogen, an aliphatic radical , cyclic fatic or heterocycloaliphatic, cyano, acyl derived from carbonic acid or a half ester or half-amide of carbonic acid, of sulfuric acid or of an aliphatic or aromatic sulfonic acid or ce phosphoric acid or of an ester of phosphonic acid; amino which is unsubstituted or aliphatically or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl, or an aromatic or heteroaromatic radical, Rg is hydrogen, an aliphatic or araliphatic radical, or acyl deriv of an aliphatic or araliphatic carboxylic acid or of an aliphatic or araliphatic half ester of carbonic acid, or R7 and Rg, together with X and the nitrogen atom linking Rg and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl unsubstituted or substituted, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, Rg is an aliphatic or araliphatic radical, or R7, Rg and R9, together with X and the nitrogen atom linking Rg, R9 and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through a quaternary nitrogen atom, where A "is the anion of a protonic acid, alk is lower alkylene, and X (except that, together with R7 and Rg and the nitrogen atom linking Rg and X or together with the nitrogen atom linking Rg, R9 and X, is part of one of the aforementioned systems more than ring) is a divalent radical aliphatic, cycloaliphatic or araliphatic or a direct bond, with the proviso that, in the compounds of the formula I where R ^ is a group of the formula le, R2 and R3 are each they independently fluorine, chlorine, bromine, methyl, ethyl or trifluoromethyl and R4 is hydrogen, when either methylene, ethylidene or propylidene the group -N (Rg) -X-R7 is not a mono-, di-, tri- or 5-membered tetra-azaheteroaryl bonded through a nitrogen atom and is optionally benzocondensate and / or substituted by alkyl having up to 5 carbon atoms inclusive, or substituted at the? by a group of the formula -N (Ra) -Rb wherein Ra and Rb are each independently hydrogen, alkyl, cycloalkyl, phenylalkyl or lower pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino group , piperazino, N '- lower alkyl piperazino, morpholino or azepino, and their pharmaceutically acceptable salts, in the preparation of a medicament for the treatment of pathological conditions that respond to blocking of the binding sites of AMPA, kainate and / or glycine of the NMDA receptor, and also to compounds of the formula 1, with the proviso that, in the compounds of the formula 1 wherein Rj, R3 and R4 are hydrogen and R2 is a group of the formula Ib, when alq is methylene, R is not amino or R7 is not carboxy, with the additional proviso that, in the compounds of formula I wherein Rj, R3, and R4 are hydrogen and R2 is a group of the formula le, when alq is methylene, the group -N (Rg) -X-R7 is not l-imidazolyl, or when alq is ethylene, the group -N (R8) -X-R7 is not amino, dipropylamino, N- (2-phenylethyl) -N-propyl-amino and N '- (2-chlorophenyl) piperazino, and with the final condition that, in the compounds of formula I where Rj is a group of the formula it, R 2 and R are each independently fluorine, chlorine, bromine, methyl, ethyl or trifluoromethyl and R 4 is hydrogen, when al is methylene, ethylene, or propylidene, the group -N (Rg) -X-R 7 is not a a 5-membered mono-, di-, tri- or tetra-azaheteroaryl radical linked through a nitrogen atom and optionally benzocondensated and / or substituted by alkyl having up to and including 6 carbon atoms, or substituted the position ? by a group of the formula -N (Ra) -Rb wherein Ra and Rb are each independently hydrogen, alkyl, cycloalkyl, phenylalkyl or lower pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino group , piperazino, N'-lower alkyl-piperazino, morpholino or azepino, as such and their salts, to processes for their preparation and to pharmaceutical compositions comprising them. An unsubstituted or lower alkylated and / or lower alkanoyl-amino is, for example, amino, lower-amino-alkyl, lower-amino-alkanoyl, N-lower-alkyl-N-lower alkanoyl or lower-dialkyl-amino.

The aliphatic radicals are, for example, lower alkyl, amino-lower alkyl, lower alkyl-amino-lower alkyl, di-lower alkyl-amino-lower alkyl, lower alkanoyl-amino-lower alkyl, hydroxy-lower alkyl, lower alkanoyloxy lower alkyl, lower polyhaloalkyl, lower alkoxy lower alkyl, lower hydroxyalkoxy lower alkyl, lower alkoxy lower alkoxy lower alkyl or polyhalo lower alkoxy lower alkyl. The cycloaliphatic radicals are, for example, 3 to 8 membered cycloalkyl radicals, especially 3 to 7 membered, unsubstituted or substituted by free or aliphatically esterified carboxy and / or by amino unsubstituted or lower alkylated and / or lower alkanoylated, as the corresponding cycloalkyl, carboxycycloalkyl, lower alkoxycarbonylcycloalkyl, aminocycloalkyl or mono- or di-lower alkyl-aminocycloalkyl, namely cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo-octyl, 2-aminocyclohexyl, 4-carboxycyclohexyl, 3-carboxycyclohexyl or 2-carboxycyclopentyl-lo. The heterocycloaliphatic radicals are, for example, mono- or di-azacycloalkyl, azoxacycloalkyl or azathiacycloalkyl radicals having between 3 and 8 inclusive, especially between 3 and 6, ring members unsubstituted or substituted by oxo, hydroxy and / or carboxy free or aliphatically esterified, such as the corresponding pyrrolidin-1-yl (pyrrolidino), pyrrolidin-2-yl, piperidin-1-yl (piperidino), piperidin-2-yl, morpholino, thiomorpholino or unsubstituted or lower alkanoylated or alkylated piperazino lower, for example pyrrolidino, oxopyrrolidinyl, piperidino, carboxypiperidino, lower alkoxycarbonylpiperidino, morpholino or thiomorpholino, especially morpholino, 5-oxopyrrolidin-2-yl or 2-carboxypyrrolidino. Acyl derived from carbonic acid or a half ester or half carbon dioxide is derived, for example, from an aliphatic or araliphatic half ester or from an unsubstituted or aliphatic, araliphatic or aromatically substituted amide of carbonic acid and is, for example, free carboxy or aliphatic or araliphatically esterified, such as lower alkoxycarbonyl or lower phenylalkoxycarbonyl substituted or unsubstituted by lower alkyl, lower alkoxy, hydroxy, halogen and / or by trifluoromethyl, or unsubstituted or aliphatic, araliphatic or aromatically substituted carbamoyl, such as carbamoyl, lower alkyl-carbamoyl, lower dialkyl-carbamoyl, lower alkoxy-carbonylalkyl-lower carbamoyl, carboxyalkyl-lower carbamoyl, carbamoylalkyl-carbamoyl, N-carbamoylalkyl-N-lower alkyl-carbamoyl, or phenylcarbamoyl or phenylalkyl-carbamoyl unsubstituted or substituted by lower alkyl, lower alkoxy, p lower olihaloalko-xi, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy and / or trifluoromethyl.

The acyl derived from sulfuric acid or an aliphatic or aromatic sulfonic acid is, for example, sulfo, lower alkane-sulfonyl, or unsubstituted benzylsulfonyl or substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, carboxy and / or lower alkoxycarbonyl , or unsubstituted naphthalenesulfonyl or substituted by lower dialkyl amino. Acyl derived from phosphoric acid or phosphoric acid ester is, for example, phosphono or lower trialkyl phosphono. The amino unsubstituted or aliphatically or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl is, for example, amino, lower alkyl-amino, lower dialkyl-amino, lower alkanoyl-amino, or phenylalkyl, benzoyl- or naphthoyl- amino unsubstituted or substituted by lower alkyl, lower alkoxy, halogen and / or trifluoromethyl, or ureido or amidino. The unsubstituted or substituted aromatic radicals are, for example, phenyl or unsubstituted naphthyl or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, sulfamoyl, lower alkoxycarbonyl, lower alkanoyl, halogen and / or trifluoromethyl. The unsubstituted or substituted heteroaromatic radicals are optionally and partially hydrogenated 5 or 6-membered monocyclic or heteroaryl heteroaryl, composed of 5 or 6 membered rings, such as the corresponding furyl, lower alkyl-furyl, for example 4-methylfur-2- ilo, thienyl, imidazolyl, for example imidazol-4-yl, oxazolyl, carboxyalkyl lower- (oxo) oxazolyl, for example 2,5-dihydro-3-oxo-l, 2-oxazolyl, thiazolyl, dihydrothiazolyl, for example 4, 5-dihydrothiazolyl, lower carboxyalkyl-thiazolyl, for example 4-carboxymethylthiazolyl, lower alkoxycarbonylalkyl-lower alkylthiazolyl, for example 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylmethylthiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, for example indole-3-yl, quinolinyl , for example quinolin-4-yl, benzazepinyl or lower carboxyalkyl-2, 3,4,5-tetrahydro-lH-1-benzazepine, for example l-carboxymethyl-2, 3,4,5-tetrahydro-lH-1- Benzazepine Araliphatic radicals are, for example, unsubstituted lower phenylalkyl or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. Acyl derived from an aliphatic or araliphatic carboxylic acid is, for example, lower alkanoyl, lower alkenoyl or lower phenylalkanoyl unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl.

The acyl derived from an aliphatic or araliphatic half ester of carbonic acid is, for example, lower alkoxycarbonyl, or phenylalkoxy lower carbonyl, unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylenedioxy, hydroxy, lower alkoxycarbonyl , carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. Unsubstituted or substituted radicals of mono- or di-azacycloalkyl, azoxacycloalkyl, azathiacycloalkyl or optionally oxidized tricycloalkyl radicals formed by R7 and R8 together with X and the nitrogen atom linking Rg and X and linked through a nitrogen atom are , for example monocyclic or di-azacycloalkyl, azoxacycloalkyl, azathiacycloalkyl radicals of 3 to 7 members, especially 5 to 7 members, or optionally oxidized thiacyl-chloralkyl radicals composed of 5 and / or 6-membered rings, preferably pyrrolidino, imidazolidino, tetrahydrothiazolyl, piperidino, morpholino, thiomorpholino, piperazino, homopiperidino or 1-azabicyclonononyl unsubstituted or substituted by aliphatic, araliphatic or aromatic radicals, such as lower alkyl, hydroxyalkyl, lower phenylalkyl or unsubstituted or substituted phenyl radicals, free carboxy, esterified or amidated, such as carboxy, lower alkoxycarbonyl, f enylcarbamoyl unsubstituted or substituted, amino unsubstituted or lower alkylated and / or lower alkanoylated, such as lower dialkyl-amino or lower alkanoyl-amino, 2-oxoimidazolidino, free phosphono or esterified, such as phosphono or lower trialkyl-phosphono, tetrazolyl, acyl derivative of an aliphatic or aromatic carboxylic acid, such as unsubstituted or substituted lower alkanoyl or benzoyl, for example fluorobenzoyl, hydroxy, oxo and / or lower alkoxy, such as pyrrolidino, lower alkyl-pyrrolidino, carboxypyrrolidino, for example 2-carboxy-pyrrolidino, lower alkoxycarbonylpyrrolidino, hydroxypyrrolidino, for example 3-hydroxypyrrolidino, lower hydroxyalkyl-pyrrolidino, for example 2-hydroxymethylpyrrolidino, mono- or di-oxopyrrolidino, for example 2-oxopyrrolidino or 2,5-dioxopi-rrolidino, alkyl lower (oxo) pyrrolidino, for example 2-methyl-5-oxo-pyrrolidino, lower hydroxyalkyl (oxo) pyrrolidino, for example 2-hydroxymethyl-5-oxo-pyrrolidi no, carboxy (oxo) pyrrolidiene, for example 5-carboxy-2-oxo-pyrrolidino, 2-carboxy-4-hydroxy-pyrrolidino, or 2-carboxy-3-hydroxy-pyrrolidino, lower alkoxy-carbonyl (oxo) pyrrolidino, 2-oxoimidazolidino, for example 2-oxo-3-phenylimidazolidino, tetrahydrothiazolyl, for example tetrahydrothiazol-1-yl, piperidino, lower alkyl-piperidino, for example 4-methylpiperidino, 3-methylpiperidino, or 4-butylpiperidi-no, lower dialkyl piperidino, for example 2, 6-dimethylpiperi-dino, carboxypiperidino, for example 4-carboxypiperidino, 2-carboxypiperidino or 3-carboxypiperidino, lower alkoxycarbo-nylpiperidino, for example, 4-ethoxycarbonylpiperidino or 2-ethoxycarbonylpiperidino, phenylcarbamoylpiperidino , for example 3-phenylcarbamoylpiperidino, 2-phenylcarbamoylpiperidino, or 4-phenylcarbamoylpiperidino, oxopiperidino, for example 4-oxopiperi-dino, dioxopiperidino, for example 3, 6-oxo (phenylalkyl) piperidino, for example 2-benzyl-4-oxo -piperidino, dioxopi-peridino, oxo (phenyl) piperidino, for example 2-oxo-3-phenylpiperi-dino or 2-oxo-5-phenyl-piperidino, hydroxypiperidino, for example 4-hydroxypiperidino or 3-hydroxypiperidino, hydroxy (phenylalkyl) piperidino, for example 2-benzyl-4 -hydroxy-piperidino, carboxy (hydroxy) piperidino, for example 2-carboxy-4-hydroxy-piperidino, lower dialkyl-aminopiperidino, for example 4-dimethylaminopiperidino, lower alkanoyl-aminopiperidino, for example 4-acetylaminopiperidino, lower alkanoyl-amino ( lower phenylalkyl) piperidino, for example 4-acetylamino-2-benzyl-piperidino, lower alkanoyl-amino (phenyl) piperidino, for example 4-acetylamino-2-phenyl-piperidino, phenylpiperidino, for example 4-phenylpiperidino, lower alkoxy-piperidino, for example 4-methoxypiperidino, lower alkoxy (lower alkyl) piperidino, for example 4-methoxy-4-methyl-piperidino, dialkoxy inferior-piperidino, for example 4.4 dimethoxypiperidino, lower dialkoxy (lower alkyl) piperidino, for example 2-benzyl-4,4-dimethoxypiperidino, lower alkylenedioxy-piperidino, for example 4-ethylenedioxypiperidino, hydroxyalkyl-lower piperidino, for example 2- (2-hydroxyethyl) piperidino, 2-hydroxymethylpiperidino, 4- (1-hydroxyethyl) piperidino, 4-hydroxymethylpiperidino, unsubstituted or halogenated benzoylpiperidino, for example 4- (4- i 12 fluorobenzoyl) iperidino, lower alkanoyl-piperidino, for example 4-acetylpiperidino, or oxoimidazolidinopiperidino , for example, 4- (2-oxoimidazolidino) piperidino, homopiperidino, oxohomopiperidino, for example 2-oxohomopiperidino, azabicyclono-nile, for example 1-azabicyclononyl, piperazino, lower alkyl-piperazino, for example 4-methylpiperazino, oxopiperazine, for example 3-oxopiperazino, dioxopiperazino, for example 3,5-dioxopiperazino, unsubstituted phenylpiperazino or lower alkoxylation, for example 4- (4-methoxyphenyl) piperazino, morpholino, lower dialkyl-morpholino, example 3, 5-dimethylmorpholino, or thiomorpholino. Unsubstituted or optionally partially hydrogenated substituted aryl radicals, formed by R7 and R together with X and the nitrogen atom linking Rg and X are, for example, phenyl, cyclohexadienyl, naphthyl or tetrahydronaphthyl radicals unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, carboxy, lower alkoxycarbonyl and / or trifluoromethyl, such as phenyl, 4-hydroxyphenyl, 3-methoxyphenyl, 3-carboxyphenyl, 4-fluorophenylene, 2-fluorophenyl, 3-fluorophenyl, 3, 5 bistrifluoromethylphenile, cyclohexa-1,3-dien-5-yl or 1, 2, 3, 4-tetrahydronaphthyl. Unsubstituted or substituted, optionally partially hydrogenated heteroaryl radicals formed by R7 and R8 together with the nitrogen atom linking Rg and X are, for example, optionally partially hydrogenated pyrrolyl unsubstituted or substituted by carboxy, lower alkoxycarbonyl and / or by lower alkanoyl, such as pyrrol-1-yl, 1,5-dihydropyrrol-1-yl, carboxypyrrolyl, for example 2-carboxypyrrol-1-yl or 3-carboxypyrrol-1-yl, lower alkoxy-carbonyl-pyrrolyl , for example 3-methoxycarbonylpyrrol-1-yl, 3-ethoxycarbonylpyrrol-1-yl or 3-butyloxycarbonylpyrrol-1-yl, lower alkanoyl-pyrrolyl, for example 3-acetylpyrrol-1-yl, -furyl, for example fur-2 ilo; thienyl, for example thien-2-yl or thien-3-yl; imidazolyl unsubstituted or substituted by lower alkyl, lower hydroxyalkyl, carboxy, lower carboxyalkyl and / or lower alkoxycarbonylamino-lower alkyl, such as imidazol-1-yl, lower alkyl imidazolyl, for example 4-methylimidazol-1-yl, -methylimidazol-1-yl or 2-ethylimidazol-1-yl, lower dialkyl-imidazolyl, for example 2-ethyl-4-methyl-imidazol-1-yl, hydroxyalkyl-lower imidazolyl, for example 4-hydroxymethylimidazole-1 -yl, lower carboxyalkyl-imidazolyl, for example carboxymethylimidazol-1-yl, carboxy (lower alkoxy-carbonylamino-lower alkyl) imidazolyl, for example 4- (tert-3-butyloxy-carbonylaminoprop-1-yl) -2- (2- carboxyethyl) -imidazol-1-yl; optionally partially hydrogenated thiazolyl which is unsubstituted or substituted by lower carboxyalkyl and / or lower alkoxycarbonylalkyl, such as thiazol-2-yl, 3,4-dihydrothiazol-2-yl, lower carboxyalkyl-thiazolyl, for example 4-carboxymethylthiazole -2-yl, lower alkoxycarbonylalkyl-thiozolyl, for example 4-ethoxycarbonylethylthiazol-2-yl; pyrazolyl unsubstituted or substituted by lower alkyl, such as pyrazol-1-yl, or dialkyl-lower pyrazolyl, for example 3, 5-dimethylpyrazol-1-yl; triazolyl, such as 1,2,4-triazol-1-yl ?; pyridinyl unsubstituted or substituted by oxo, optionally partially hydrogenated, such as pyridinyl, for example pyridin-2-yl, 1, 2, 5, 5-tetrahydropyridin-1-yl, oxodihi-dropyridinyl, for example 2-oxo-l, 2 -dihydropyridin-1-yl, oxotetrahydropyridinyl, for example 2-oxo-1,2,4,4-tetrahydropyridin-1-yl; pyrazinyl, for example pyrazin-2-yl; indolyl which is unsubstituted or substituted by carboxy, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower cyanoalkyl and / or by nitro, such as indole-2-yl, carboxy indolyl, for example 2-carboxy -indol-1-yl or 3-carboxy-indole-1-yl, lower carboxyalkyl-indolyl, for example 3-carboxymethylindol-1-yl, lower alkoxycarbonylindole, for example 3-methoxycarbonylindol-1-yl or butyloxycarbo-nylindol-1-yl, lower alkoxycarbonylalkyl-lower alkyl indolyl, for example 3-ethoxycarbonylmethylindol-1-yl, lower cyanoalkyl-indolyl, for example 3-cyanomethylindol-1-yl, nitroin-dolyl, for example 5- nitroindol-l-yl; benzofuranyl, for example benzofuran-2-yl, • benzimidazolyl unsubstituted or substituted by nitro, such as benzimidazolyl, 5-nitrobenzimidazol-1-yl, + 66-nitrobenzimidazol-1-yl; tetrahydroquinolinyl such as 1, 2, 3,4, -tetrahydroquinolin-1-yl; tetrahydroisoquinolinyl unsubstituted or substituted by oxo, such as 1, 2, 3, 4-tetrahydroi-soquinolin-1-yl or 2-oxo-l, 2, 3, 4-tetrahydroisoquinolin-1-yl, or tetrahydrobenzazepinyl, such as 2, 3, 4, 5-tetrahydro-lH-l-benzazepin-1-yl. The divalent aliphatic radicals X are, for example, lower alkylene, lower alkenylene, and lower alkylidene radicals that are unsubstituted or substituted by oxo, hydroxy, and / or by amino, such as lower alkylene, lower alkylidene, lower alkenylene, oxo- lower alkylene, including -carbonyl, lower oxo-alkylidene, lower dioxo-alkylene, lower-oxo-alkenylene, lower-hydroxyalkylidene, oxo (hydroxy) -lower-lower alkylene, lower-aminoalkylene, lower-aminoalkylidene, lower-carboxyalkylene, lower-carboxyalkylidene, lower-carbamoylalkylidene, alkoxy lower-carbonylalkylidene-non-lower, lower alkoxy-lower carbonylalkylene, or? -aza-a-oxo-lower alkylene, or? -aza-a-oxo-lower alkenylene. The divalent cycloaliphatic radicals X are, for example, 3- to 7-membered cycloalkylidene radicals, especially 3 to 5 membered, such as cyclopropylidene, cyclobutylidene or cyclopentylidene. The divalent araliphatic radicals X are, for example, phenylalkylidene lower or lower phenylalkylene unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. As used above and to be used in the following, the "lower" radicals and compounds will be considered as those which, for example, contain up to and including 7, especially up to and including 4, carbon atoms. Lower aminoalkyl is, for example, aminoalkyl of 1 to 4 carbon atoms, such as aminomethyl, 2-aminoethyl, 3-aminopropyl or 4-aminobutyl. Lower aminoalkylene is, for example, aminoalkylene of 1 to 4 carbon atoms, such as aminomethylene, 2-aminoethylene, 3-aminopropylene or 4-aminobutylene. Lower aminoalkylidene is, for example, aminoalkylidene of 1 to 4 carbon atoms, such as aminomethylene, 2-aminoethylidene, 3-aminopropylidene or 4-an-butylbutylidene. Carbamoyl-carbamoylalkyl lower is, for example, carbamoylalkyl of 1 to 4 carbon atoms-carbamoyl, such as carbamoylmethylcarbamoyl, 2-carbamoylethylcarbamoyl, 3-carbamoyl-propylcarbamoyl, or 4-carbamoylbutylcarbamoyl. Carbamoylalkylidene lower is, for example, carbamoylalkylidene of 1 to 7 carbon atoms, such as carbamoyl e-tylene, 2-carbamoylethylidene, 3-carbamoylpropylidene, 4-carbamoylbutylidene, 5-carbamoylpentylidene, or 6-carbamoylhexylidene. N-carbamoylalkyl-N-lower alkylcarbamoyl is, for example, N-carbamoylalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamoyl, such as especially N-carboxymethyl-N- methyl-carbamoyl. Lower carboxyalkyl is, for example, carboxyalkyl of 1 to 4 carbon atoms, such as carboxymethyl, 1- or 2-carboxyethyl, 3-carboxypropyl or 4-carboxybutyl. Carboxyalkyl lower carbamoyl is, for example, carboxyalkyl of 1 to 4 carbon atoms-carbamoyl, such as carboxymethylcarbamoyl, 2-carboxyethylcarbamoyl, 3-carboxypropaccarbamoyl or 4-carboxybutylcarbamoyl. Lower carboxyalkylene is, for example, carboxymethylene, 1- or 2-carboxyethylene, 1,3- (1-carboxy) propylene, 1,3- (3-carboxy) propylene or 1,4- (4-carboxy) butylene. Lower carboxyalkylidene is, for example, carboxyalkylidene of 1 to 7 carbon atoms, such as carboxymethylene, 2-carboxyethylidene, 3-carboxypropylidene, 4-carboxybutylidene, 5-carboxypentilidene or 6-carboxyhexylidene. Lower cyanoalkyl is, for example, cyanoalkyl of 1 to 4 carbon atoms, such as cyanomethyl, 1- or 2-cyanoethyl, 3-cyanopropyl or 4-cyanobutyl. Lower dialkylaminocycloalkyl is, for example, dialkyl of 1 to 4 carbon atoms-aminocycloalkyl, such as dimethylaminocycloalkyl, diethylaminocycloalkyl, N-ethyl-N-methylaminocycloalkyl, N-propyl-N-methyl-aminocycloalkyl, N-isopropyl-N- methyl-aminocycloalkyl or N-butyl-N-methyl-aminoci-chloralkyl, wherein cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

Lower-amino dialkyl is, for example, dialkyl of 1 to 4 carbon-amino atoms, such as dimethylamino, diethylamino, N-ethyl-N-methyl-amino, N-propyl-N-methyl-amino, N-isopropyl- N-methyl-amino or N-butyl-N-methyl-amino. Lower dialkyl-amino-lower alkyl is, for example, dialkyl of 1 to 4 carbon atoms-aminoalkyl of 1 to 4 carbon atoms, such as dimethylaminomethyl, diethylaminomethyl, N-ethyl-N-methyl-aminomethyl, -propyl -N-methyl-aminomethyl, N-isopropyl-N-methyl-aminomethyl or N-butyl-N-methyl-aminome-tyl. Lower dialkyl-carbamoyl is, for example, dialkyl of 1 to 4 carbon atoms-carbamoyl, such as dimethylcarba-moyl, diethylaminomethyl, N-ethyl-N-methyl-carbamoyl, N-propyl-N-methyl-carbamoyl, N- isopropyl-N-methyl-carbamoyl or N-butyl-N-methyl-carbamoyl. Lower dioxoalkylene is, for example, dioxoalkylene of 2 to 4 carbon atoms, such as 1,2-dioxoethylene (oxalo), 1, 3- (1, 2-dioxo) propylene, 1, 3- (2,3-dioxo) ) propylene or 1,4- (1,2-dioxo) propylene. Halogen is, for example, halogen having an atomic number of up to 35 inclusive, such as chlorine, fluorine or bromine. Lower hydroxyalkoxy-lower alkyl is, for example, hydroxyalkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as 2-hydroxyethoxymethyl, 2-hydroxymethyl-ethyl, 2- (2-hydroxyethoxy) ethyl or -hydroxy ethoxypropyl.

Lower hydroxyalkoxy is, for example, hydroxyalkyl of 1 to 4 carbon atoms, such as hydroxymethyl, 2-hydroxyethyl, 3-hydroxypropyl or 4-hydroxybutyl. Lower hydroxyalkylidene is, for example, hydroxyalkylidene of 1 to 4 carbon atoms, such as hydroxymethylene, 2-hydroxypropylidene, 2-hydroxyethylidene, 3-hydroxypropylidene or 4-hydroxybutylidene. N-lower alkyl-N-lower alkanoyl-amino is, for example, N-alkanoyl of 1 to 7 carbon atoms-N-alkyl of 1 to 4 carbon-amino atoms, such as N-acetyl-N-methyl- amino, N-propionyl-N-methyl-amino, N-butyryl-N-methyl-amino, N-isobutyryl-N-methyl-amino or N-pivaloyl-N-methyl-amino. Lower dioxyalkylidene is, for example, dioxyalkylene with 1 to 4 carbon atoms, such as dioxymethylene, dioxyethylidene or dioxyisopropylidene, lower dioxyalkylene, for example dioxyalkylene of 1 to 4 carbon atoms, as sorb. dioxyethylene or 1,3-dioxypropylene. Lower alkanoyl is, for example, alkanoyl of 1 to 7 carbon atoms, such as acetyl, propionyl, butyryl, isobutyryl or pivaloyl. Lower alkanoyl amino is, for example, alkanoyl of 1 to 7 carbon-amino atoms, such as acetylamino, propionylamino, butyrylamino, isobutyrylamino or pivaloylamino. Lower alkanoyl-lower aminoalkyl is, for example, alkanoyl of 1 to 7 carbon atoms-aminoalkyl of 1 to 4 carbon atoms, such as acetylaminomethyl, propionylaminomethyl, butyrylaminomethyl, or isobutyrylaminomethyl, and also pivaloylaminomethyl. Lower alkanoyloxy-lower alkyl is, for example, alkanoyloxy of 1 to 7 carbon atoms-alkyl of 1 to 4 carbon atoms, such as acetoxymethyl, propionyloxymethyl, butyryloxymethyl, or isobutyryloxymethyl, and also pivaloyloxymethyl. Lower alkenoyl is, for example, alkenoyl of 3 to 7 carbon atoms, such as acryloyl, methacryloyl, crotonyl, or vinylacetyl. Lower alkenylene is, for example, alkenylene of 2 to 7 carbon atoms, such as vinylene, 1,3-prop-2-enylene, 1,2-prop-2-enylene, 1,4-but-2-enylene, 1,2-but-3-enylene, 1,2-pent-4-enylene, 1,2-hex-4-enylene or 1,2-hex-5-enylene. Lower alkoxy is, for example, alkoxy of 1 to 7 carbon atoms, preferably alkoxy of 1 to 4 carbon atoms, such as methoxy, ethoxy, propyloxy, isopropyloxy, or butyloxy, but may also be isopropyloxy, secondary butyloxy, butyloxy tertiary, or a pentyloxy, hexyloxy, or heptyloxy group. Lower alkoxycarbonyl is, for example, alkoxy of 1 to 7 carbon atoms-carbonyl, preferably alkoxy of 1 to 4 carbon atoms-carbonyl, such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, isopropyloxycarbonyl, or butyloxycarbonyl, but may also be isobutyloxycarbonyl, secondary butyloxycarbonyl, tertiary butyloxycarbonyl, or a pentyloxycarbonyl, hexyloxycarbonyl, or heptyloxycarbonyl group. Lower alkoxycarbonylamino is, for example, alkoxy of 1 to 7 carbon atoms-carbonylamino, preferably alkoxy of 1 to 4 carbon atoms-carbonylamino, such as methoxycarbonylamino, ethoxycarbonylamino, propyloxycarbonylamino, isopropyloxy-carbonylamino, or butyloxycarbonylamino. Lower alkoxycarbonylaminoalkyl is, for example, alkoxy of 1 to 7 carbon atoms-carbonylaminoalkyl of 1 to 4 carbon atoms, preferably alkoxy of 1 to 4 carbon atoms-carbonylaminoalkyl of 1 to 4 carbon atoms, such as methoxycarbonylaminomethyl, ethoxycarbonylaminomethyl, propyloxycarbonylaminomethyl, isopropyloxycarbonylaminomethyl or butyloxycarbonylaminomethyl. Lower alkoxycarbonylalkyl lower carbamoyl is, for example, alkoxy of 1 to 7 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms-carbamoyl, preferably alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms carbon-carbamoyl, such as methoxycarbonylmethylcarbamoyl, ethoxycarbo-nylmethylcarbamoyl, propyloxycarbonylmethylcarbamoyl, isopropyl-xicarbonylmethylcarbamoyl, or butyloxycarbonylmethylcarbamoyl. Lower alkoxycarbonylcycloalkyl is, for example, alkoxy of 1 to 7 carbon atoms-carbonylcycloalkyl, preferably alkoxy of 1 to 4 carbon atoms-carbonylcycloalkyl, such as methoxycarbonylcycloalkyl, ethoxycarbonylcarbamoyl-cycloalkyl, propyloxycarbonylcycloalkyl, isopropyloxycarbo-nylcycloalkyl, or butyloxycarbonylcycloalkyl, wherein cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Lower alkoxycarbonylalkyl-lower alkyl is, for example, alkoxy of 1 to 7 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms, preferably alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms, such as methoxycarbonylmethyl, methoxycarbonylethyl, ethoxycarbonylmethyl, ethoxycarbonylethyl, methoxycarbonylpropyl, ethoxycarbonylpropyl, propyloxycarbonylmethyl, propyloxycarbonylethyl, isopropyloxycarbonylmethyl, isopropyloxycarbonylethyl, obutyloxycarbonylmethyl. Lower alkoxycarbonylalkylene lower is, for example, alkoxy of 1 to 7 carbon atoms-carbonyl alkylene of 2 to 4 carbon atoms, preferably C 1 -C 4 alkoxycarbonylalkylene of 2 to 4 carbon atoms, such as 1-methoxycarbonylethylene, 1-ethoxycarbonylethylene, 1,3- (methoxycarbonyl) propylene, 1, 3- (ethoxycarbonyl) propylene, 1,3- (propyloxycarbonyl) propylene, 1,3- (butyloxycarbonyl) propylene, 1,3- (secondary butyl-oxycarbonyl) propylene, or 1,3- (tertiary butyloxycarbonyl) propylene. Lower alkoxy-lower carbonylalkylidene is, for example, alkoxy of 1 to 4 carbon atoms-carbonylalkylidene of 1 to 7 carbon atoms, such as methoxycarbonylmethylene, ethoxycarbonylmethylene, 2-methoxycarbonylethylidene, 2-ethoxycarbonyl ethylidene, 3-methoxycarbonylpropylidene, 3- ethoxycarbonylpropylidene, 4-methoxycarbonylbutylidene, 4-ethoxycarbonylbutylidene, 5-methoxycarbonylpentylidene, 5-ethoxycarbonylpentylidene, 6-methoxycarbonylhexylidene or 6-ethoxycarbonylhexylidene. Lower alkoxy-lower alkoxy-lower alkyl is, for example, alkoxy of 1 to 4 carbon atoms-to the coxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as 2-methoxyethoxymethyl, 2- ethoxyethoxymethyl, 2- (2-methoxyethoxy) ethyl or 2- (2-ethoxyethoxy) ethyl. Lower alkoxy-lower alkyl is, for example, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as 2-methoxyethyl, ethoxymethyl, 2-methoxyethyl, 2-ethoxyethyl, 3-methoxypropyl, or -methoxybutyl. Lower alkyl aminocycloalkyl is, for example, alkyl of 1 to 4 carbon atoms-aminocycloalkyl, such as methylaminocycloalkyl, ethylamino cycloalkyl, propylamino-chloroalkyl, isopropylamino cycloalkyl, obutylamino cycloalkyl, wherein cycloalkyl is, for example, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. . Lower alkyl is, for example, alkyl of 1 to 7 carbon atoms, preferably alkyl of 1 to 4 carbon atoms, such as especially methyl or secondly ethyl, propyl, isopropyl, or butyl, but can also be isobutyl, secondary butyl, tertiary butyl, or an alkyl group of 5 to 7 carbon atoms, such as a pentyl, hexyl, or heptyl group. Lower-amino alkyl is, for example, alkyl of 1 to 4 carbon-amino atoms, such as methylamino, ethylamino, propylamino, isopropylamino, or butylamino. Lower alkyl-lower aminoalkyl is, for example, alkyl of 1 to 4 carbon atoms-aminoalkyl of 1 to 4 carbon atoms, such as methylaminomethyl, ethylaminomethyl, 2-methylaminoethyl, 2-ethylaminoethyl, propylaminomethyl, isopropyl-minomethyl, or butylaminomethyl . Lower alkylaminocarbamoyl is, for example, alkyl of 1 to 4 carbon atoms-aminocarbamoyl, such as methylaminocarbamoyl, ethylaminocarbamoyl, propylaminocarbamoyl, isopropylaminocarbamoyl, or butylaminocarbamoyl. Lower alkylene may be straight or branched chain, and may be attached at any position, and is, for example, straight or branched chain 1 to 4 carbon alkylene, such as especially methylene, and also 1,2-ethylene , 1,3- or 1, 2-propylene, or 1,4-, 1,3- or 2,3-butylene. Lower alkylidene may be straight or branched chain, and may be geminally linked in any position, and is, for example, straight or branched chain 1 to 4 carbon alkylene, such as especially methylene, 1, 1-ethylidene, 1,1- or 2, 2-propylidene or 1,1-butylidene. N-lower alkyl-N-lower alkanoyl-amino is, for example, N-alkanoyl of 1 to 7 carbon atoms-N-alkyl of 1 to 4 carbon-amino atoms, such as N-acetyl-N-methyl-amino, N-propionyl-N-methyl-amino, N-butyryl-N-methyl-amino, N-isobutyryl-N-methyl-amino, or N-pivaloyl-N-methyl-amino. Lower alkane sulfonyl is, for example, alkane of 1 to 4 carbon atoms-sulfonyl, such as methanesulfonyl, ethanesulfonyl, or propansulfonyl. Oxo (hydroxy) -lower alkylene is, for example, oxo (hydroxy) -alkylene of 2 to 4 carbon atoms, such as 1-oxo-2-hydroxyethylene, 1, 3- (l-oxo-2-hydroxy) propylene , 1, 3- (1-oxo-3-hydroxy) propylene, 1, 3- (2-oxo-3-hydroxy) propylene, or 1,4- (1-oxo-2-hydroxy) butylene. Lower oxo-alkylene, including carbonyl, are linked with the group -N (Rg) - or the oxy or thio group, preferably by means of the carbon atom bearing the oxo group, and is, for example, the corresponding oxo-alkylene from 1 to 4 carbon atoms, such as carbonyl or 1, 2- (1-oxo) ethylene, and also 1,3- (1-oxo) propylene or 1,4- (1-oxo) utylene. Lower phenylalkoxycarbonyl is, for example, phenylalkoxy of 1 to 4 carbon atoms-carbonyl, such as benzyloxycarbonyl or 1-phenylethoxycarbonyl, which is unsubstituted 0 substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, hydroxy, halogen, and / or trifluoromethyl. Lower phenylalkyl is, for example, phenylalkyl 1 to 4 carbon atoms, such as benzyl, 1- or 2-phenylethyl, 3-phenylpropyl, or 4-phenylbutyl, which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylenedioxy, hydroxy, lower alkoxy- carbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. Lower-amino-phenylalkyl is, for example, phenylalkyl of 1 to 4 carbon atoms-amino, such as benzylamino, 1-or 2-phenylethylamino, 3-phenylpropylamino or 4-phenylbutylamino, which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. Lower phenylalkylene is, for example, lower phenylalkylene of 2 to 4 carbon atoms, such as phenylethylene, 1- or 2-phenylpropylene, or 1- or 2-phenylbutylene, which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy , lower alkylenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl. Lower phenylalkylidene is, for example, phenylalkylidene of 1 to 7 carbon atoms, such as benzylidene, 2-phenylethylidene, 3-phenylpropylidene, 4-phenylbutylidene, 5-phenyl-pentylidene, or 6-phenylhexylidene. Lower polyhaloalkoxy-lower alkyl is, for example, trifluoromethoxyalkyl of 1 to 4 carbon atoms, such as trifluoromethoxymethyl, 2-trifluoromethoxyethyl, 3-trifluoromethoxypropyl or 4-trifluoromethoxybutyl.

Lower polyhaloalkyl is, for example, trifluoromethyl. Trialkyl lower phosphono is, for example, trialkyl of 1 to 7 carbon atoms-phosphono, preferably trialkyl of 1 to 4 carbon atoms-phosphono, such as especially trimethylphosphono, or in the second place triethylphosphono, tripropylphosphono, tri- trofen. isopropylphosphono, or tributylphosphono. "Aza-a-oxo-lower alkenylene is, for example, 1,3- (3-aza-1 -oxo) prop-2-enylene. "Aza-ce-oxo-lower alkylene is, for example, 1,3- (3-aza-1-oxo) propylene. The compounds of the formula I having acidic groups can form salts with bases. The compounds of formula I having basic groups can also form acid addition salts, and where at least one acid group is present in addition, they can also form internal salts. The salts of the compounds of the formula I with bases are, for example, the salts thereof with pharmaceutically acceptable bases, such as non-toxic metal salts derived from metals of the groups la, Ib, lia, and Ilb, for example alkali metal salts, especially sodium or potassium salts, alkaline earth metal salts, especially calcium magnesium salts, and also ammonium salts with ammonia or organic amines or quaternary ammonium bases, such as optionally C-hydroxylated aliphatic amines. , especially lower mono-, di- or tri-alkylamines, for example methyl, ethyl, or diethyl amine, mono-, di-, or tri- (lower hydroxyalkyl) amines, such as ethanolic amine, dietanolic amine, or trietanolic amine , tris (hydroxymethyl) methyl amine, or tertiary 2-hydroxybutyl amine, or lower N- (lower hydroxyalkyl) -NN-dialkyl amines, or N- (lower polyhydroxyalkyl) -N-lower alkyl amines resins, such as 2- (dimethylamino) e-tanol or D-glucamine or choline, or aliphatic quaternary ammonium hydroxides, for example tetrabutyl ammonium hydroxide. The acid addition salts of the compounds of formula I are, for example, pharmaceutically acceptable salts thereof with suitable mineral acids, such as hydrohalic acids, sulfuric acid or phosphoric acid, for example hydrochlorides, hydrobromides, sulfates, or hydrogen phosphates, salts with suitable carboxylic acids, such as optionally hydroxylated lower alkanoic acids, for example acetic acid, glycolic acid, propionic acid, lactic acid, or pivalic acid, optionally hydroxylated lower alkane dicarboxylic acids and / or oxo- substituted, for example oxalic acid, succinic acid, fumaric acid, maleic acid, tartaric acid, citric acid, pyruvic acid, malic acid, ascorbic acid, and also with heteroaromatic or araliphatic carboxylic acids, such as benzoic acid, nicotinic acid, or acid mandelic acid, and salts with suitable aliphatic or aromatic sulfonic acids, or with N-substituted sulfamic acids, for example methanesulfonates, benzenesulfonates, p-toluenesulfonates, or N-cyclohexyl sulfamates (cyclamates). Also included are total and partial salts, i.e., salts with 1, 2, or 3, preferably 2 equivalents of base per mole of acid of the formula I, or salts with 1, 2, or 3 equivalents, preferably 1 equivalent , of acid per mole of base of formula I. For the purposes of isolation or purification, it is also possible to use pharmaceutically unacceptable salts. Only pharmaceutically acceptable non-toxic salts are used therapeutically, and therefore, are preferred. The compounds of the formula I have valuable pharmacological properties. They exhibit a high degree of binding affinity for AMPA receptors, kainate receptors, and / or the glycine binding sites of NMDA receptors. The affinity for the receptors mentioned is global or selective according to the structure. The selected compounds of the formula I exhibit especially a strong affinity for AMPA and / or the binding sites of kainate, and a less strong affinity for the glycine binding sites of the NMDA receptor. The binding capacity of the compounds prepared according to the invention and their salts can be demonstrated radiographically in brain membranes of rats (mice, rats) with reference to the displacement of [3H] -AMPA, [3H] - kainate, or [3H] -DCKA (5,7-dichloroquinuric acid), the concentration required for a 50 percent shift (IC50) being determined for various concentrations. In order to determine the binding affinity for AMPA receptors it is possible to use, for example, the radio-receptor assay of Honore T., Lauridsen J. and Krogsgaard-Larsen according to J. Neurochem 3.8, 173-178, in the which compounds of formula I exhibit IC50 values of from about 0.05 to about 5 μM. For N- (2, 3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-2-thiazoline hydrobromide, for example, an IC value was determined. Q of 0.3 micromoles / liter. The binding affinity for cainatc receptors can be measured, for example, by the radio-receptor assay of Simón J. R., Contrera J.F. and Kuhn M.J., J. Neurochem, 26, 141-147, in which the compounds of formula I exhibit IC5Q values of from about 0.5 to about 5 μM. The binding capacity of the compounds of the formula I with the glycine binding sites of the NMDA receptor can be determined, for example, in the radio-receptor assay according to Baron M.B, Siegel B.W. and collaborators, Eur. J. Pharmacol., Molec. Pharmacol. Section 206, pages 149-154 (1991), and Canton T., Double A. et al., J. Pharm. Pharmacol 44., pages 812-816 (1992) on rat cortex and rat hippocampal membranes. In that experimental procedure, the IC 50 of the compounds of formula I is in the range of about 0.005 to about 5 μM. For acetamide N- (7-bromo-2,3-dioxo-l, 2,3,4-te rahidroquinoxalin-5-ylmethyl) -3-thienyl acetamide, for example, an IC50 value of 0.007 micromoles / liter was determined . By virtue of these properties, the compounds of the formula I have pronounced anticonvulsant properties which are determined in vivo, for example, in mice, referring to their pronounced protective action with respect to seizures triggered by electric shock or by metrazole, being possible to use, for example, the well-established electric shock mouse model, or the mouse model for seizures induced by metrazol according to Schmutz et al., Naunyn-Schmiedeberg1 s Arch. Pharmacol. 342. 61-66 (1990). The compounds of the formula I, and the pharmaceutically acceptable salts thereof, according to the foregoing, are excellently suited for the prophylactic and therapeutic treatment of pathological conditions which respond to the blockade of one or more of the mentioned subtypes of amino acid receptors. of excitation, for example, neurodegenerative disorders, such as those presented by embolism, hypoglycemia, anoxia, or symptoms of cerebral palsy; ischemic brain disorders, such as cerebral ischemia, cerebral ischemia in cardiac surgery or in cardiac arrest, perinatal asphyxia, epileptic seizures, Huntington's chorea, Alzhei-mer's disease, and Parkinson's disease, amyotrophic lateral sclerosis, spinal and cerebral trauma, and also symptoms of poisoning resulting from neurotoxins or drug abuse; and ischemic disorders of the eyes; vascular and muscular spasms, such as migraine or local or general spasticity; seizures, such as epilepsy; and states of anxiety and pain, such as trigeminal neuralgia. The structurally simplest compounds of the formula I, wherein the radical Rj or R2 which is different from R5 is, for example, lower aminoalkyl or lower hydroxyalkyl, can also be used as intermediates in the preparation of the compounds of the formula I which they have a side chain of a more complex structure, substituting the former in the customary manner, for example, by the use of customary nucleophilic substitution procedures, in the amino or hydroxy group. The invention especially relates to compounds of the formula I wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), - alq-CH (R6) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk- N + (R8) (R9) -X-R7 A "(Id), -alq- 0-X-R7 (Ie) or -alk-SX-R7 (If), R3> R4 »and R5 are each independently of the others, hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, R is amino, lower alkyl-amino, lower alkanoyl-amino, lower N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-aminoalkyl lower, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, polyhalo lower alkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, or polyhaloalkoxy rior-lower alkyl, 3- to 8-membered cycloalkyl, carboxycycloalkyl, lower alkoxycarbonylcycloalkyl, aminocycloalkyl, or mono- or di-lower alkyl-aminocycloalkyl, pyrrolidino, oxopyrrolidinyl, carboxypyrrolidino, piperidino, carboxypiperidino, lower alkoxycarbonylpiperidino, morpholino , or thiomorpholino, carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl, cyano, lower alkylcarbamoyl, lower dialkylcarbamoyl, lower alkoxycarbonylalkyl-lower carbamoyl, lower carboxyl-carbamoyl, carbamoylalkyl-carbamoyl, N-carbamoylalkyl-N-lower alkyl-carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, polyhaloalkoxy lower, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; sulfo, lower alkane sulphonyl; benzylsulfonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, carboxy, and / or by lower alkoxycarbonyl; naphthalenesulfonyl unsubstituted or substituted by lower dialkyl amino, phosphono, lower trialkyl phosphono, amino, lower alkyl amino, lower dialkylamino, lower alkanoyl amino; phenylalkyl-amino, benzpylamino, or naphthoylamino which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl; ureido, amidino; phenyl or naphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, sulphamoyl, lower alkoxycarbonylamino, lower alkanoyl, halogen, and / or by trifluoromethyl; furyl, lower alkyl-furyl, thienyl, imidazolyl, oxazolyl, oxazolinyl (dihydrooxazolyl), carboxyalkyl (oxo) oxazolinyl, thiazolyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl-lower thiazolyl, lower alkoxycarbonylalkyl-thiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl , quinolinyl, benzazepinyl, or lower carboxyalkyl-2,3,4,5-tetrahydro-lH-l-benzazepinyl, R8 is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-lower aminoalkyl, lower alkanoyl- lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, polyhaloalkyl lower, lower alkoxy-lower alkyl, hydroxyalkoxy lower-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, polyhaloalkoxy lower-lower alkyl; lower phenylalkyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkydenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl; lower alkanoyl, lower alkenoyl; lower phenylalkanoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl; lower alkoxycarbonyl, or lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenekoxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl, or R7 R8 'together with X and the nitrogen atom linking R8 and X, form pyrrolidino, imidazolidino, tetrahydrothiazolyl, piperidino, morpholino, thiomorpholino, piperazino, homopiperidino or 1-azabicyclononyl which is unsubstituted or substituted by lower alkyl , lower hydroxyalkyl, lower phenylalkyl or unsubstituted or substituted phenyl, carboxy, lower alkoxycarbonyl, unsubstituted or substituted phenylcarbamoyl, lower-amino dialkyl, lower-amino alkanoyl, 2-oxoimidazolidino, phosphono, lower trialkyl-phosphono, tetrazolyl, lower alkanoyl, unsubstituted or substituted benzoyl, hydroxy, oxo, and / or lower alkoxy; optionally partially hydrogenated pyrrolyl which is unsubstituted or substituted by carboxy, lower alkoxycarbonyl, and / or by lower alkanoyl; Furyl thienyl; imidazolyl which is unsubstituted or substituted by lower alkyl, lower hydroxyalkyl, carboxy, lower carboxyalkyl, and / or by lower alkoxycarbonylaminoalkyl; optionally partially hydrogenated thiazolyl which is unsubstituted or substituted by lower carboxyalkyl, and / or by lower alkoxycarbonylalkyl; pyrazolyl unsubstituted or substituted by lower alkyl, -triazolyl; pyridinyl optionally partially hydrogenated, unsubstituted or substituted by oxo; optionally partially hydrogenated pyrimidinyl unsubstituted or substituted by oxo; pyrazinyl; indolyl which is unsubstituted or substituted by carboxy, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower cyanoalkyl, and / or by nitro; benzofuranyl; benzimidazolyl unsubstituted or substituted by nitro, -tetrahydro-quinolinyl; tetrahydroisoquinolinyl unsubstituted or substituted by oxo; tetrahydrobenzazepinyl; or phenyl, cyclohexadienyl, naphthyl or tetrahydronaphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, carboxy, lower alkoxycarbonyl, and / or trifluoromethyl; R9 is lower alkyl, lower alkenyl, lower alkynyl, or lower phenylalkyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or R7, R8, and R9, together with X and the nitrogen atom which bind R8, R9, and X, form a pyridinium radical which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, amino, alkyl of 1 to 4 carbon atoms-amino, or by dialkyl of 1 to 4 atoms carbon-amino, where A "is the anion of a hydrohalic acid, lower alkane sulphonic acid, or unsubstituted benzenesulfonic acid or substituted by lower alkyl or by halogen, alk is lower alkylene, and X (unless, together with R7 and R8 and the nitrogen atom linking R8 and X, or together with the nitrogen atom linking R8, R9, and X, is part of one of the ring systems mentioned) is lower alkylene, lower alkylidene, lower alkenylene, oxo -lower alkylene including carbonyl, oxo-lower alkylidene, dioxo-lower alkylene, lower oxo-alkenylene, lower hydroxyalkylidene, oxo (hydroxy) lower alkylene, lower aminoalkylene, lower aminoalkylidene, lower carboxyalkylene, lower carboxyalkylidene, lower carbamoylalkylidene, lower alkoxycarbonylalkylidene, lower alkoxycarbonylalkylene lower,? -aza-a-oxo-lower alkylene, or? -aza-a-oxo-lower alkenylene, 3-cycloalkylidene to 7 members, or lower phenylalkylidene or lower phenylalkylene unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidene-xi, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl, and you come out of them. The invention especially relates, on the one hand, for example, to compounds of the formula I wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -alq-CH (R6) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-0-X-R7 (Ie) or -alq-SX-R7 (If), R3 R4 and R5 are each independently of the others, hydrogen, lower alkyl, halogen, cyano, or nitro, R 6 is amino, lower alkyl-amino, lower alkanoyl-amino, N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R 7 is carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; phosphono, mono-, di-, or lower trialkyl-phosphono, or tetrazolyl, R8 is hydrogen, lower alkyl, or together with X and the nitrogen atom linking R8 and X, forms a radical of pyrrolidinylene, piperidinylene, or piperazinylene, alk is lower alkylene, and X is lower alkylene, lower oxo-alkylene, including carbonyl, lower alkylidene, lower aminoalkylidene, lower carboxyalkylidene, lower alkoxycarbonylalkylidene, lower carbamoyl alkylene, or, with the group N (R8),? α-α-cü-oxo-lower alkylene or α-aza-α-oxo-lower alkenylene linked via the a-carbon atom; lower phenylalkylidene which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or in the formula le, together with R8 and the nitrogen atom linking R8 and X, forms a pyrrolidinyl, piperidinyl radical, or piperazinyl, and salts thereof. The invention especially relates, for example, to compounds of the formula I in which: one of the radicals R j and R 2 is a group R 5, and the other is a group of the formula -alk-N (R 8) -X-R7 (Ic), R3 »R4» and R5 are each independently of the others, hydrogen, lower alkyl, halogen, cyano, nitro, R7 is a radical of phenyl, naphthyl, furyl, thienyl, pyridyl, or cycloalkyl from 3 to 8 members which is unsubstituted or substituted by lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, unsubstituted lower phenylalkoxycarbonyl or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl, phenylcarbamoyl unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; cyano, nitro, halogen, and / or trifluoromethyl; or is lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-lower aminoalkyl, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, polyhalo lower alkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, or lower polyhaloalkoxy-lower alkyl, R8 is hydrogen or lower alkyl, alk is lower alkylene, and X is lower oxo-alkylene, and salts thereof. The invention especially relates to compounds of the formula I wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), - alq-CH (R6) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-N + (R8) (R9) -X-R7 A '(Id), -alq- 0-X-R7 (le) or -alk-SX-R7 (If), 3 / R4 / and R5 are each independently of the others, hydrogen, alkyl of 4 carbon atoms, such as methyl or ethyl, halogen having an atomic number of up to and including 35, such as chlorine, fluorine, or bromine, trifluoromethyl, cyano, nitro. R6 is amino, alkyl of 1 to 4 carbon atoms-amino, alkanoyl of 1 to 4 carbon atoms-amino, N-alkyl of 1 to 4 carbon atoms-N-alkanoyl of 1 to 4 carbon atoms-amino, or dialkyl of 1 to 4 carbon atoms-amino, R is hydrogen, alkyl of 1 to 7 carbon atoms, such as methyl, ethyl, isopropyl, butyl, tertiary butyl, pent-4-yl, hept-4-yl, hydroxyalkyl of 1 to 4 carbon atoms, such as 2-hydroxyethyl, polyhaloalkyl of 1 to 4 carbon atoms, such as trifluoromethyl, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as methoxymethyl or 2-methoxyethyl, 3-6 membered cycloalkyl, such as cyclopropyl or cyclohexyl, 3-6 membered carboxycycloalkyl, such as 2-carboxycyclopentyl or 3- or 4-carboxycyclohexyl, aminocycloalkyl 3-6 membered, such as 2- aminocyclohexyl, pyrrolidine, carboxypyrrolidine, for example 2-carboxypyrrolidino, oxopyrrolidino, for example 5-oxopyrrolidin-2-yl, piperidino, carb oxypiperidino, morpholino or thiomorpholino, carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl, such as methoxycarbonyl, ethoxycarbonyl, or tertiary butyloxycarbonyl; phenylalkoxy of 1 to 4 carbon atoms-carbonyl, such as becyloxycarbonyl, carbamoyl, cyano, alkyl of 1 to 4 carbon atoms-carbamoyl, such as methylcarbamoyl, alkoxy of 1 to 4 carbon atoms-carbonylcarbamoyl, such as ethoxycarbonylmethylcarbamoyl or - ethoxycarbonyl ethylcarba oyl, carboxyalkyl of 1 to 4 carbon atoms - carbamoyl, such as carboxymethylcarbamoyl, carbamoylalkyl of 1 to 4 carbon atoms - carbamoyl, N-carbamoylalkyl of 1 to 4 carbon atoms - N-alkyl of 1 to 4 carbon atoms carbon-carbamoyl, N-carboxyalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamoyl, such as N-carboxymethyl-N-methylcarbamoyl, carbamoylalkyl of 1 to 4 carbon atoms-carbamoyl, such as carbamoylmethylcarbamoyl, phenylalkyl of 1 to 4 carbon atoms-carbamoyl unsubstituted or substituted by carboxy, such as benzylcarbamoyl or 1-carboxy-3-phenylpropylcarbamoyl; phenylcarbamoyl which is unsubstituted or substituted by alkoxy of 1 to 4 carbon atoms, nitro, polyhaloalkoxy of 1 to 4 carbon atoms, phenyloxy, or of alkoxy of 1 to 4 carbon atoms-carbonyl, such as phenylcarbamoyl, 4- trifluoromethoxyphenylcarbamoyl, 4-methoxyphenylcarbamoyl, 2-methoxyphenylcarbamoyl, 4-ethoxycarbonylphenylcarbamoyl, 3-ethoxycarbonylphenylcarbamoyl, 4-phenyloxyphenylcarbamoyl, or 4-nitrofenylcarbamoyl; sulfo, alkane of 1 to 4 carbon atoms-sulfonyl, such as methanesulfonyl; benzylsulfonyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, and / or by carboxy, such as benzenesulfonyl, toluensufonyl, 2-carboxybenzylsulfonyl, or 4-methoxybenzenesulfonyl; unsubstituted or substituted naphthalenesulfonyl by dialkyl of 1 to 4 carbon atoms-amino, such as 5-dimethylaminonaphthalenesulfonyl, phosphono, amino, alkyl of 1 to 4 carbon atoms-amino, dialkyl of 1 to 4 carbon atoms-amino, such as dimethylamino, alkanoyl of 1 to 4 carbon atoms-amino, such as acetylamino, phenylalkyl of 1 to 4 carbon atoms-amino, such as benzylamino, benzoylamino, or naphthoylamino, ureido, amidino, phenyl or naphthyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkylenedioxy of 1 to 4 carbon atoms, alkylidenedioxy of 1 to 4 carbon atoms, carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms -carbonylamino, alkanoyloxy having 1 to 4 carbon atoms, hydroxy, halogen, and / or trifluoromethyl, such as phenyl, naphthyl, 2-methylphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 3,4,5-trimethoxyphenyl, 3,4-methylenedioxyphenyl, 2-carboxyphenyl, 3-carboxyphenyl, 4-carboxyphenyl or 8- carboxynaphthyl, 4-sulfamoylphenyl, tert-4-butyloxycarbonylaminophenyl, tertiary-2-butyloxycarbonylaminophenyl, 2-acetoxyphenyl, 3,4-dihydroxyphenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,4-dichlorophenyl, or , 5-bistrifluoromethylphenyl; furyl, such as 2-furyl, C 1 -C 4 alkyl furyl, such as 4-methylfur-2-yl, thienyl, imidazolyl, such as imidazol-1-yl or imidazol-4-yl, (oxo) oxazolinyl, such as 2,5-dihydro-3-oxo-1,2-oxazolyl, thiazolyl, thiazolinyl (dihydrothiazolyl), such as 4,5-dihydrothiazolyl, carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, such as 4- carboxymethylthiazolyl, alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms-thiazolyl, such as methoxycarbonylmethylthiazolyl or ethoxycarbonyl-methylthiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, such as indole-3-yl, quinolinyl, such as quinolin-4-yl, benzaze-phenyl or carboxyalkyl of 1 to 4 carbon atoms-2, 3, 4, 5-tetrahydro-lH-1-benzazepinyl, such as l-carboxymethyl-2,3,4,5-tetrahydro -lH-1-benzazepine. R8 is hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl, ethyl, isopropyl, hydroxyalkyl of 1 to 4 carbon atoms, such as 2-hydroxyethyl, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as 2-methoxyethiol, hydroxyalkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, such as 2- (2-hydroxyethoxy) ethyl, phenylalkyl of 1 to 4 carbon atoms, such as benzyl, pyridylalkyl of 1 to 4 carbon atoms, such as pyridylmethyl, alkanoyl of 1 to 4 carbon atoms, such as acetyl , phenylalkanoyl of 1 to 4 carbon atoms, such as phenylacetyl, alkoxy of 1 to 4 carbon atoms-carbonyl, such as tertiary butyloxycarbonyl or phenylalkoxy of 1 to 4 carbon atoms-carbonyl, such as benzyloxycarbonyl, or R7 and R8"together with X and the nitrogen atom linking R8 and X form pyrrolidino, carboxypyrrolidino, for example 2-carboxypyrrolidino, hydroxypyrrolidino, for example 3-hydroxypyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms-pyrrolidino, for example 2-hydroxymethylpyrrolidino, mono- or di-oxopyrrolidino, for example 2-oxopyrrolidino or 2,5-dioxopyrrolidino, alkyl of 1 to 4 carbon atoms (oxo) pyrrolidino, for example 2-methyl-5-oxo-pyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms (oxo) -pyrrolidino, for example 2-hydroxymethyl-5-oxo-pyrrolidino, carboxy (oxy) pyrrolidino, for example 5-carboxy-2-oxo-pyrrolidino, 2-carboxy-4-hydroxy-pyrrolidino, or 2-carboxy-3-hydroxy-pyrrolidino, -oxoimidazolidino, for example 2-oxo-3-phenyl-imidazolidino, tetrahydrothiazolyl, for example tetrahydrothiazol-1-yl, piperidino, alkyl of 1 to 4 carbon atoms-piperidino, for example 4-methylpiperidino, 3-methylpiperidino, or 4-butylpiperidino, dialkyl of 1 to 4 carbon atoms-piperidino, for example 2,6-dimethylpiperidino, carboxypiperidino, for example 2-carboxy-piperidino, 3-carboxypiperidino or 4-carboxipiperidino, alkoxy of 1 to 4 carbon atoms- carbonylpiperidino, for example 2-ethoxycarbonylpiperidino, or 4-ethoxycarbonylpiperidino, phenylcarbamoylpiperidino, for example 2-phenylcarbamoylpiperidino, 3-phenylcarbamoylpiperidino, or 4-phenylcarbamoylpiperidino, oxopipe-ridino, for example 4-oxopiperidino, dioxopiperidino, oxo (phenylalkyl) 1 to 4 carbon atoms) piperidino, for example 2-benzyl-4- oxo-piperidino, oxo (phenyl) piperidino, for example 2-oxo-3-phenyl-piperidino or 2-oxo-5-phenyl-piperidino, hydroxypiperidino, for example 3-hydroxypiperidino or 4-hydroxypiperidino, hydroxy (p-phenylalkyl) at 4 carbon atoms) piperidino, for example 2-benzyl-4-hydroxy-piperidino, carboxy (hydroxy) piperidino, for example 2-carboxy-4-hydroxy-piperidino, dialkyl of 1 to 4 carbon atoms-aminopiperidino, example 4-dimethylaminopiperidino, alkanoyl of 1 to 4 carbon atoms-aminopiperidino, for example 4-acetylaminopiperidino, alkanoyl of 1 to 4 carbon atoms-amino (phenylalkyl of 1 to 4 carbon atoms) piperidino, for example 4-acetylamino- 2-benzyl-piperidino, alkanoyl of 1 to 4 carbon atoms-amino (phenyl) piperidino, for example 4-acetyl-mino-2-phenyl-piperidino, phenylpiperidino, for example 4-phenylpiperidino, alkoxy of 1 to 4 carbon-piperidino atoms, for example 4-methoxypiperidino, alkoxy of 1 to 4 carbon atoms- (alkyl of 1 to 4 carbon atoms) carbon) piperidino, for example 4-methoxy-4-methyl-piperidino, dialkoxy of 1 to 4 carbon atoms-piperidino, for example 4,4-dimethoxypiperidino, dialkoxy of 1 to 4 carbon atoms (phenylalkyl of 1 to 4 atoms carbon) piperidino, for example 2-benzyl-4,4-dimethoxypiperidino, alkylenedioxy of 1 to 4 carbon atoms-piperidino, for example 4-ethylene-dioxypiperidino, hydroxyalkyl of 1 to 4 carbon atoms-piperidino, for example 2 -hydroxymethylpiperidino, 4-hydroxymethyl-piperidino, 2- (2-hydroxyethyl) piperidino, or 4- (l-hydroxyethyl) pipe-ridino, unsubstituted or halogenated benzoylpiperidino, for example 4- (4-fluorobenzoyl) piperidino, alkanoyl of 1 to 4 carbon atoms-piperidino, for example 4-acetylpiperidino, oxoimida-zolidinopiperidino, for example 4- (2-oxoimidazolidino) piperidino, homopiperidino, oxohomopiperidino, for example 2-oxohomopiperidino, azabiciclononilo, for example 1-azabiciclononilo, piperazino, alkyl 1 to 4 carbon atoms-piperazino, for example 4 -methylpiperazino, oxopiperazino, for example 3-oxopiperazino, dioxopiperazino, for example 3,5-dioxopiperazino, unsubstituted phenylpiperazino or lower alkoxylation, for example 4- (4-methoxyphenyl) -piperazino, morpholino, dialkyl of 1 to 4 carbon atoms-morpholino, for example 3, 5-dimethylmorpholino, thiomorpholino, phenyl, cyclohexa-1,3-dien-5-yl, hydroxyphenyl, such as 4-hydroxyphenyl, alkoxy of 1 to 4 carbon atoms-phenyl, such as 3-methoxyphenyl, carboxyphenyl, such as 3-carboxyphenyl, halo -nyl, such as 2-fluorophenyl, 3-fluorophenyl, or 4-fluorophenyl, trifluoromethylphenyl, bistrifluoromethylphenyl, such as 3,5-bistrifluoromethylphenyl, naphthyl, or tetrahydronaphthyl, such as 1, 2, 3, 4-tetrahydronaphthyl, nitrobenzimidazolyl, such such as 5-nitrobenzimidazol-1-yl, or 6-nitrobenzimidazol-1-yl, tetrahydro-quinolinyl, such as 1, 2, 3,4-tetrahydroquinolin-1-yl, unsubstituted tetrahi-droisoquinolinyl or substituted by oxo, such as 1 , 2, 3,4-tetrahydroisoquin-2-yl or l-oxo-1,2,3,4-tetrahydroiso-quin-2-yl, or tetrahydrobenzazepinyl , such as 2, 3, 4, 5-tetrahydro-lH-1-benzazepin-1-yl.

R9 is lower alkyl, or R7 # R8"and R9" together with X and the nitrogen atom linking R8, R, and X, form a pyridinium radical which is unsubstituted or substituted by amino, alkyl of 1 to 4 carbon atoms. carbon-amino, or by dialkyl of 1 to 4 carbon-amino atoms, where A "is the anhydride of a hydrohalic acid, alkyl is alkyl (id) ene of 1 to 4 carbon atoms, such as methylene, ethylene, or ethylidene , and X (unless, together with R7 and R and nitrogen atom linking R and X, or together with the nitrogen atom linking R8, R9, and X, is part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 4 carbon atoms, such as ethylene, propylene, or butylene, alkylidene of 1 to 4 carbon atoms, such as methylene, ethylidene, isopropyl-lead, isobutylidene, or dimethylpropylidene, alkenylene of 1 to 4 carbon atoms, such as 1,2-pent-4-enylene, oxoalkylene of 1 to 4 carbon atoms, including carbonyl, such as carbonyl oxoeti 1, 3- (1-oxo) propylene, 1,3- (1-oxo) propylene or 1,4- (1-oxo) butylene, dioxoalkylene of 1 to 4 carbon atoms, such as oxalo, oxoalkenylene of 1 to 4 carbon atoms, such as 1-oxoprop-2-enylene, hydroxyalkylidene of 1 to 4 carbon atoms, such as 2-hydroxyethylidene or 2-hydroxypropylidene, oxo (hydroxy) -alkylene of 1 to 4 carbon atoms, such as 1-oxo-2-hydroxy-ethylene, aminoalkylene of 1 to 4 carbon atoms, such as aminoethylene, aminoalkylidene of 1 to 4 carbon atoms, such as 5-aminopentylene, carboxyalkylene of 1 to 4 carbon atoms, such as 1-carboxyethylene or 1, 3- (1-carboxy) propylene, carboxyalkylidene of 1 to 4 carbon atoms, such as 3-carboxypropylidene, alkoxy of 1 to 4 carbon atoms-carboni-lalkylidene of 1 to 4 carbon atoms , such as ethoxycarbonylmethylene, alkoxy of 1 to 4 carbon atoms-carbonylalkylene of 1 to 4 carbon atoms, such as 1,3- (1-tertiary butyloxycarbonyl) propylene, α-aza-a-oxo-alkyl 1 to 4 carbon atoms, such as 1, 3- (l-oxo-3-aza) propylene, or α-aza-a-oxo-alkenylene of 1 to 4 carbon atoms, such as 1,3- (3-aza-l-oxo) prop-2-enylene, 3- to 7-membered cycloalkylidene, such as cyclopropylidene, or phenylalkylidene of 1 to 4 carbon atoms or phenylalkylene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and or trifluoromethyl, such as 2-phenylethylene, 1, 2- (1-phenyl) ethylene, 1,2- [1- (4-chlorophenyl) ethylene, or 1,3- (3-phenyl) propylene, and salts of them. The invention also relates in particular to those of the aforementioned compounds of the formula I, in which: Rj is a group of the formula -CHfRg) -alk-R7 (Ia), -alk-CH (R6) - R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-N + (Rg) (R9) -XR? A '(Id), -alq-0-X-R7 (Ie) or -alq-SX-R7 (If), and R2 is a group R5, wherein R3, R4, R5, Rg, R7, R, R9 , alq, and X are as defined, with the proviso that, in the compounds of the formula I where Rj is a group of the formula le, R2 and R3 are each independently of the other, fluorine, chlorine, bromine, methyl, ethyl, or trifluoromethyl, and R 4 is hydrogen, when either methylene, ethylidene, or propylidene, the group -N (R 8) -X-R 7 is different from a mono-, di-, tri-, or tetra 5-membered azaheteroa-rile linked by means of a nitrogen atom and optionally benzocondensate and / or substituted by alkyl having up to and including 6 carbon atoms, or substituted at the position? by a group of the formula -N (Ra) -Rb wherein Ra and Rb are each independently of the other, hydrogen, alkyl, cycloalkyl, phenylalkyl, or pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino, piperazino, N'-lower alkyl-piperazino, morpholino, or azepino group, and salts thereof. The invention preferably relates to the compounds of the formula I wherein: R j is a group of the formula: -CH (R 6) -alk-R 7 (Ia), -alk-CH (R 6) -R 7 (Ib), -alk-N (R8) -X-R7 (Ic), or -alk-N + (R8) (R9) -X-R7 A " (Id), and R2 is a group R5, R3 »R4 and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl or ethyl, halogen having an atomic number of up to and including including 35, such as chloro, fluoro, or bromo, trifluoromethyl, cyano or nitro, Rg is amino, alkyl of 1 to 4 carbon atoms-amino, alkanoyl of 1 to 4 carbon atoms-amino, N-alkyl of 1 to 4 carbon atoms-N-alkanoyl of 1 to 4 carbon-amino atoms, or dialkyl of 1 to 4 carbon atoms-amino, R7 is hydrogen, alkyl, such as ethyl, hydroxyalkyl of 1 to 4 carbon atoms, as 2-hydroxyethyl, polyhaloalkyl of 1 to 4 carbon atoms, such as trifluoromethyl, cycloalkyl of 3 to 6 members, such as cyclopropyl, azoxacycloalkyl of 3 to 6 members, such as morpholino, carboxy, alkoxy of 1 to 4 carbon-carbonyl atoms, such as methoxycarbonyl, ethoxycarbonyl, or tertiary butyloxycarbonyl, phenylalkoxy of 1 to 4 carbon atoms-carb onyl, such as becyloxycarbonyl, carbamoyl, phenylcarbamoyl, alkane of 1 to 4 carbon atoms-sulfonyl, such as methanesulfonyl, amino, morpholino, benzoylamine; phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, alkanoyloxy of 1 to 4 carbon atoms, halogen, and / or by trifluoromethyl, such as phenyl, 3-methoxyphenyl, 3-carboxyphenyl, -fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 3,5-bistrifluoromethylphenyl; furyl, thienyl, thiazolyl, thiazolinyl (dihydrothiazolyl), such as 4,5-dihydrothiazolyl, carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, such as 4-carboxymethylthiazolyl, alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon-thiazolyl atoms, such as 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylthiazolyl, or pyridyl, R is hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl, or ethyl, hydroxyalkyl of 1 to 4 carbon atoms, such as 2-hydroxyethyl, phenylalkyl of 1 to 4 carbon atoms, such as benzyl, or pyridylalkyl of 1 to 4 carbon atoms, such as pyridylmethyl, or R7 and R8, together with X and the linking nitrogen atom R8 and X form pyrrolidino, carboxypyrrolidino, for example 2-carboxypyrrolidino, hydroxypyrrolidino, for example 3-hydroxypyrrolidino, tetrahydrothiazolyl, for example tetrahydrothiazol-1-yl, piperidino, alkyl of 1 to 4 carbon atoms-piperidino, for example , 4-methylpiperidino, dialkyl of 1 to 4 carbon atoms-piperidino, for example 2,6-dimethylpiperidino, carboxypiperidino, for example 2-carboxypiperidino, 3-carboxypiperidino or 4-carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonil -piperidino, for example 2-ethoxycarbonylpiperidino or 4-ethoxycarbo-nilpiperidino, phenylcarbamoylpiperidino, for example 2-phenylcarbamoylpiperidino, 3-phenylcarbamoylpiperidino, or 4-phenylcarbamoyl-piperidino, oxopiperidino, for example 4-oxopiperidino, dialkyl of 1 to 4 atoms of carbon-aminopiperidino, for example 4-dimethylaminopiperidino, hydroxyalkyl of 1 to 4 carbon atoms-piperidino, for example 2- (2-hydroxyethyl) piperidino, homopiperidino, azabiciclononilo, for example 1-azabicyclononyl, piperazino, alkyl of 1 to 4 carbon atoms-piperazino, for example 4-methylpiperazino, unsubstituted phenylpiperazino or lower alkoxylation, for example 4- (4-methoxyphenyl) piperazino, morpholino, thiomorpholino, phenyl, cyclohexa-1, 3-dien-5-yl, hydroxyphenyl, such as 4-hydroxyphenyl, alkoxy of 1 to 4 carbon atoms-phenyl, such as 3-methoxyphenyl, carboxyphenyl, such as 3-carboxyphenyl, halophenyl, such as 2-fluorophenyl, -fluorophenyl, or 4-fluorophenyl, trifluoromethylphenyl, bistrifluo-romethylphenyl, such as 3,5-bistrifluoromethylphenyl, nitrobenz-midazolyl, such as 5-nitrobenzimidazol-1-yl, or 6-nitrobenzim-dazol-1-yl, tetrahydroquinolinyl, such such as 1, 2,3,4-tetrahydro-quin-1-olin-1-yl, or tetrahydroisoquinolinyl unsubstituted or substituted by oxo, such as 1, 2, 3, 4-tetrahydroisoquin-1-olin-1-yl, R 9 is lower alkyl, or R7 »R8» and R9 »together with X and the nitrogen atom linking R8, R9, and X, form a pyridinium radical unsubstituted or substituted by amino, where A" is the anion of a halohydric acid, is alkyl (id) ene of 1 to 4 carbon atoms, such as methylene and X (unless, together with R7 and Rg and the nitrogen atom linking R8 and X, or together with the nitrogen atom linking R8) , R9, and X, is part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 7 carbon atoms, such as methylene, ethylene, propylene, or butylene, alkylidene of 1 to 4 carbon atoms , such as methylene, ethylidene, isopropylidene, or 2,2-dimethylpropylidene, oxoalkylene of 1 to 4 carbon atoms, including carbonyl, such as carbonyl, oxoethylene, 1,3- (1-oxo) propylene, 1,4- ( 1-oxo) butylene, oxoalkenylene of 1 to 4 carbon atoms, such as l-oxoprop-2-enylene, aminoalkylidene of 1 to 4 carbon atoms, such as 5-aminopentylidene, carboxyalkyl ilidene of 1 to 4 carbon atoms, such as 3-carboxypropylidene, alkoxy of 1 to 4 carbon atoms-carbonylalkylidene of 1 to 4 carbon atoms, α-aza-a-oxo-alkylene of 1 to 4 carbon atoms, such as 1, 3- (l-oxo-3-aza) propylene, or? -aza-a-oxo-alkenylene of 1 to 4 carbon atoms, such as 1, 3- (3-aza-1-oxo) prop-2-enylene, or phenylalkylidene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, such as 2-phenylethylidene, and salts thereof. The invention relates especially to the compounds of the formula I wherein: R? is a group of the formula -CH (R6) -alk-R7 (Ia), -alk-CH (R6) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), or -alq -N + (R8) (R9) -XR? A '(Id), and R2 is a group R5, R3 and R4 are each independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl or ethyl, halogen having an atomic number of up to and including 35, such as chlorine, fluorine, or bromine, or nitro, R5 is hydrogen, R7 is hydrogen, alkyl, such as ethyl, polyhaloalkyl of 1 to 4 carbon atoms, such as trifluoromethyl, cycloalkyl of 3 to 6 members, such as cyclopropyl, azoxacycloalkyl of 3 to 6 members, such as morpholino, carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl, such as methoxycarbonyl or ethoxycarbonyl; phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, halogen and / or trifluoromethyl, such as phenyl or 3-carboxyphenyl; furyl, such as 2-furyl, thiazolinyl (dihydrothiazolyl), such as 4,5-dihydrothiazolyl, carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, such as 4-carboxymethylthiazolyl, or alkoxy of 1 to 4 carbon atoms-carbonylalkyl 1 to 4 carbon atoms thiazolyl, such as 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylmethylthiazolyl, R8 is hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl, or ethyl, or pyridylalkyl of 1 to 4 carbon atoms, as pyridylmethyl, or R7 and R8 'together with X and the nitrogen atom linking Rg and X, form pyrrolidino, piperidino, carboxypiperidino, for example 3-carboxypiperidino, or 4-carboxypipéridino, alkoxy of 1 to 4 carbon atoms- carbonylpiperidino, for example 2-ethoxycarbonylperidino or 4-ethoxycarbonylpiperidino, oxopiperidino, for example 4-oxopiperidino, homopiperidino, azabiciclononilo, for example 1-azabiciclononilo, piperazino, alkyl of 1 to 4 carbon atoms piperazino, for example 4-methylpiperazino , unsubstituted phenylpiperazino or lower alkoxylation, for example 4- (4-methoxyphenyl) piperazino, morpholino, or thiomorpholino, R9 is lower alkyl, or R7, Rg, and R, together with X and the nitrogen atom linking Rg, R9 and X , form a pyridinium radical unsubstituted or substituted by amino, where A "is the anion of a hydrohalic acid, alkyl is alkyl (id) ene, of 1 to 4 carbon atoms, such as methylene, and X (unless, together with R7 and Rg and the nitrogen atom linking Rg and X, or together with the nitrogen atom linking Rg, R9, and X, is part of one of the ring systems mentioned (it is a direct bond, alkylene of 1 at 7 carbon atoms, such as methylene, ethylene, propylene, or butylene, alkylidene of 1 to 4 carbon atoms, such as methylene, ethylidene, isopropylidene or 2,2-dimethylpropylidene, oxoalkylene of 1 to 4 carbon atoms, including carbonyl, such as carbonyl, oxoethylene or 1, 3- (1-oxo) -propylene, aminoalkylidene of 1 to 4 carbon atoms arbono, such as 5-aminopentylidene, carbo-xyalkylidene of 1 to 4 carbon atoms, such as 3-carboxypro-pylidene, or phenylalkylidene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, such as 2- phenylethylidene, and salts thereof. The invention especially relates, for example, to compounds of the formula I wherein: Rj is a group of the formula -alk-CH (R6) -R7 (Ib), -alk- N (R8) -X-R7 ( Ic), -alq-0-X2-R7 (Ie) or -alq-S-X2-R7 (If), R2 is hydrogen, R3 and R4 are each independently of the other, halogen having an atomic number of up to and including including 35, such as bromine, or nitro, Rg is amino, R is carboxy, phenylalkoxy of 1 to 4 carbon atoms such as benzyloxycarbonyl; phenylcarbamoyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, such as methyl, alkoxy of 1 to 4 carbon atoms, such as methoxy, hydroxy, halogen having an atomic number of up to and including 35, such as fluorine , chlorine, or bromine, - nitro, carboxy, alkoxy of 1 to 4 carbon atoms - carbonyl, such as methoxy- or ethoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl, - or tetrazolyl, R8 is hydrogen or, together with X and the nitrogen atom linking R8 and X, forms a piperidinylene radical, alq is methylene, X is alkylidene of 1 to 4 carbon atoms, such as methylene, or in the formula is carbonyl, aminoalkylidene of 1 to 4 carbon atoms, such as 5-aminopentylidene, carboxyalkylene-lead of 1 to 4 carbon atoms, such as 4-carboxybutylidene, or, with the group N (Rg), α-aza-o; -oxo-alkylene of 3 to 5 carbon atoms, such as 1, 3- (3-aza-1-oxo) propylene, linked via the carbon atom a, or, together with Rg and the atom or of nitrogen linking R8 and X, forms a piperidinylene radical, and salts thereof. The invention relates preferably to the compounds of the formula I wherein: Rj is a group of the formula: -CH (Rg) -alq-R7 (the), -alq-CH (R6) -R7 (Ib), -alk-N (Rg) -X-R7 (le), or -alq-N + (Rg) (R9) -X-R7 A "(Id), and R2 is a group R5, R3 and R4 are each independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl, or ethyl, halogen having an atomic number of up to and including 35, such as chlorine, fluorine, or bromine, or nitro, R5 is hydrogen, R7 is hydrogen, alkyl, such as ethyl, polyhaloalkyl of 4 carbon atoms, such as trifluoromethyl, cycloalkyl of 3 to 6 members, such as cyclopropyl, 3 to 6 membered azoxacycloalkyl, such as morpholino, carboxy, C 1 -C 4 alkoxycarbonyl, such as methoxycarbonyl or ethoxycarbonyl; phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, halogen and / or by trifluoromethyl, such as phenyl or 3-carboxyphenyl; furyl, such as 2-furyl, thiazolinyl (dihydrothiazolyl), such as 4,5-dihydrothiazolyl, carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, such as 4-carboxymethylthiazolyl, or alkoxy of 1 to 4 carbon atoms-carbonylalkyl 1 to 4 carbon atoms thiazolyl, such as 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylmethylthiazolyl, R8 is hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl, or ethyl, or pyridylalkyl of 1 to 4 carbon atoms, as pyridylmethyl, or R7 and Rg, together with X and the nitrogen atom that binds Rg and X form pyrrolidino, piperidino, carboxypiperidino, for example 3-carboxypiperidino, or 4-carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonylpiperidino, for example 2-ethoxycarbonylperidino or 4-ethoxycarbonylpiperidino, oxopiperidino, for example -oxopiperidino, homopiperidino, azabicyclonononyl, for example 1-azabicyclononyl, piperazino, alkyl of 1 to 4 carbon atoms-piperazino, for example 4-methylpiperazino, unsubstituted phenylpiperazino or lower alkoxylation, for example 4- (4-methoxyphenyl) piperazino, morpholino , or thiomorpholino, alk is alkyl (id) ene of 1 to 4 carbon atoms, such as methylene, and X (unless, together with R7 and Rg and the nitrogen atom linking R8 and X, is part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 7 carbon atoms, such as methylene, ethylene, propylene, or butylene, alkylidene of 1 to 4 carbon atoms, such as methylene, ethylidene, isopropylidene or 2, 2-dimethylpropylidene , oxoalkylene of 1 to 4 carbon atoms, including carbonyl, such as carbonyl, oxoethylene, or 1, 3- (1-oxo) propylene, 1,4- (1-oxo) butylene, oxoalkenylene of 1 to 4 carbon atoms , such as l-oxoprop-2-enylene, aminoalkylidene of 1 to 4 carbon atoms, such as 5-aminopentylidene, carboxyalkylidene of 1 to 4 carbon atoms, such as 3-carboxypropylidene, alkoxy of 1 to 4 carbon atoms- carbonylalkylidene of 1 to 4 carbon atoms,? -aza-a-oxo-alkylene of 1 to 4 carbon atoms, such as l, 3- (l-oxo-3-aza) propylene, or? -aza-Qí- oxo-alkenylene of 1 to 4 carbon atoms, such as 1,3- (3-aza-1-oxo) propenyl-2-ylene, or phenylalkylidene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl , such as 2-phenylethylidene, and salts thereof. The invention preferably relates, for example, on the one hand, to the compounds of the formula I wherein: R is a group of the formula -alk-N (Rg) -X-R7 (Ic), R2 is hydrogen, R3 and R4 are each independently of the other, halogen having an atomic number of up to and including 35, such as bromine, or nitro, Rg is amino, R7 is carboxy, Rg is hydrogen or, together with X and the nitrogen atom which binds Rg and X, forms a piperidinylene radical, alk is methylene, and X is alkylidene of 1 to 4 carbon atoms, such as methylene, carbonyl, or, with the group N (R8), form? -aza-ar -oxo-alkylene of 3 to 5 carbon atoms, such as 1,3- (3-aza-1-oxo) propylene, linked by means of the carbon atom ar or, together with R 8 and the nitrogen atom linking R g and X, forms a piperidinylene radical, and salts thereof. The invention preferably also relates to the compounds of the formula I wherein: R j is a group of the formula -alk-N (R g) -X-R 7 (Ib), R 2, R 3, R 4, and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl or ethyl, halogen having an atomic number of up to and including 35, such as chlorine, fluorine or bromine, cyano or nitro, R7 is a radical of phenyl, furyl, thienyl, or pyridyl, which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, such as methyl, alkoxy of 1 to 4 carbon atoms, such as methoxy, carboxy, alkoxy 1 to 4 carbon-carbonyl atoms, such as methoxycarbonyl, carbamoyl, cyano, nitro, halogen and / or trifluoromethyl, or is unsubstituted 3 to 8 membered cycloalkyl, such as cyclopropyl alkyl of 1 to 7 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, secondary butyl or tertiary butyl, aminoalkyl of 1 to 4 carbon atoms rbono, such as aminomethyl, or polyhaloalkyl of 1 to 4 carbon atoms, such as trifluoromethyl, Rg is hydrogen, alk is methylene, and X is carbonyl, and salts thereof. The invention relates more particularly to the compounds of the formula I wherein: R 2 is a group R 5, and R j is a group of the formula -alk-N (R 8) -X-R 7 (Ic), or -alk-N + (Rg) (R9) -X-R7 A "(Id), R3 and R4 are each independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, such as methyl or ethyl, halogen having an atomic number of up to and including 35, such as chlorine, fluorine, or bromine, or nitro, R5 is hydrogen, R is cycloalkyl, 3 to 6 members, such as cyclopro-pyl, azoxacycloalkyl of 3 to 6 members, such as morpholino, carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl, such as methoxycarbonyl or ethoxycarbonyl, thiazolinyl (dihydrothiazolyl), such as 4, 5-dihydrothiazolyl, or alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms-thiazolyl, such as 4-methoxycarbonylmethylthiazolyl or 4-ethoxycarbonylmethylthiazoyl, Rg is hydrogen or alkyl of 1 to 4 carbon atoms, such as methyl or ethyl, or R and Rg, together with X and the nitrogen atom that binds R8 and X form pyrrolidino, piperidino, carboxypiperidino, for example 4-carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonylpiperidino, for example 4-ethoxycarbonylpiperidino, oxopiperidino, for example, 4-oxopiperidino, or homopiperidino, alq es methylene, and X (unless, together with R7 and Rg and the nitrogen atom linking Rg and X, is part of one of the ring systems mentioned (it is a direct bond, alkylene of 1 to 7 carbon atoms, such as methylene, ethylene, propylene or butylene, or aminoalkylidene of 1 to 4 carbon atoms, such as 5-aminopentylidene, or carboxyalkylidene of 1 to 4 carbon atoms, such as 3-carboxypropylidene, and salts thereof. specifically to the compounds of the formula I mentioned in the Examples and to salts thereof, especially the pharmaceutically acceptable salts thereof The process for the preparation of the compounds of the formula I, prepared in accordance with nvention, is as follows: a) in a compound of formula II: wherein: the radicals R 'and R "are identical or different hydroxy protecting groups, one of the radicals R'j and R'2 is a group R5, and the other is a group of the formula -CH (R, 6) -alk-R7 (IIa) -alq-CH (R 'g) -R'7 (Ilb), -alk-N (R'g) -X-R'7 (líe), -alq-N + (R' 8) (R9) -X-R'7 A "(lid), -alq-0-X-R'7 (He) or -alq-SX-R'7 (Hf), where R'g is a R6 or protected amino group, R'7 is a R7 group, protected carboxy or protected carbamoyl, and R'g is a group R8 or an amino protecting group; the hydroxy protecting groups R 'and / or R "and an amino protecting group R'8 that may be present are removed, and if present, carboxy or carbamoyl is released from the protected R'7 carboxy or protected carbamoyl R. '7, and / or) for the preparation of the compounds of the formula I, wherein one of the radicals Rj and R2 is a group of the formula Le, Le or If, and the salts thereof, the compounds of the formulas III and IV: wherein: one of the radicals R "j and R" 2 is a group R5, and the other is a group of the formula -alq-Y (Illa), one of the radicals Y and Y2 is hydroxy, mercapto or a group HN (R'g), and the other is a group that can be removed to form a bond, R'7 is a R7 group, protected carboxy or protected carbamoyl, and R'8 is an R8 group or an amino protecting group, they condense with one another; an amino protecting group R'8 that may be present is removed, and if present, carboxy or carbamoyl is released from the protected carboxy R'7 or protected carbamoyl R'7, or c) for the preparation of the compounds of the formula I, wherein one of the radicals R and R2 is a group R5, and the other is a group of the formula -alq-CH (Rg) -R7 (Ib), Rg is amino, and R7 is carboxy, a compound of the formula II: wherein: one of the radicals R "j and R" 2 is a group R5, and the other is a group of the formula -alq-C (R'7) (R'6) -R'7 (Ha '), R 'and R "are identical or different hydroxy protecting groups, R'g is protected amino and the R'7 groups are identical or different protected carboxy groups, is subjected to an acid treatment, and if desired, a resulting compound it is converted into a different compound of the formula I, a mixture of the isomers obtainable according to the process, is separated into the components, and the preferred isomer is isolated, and / or a free compound obtainable from according to the process, it becomes a salt, or a salt that can be obtained according to the process, becomes the corresponding free compound.The suitable hydroxy protecting groups R 'and R "are, for example, the hydroxy protecting groups customary for the temporary protection of lactam groups, especially ether-forming groups, such as alkyl inf erior, preferably methyl, and also trialkyl lower-silyl, such as trimethylsilyl. Amino protecting groups R'8 are, for example, acyl groups different from the groups R8, such as acyl derived from an aromatic carboxylic acid or from an aromatic half ester of carbonic acid, such as unsubstituted or substituted benzoyl, or unsubstituted or substituted phenylcarbonyl, such as phenyloxycarbonyl. The protected carboxy groups are, for example, protected in an ester form other than esterified carboxy R7, and are, for example, in an unsubstituted or substituted phenyl ester form, or in the form of trialkyl-lower alkyl silyl esters, such as trimethylsilyl esters. Protected carbamoyl groups are, for example, in the phthalic imide form. The removal of the mentioned protective groups R 'and / or R ", according to Process Variant a), or the release of the protected groups from groups R'7 and / or R'8, is effected by the manner customary, for example, by acid treatment, with, for example, from about 20 percent to about 40 percent hydrobromic acid in acetic acid, or moderately acidic hydrolysis, such as treatment with an acid mixture hydrochloric acid from about IN to about 4N and acetic acid or tetrahydrofuran / ethanol The starting materials of the formula II, wherein alk is 1, 1-alkylene lower, are prepared, for example, as follows: corresponding compound of formula V: wherein one of the radicals R '"j and R'" is lower alkyl, such as especially methyl, the nitro group is reduced to amino in the customary manner, for example by catalytic hydrose-nation in the presence of Palladium or Rane nickel The resulting phenylene 1,2-dαamine is condensed with oxalic acid under acidic conditions, for example in the presence of hydrochloric acid, to form the corresponding quinoxalindione of the formula VI: this compound is converted by its reaction with a halogenating agent that introduces halogen Hal, for example phosphorus oxychloride, into the corresponding 2,3-dihaloquinoxaline of formula VII: in this compound, the Hal groups are replaced by protected hydroxy -OR 'or -OR ", such as lower alkoxy, especially methoxy, in the customary manner, for example by their reaction with an alkali metal lower alkanolate, such as methanolate sodium, - and the resulting compound of formula VIII: is halogen in the side chain using a halogenating agent that introduces halogen Yj, such as N-bromosucciimide, in the presence of azoisobutyronitrile, to form a corresponding compound of formula VIII, wherein one of the radicals R '"j and R '"is a group of the formula -alq-Yj, and the other is a group R5, where Yj is halogen, especially bromine, and R' and R" are hydroxy protecting groups, then this compound can be further reacted with a compound of the formula CH2 (R'6) -R'7 (Villa), H- N (R'8) -X-R'7 (HIVb), HO-X-R'7 (VIIIc) or HS -X-R'7 (HIVd), wherein R'g is an amino group protected by a divalent araliphatic radical, such as benzylidene, or especially benzhydryl, R'7 is an R group, protected carboxy or protected carbamoyl, and R g is an Rg group or an amino protecting group This process is especially suitable for the preparation of the compounds of the formula II, wherein one of the radicals R'j and R'2 is a group for R5, and the other is a group of the formula -alq-CH (Rg) -R'7 (Il'b), where Rg is amino, a group? e the formula -alq-N (R'g) -X-R'7 (He), where R'7 is a radical? .- different from hydrogen, X has no oxo group at position a, and is, for example, lower alkylene or lower alkylidene, and R is hydrogen or an aliphatic or araliphatic radical, or R'7 and R'g, together with X and the nitrogen atom linking R'g and X, form ur. unsubstituted or substituted mono- or di-azacycloalkyl, azoxacycloalkyl, azathiacycloalkyl, or an optionally oxidized tiacycloalkyl radical linked via a nitrogen atom, or a group of the formula -alk-SX-R'7 (Ilf), where R'7 is a group R. For the preparation of the compounds of the formula II, wherein one of the radicals R 'and R'2 is a group of the formula -alk-N (R'g) -X-R'7 (He; Rg = hydrogen), and the other is a group R5, it is also possible to react a compound of the formula IX: wherein the radicals R 'and R "are identical or different hydroxy protecting groups, one of the radicals Rla and R-> is a group Rg, and the other is lower alkanoyl, such as acetyl or especially formyl, with an amine of the formula HN (R'8) -X-R'7 under reducing conditions, for example in the presence of a light dimethyl hydride, such as an alkali metal borohydride The compounds of the formula II wherein one of the Rla radicals and R2a is a group R5, and the other is a group of the formula -CH (R '6) -alk-R7 (lia), wherein R7 is carboxy, and alk is preferably methylene, can be obtained, for example, by the reaction of an aldehyde of the formula IX wherein one of the radicals Rla and Ra is a group R < j, and the other is formium, in the presence of an etherate of boron trifluoride with a carbamate of lower alkyl and lower? -trialkyl-lower silylamino of the formula H-CH = CH-alk-Si (lower alkyl) 3, the group being rmilo in a group of the formula -CH (R'g) -alq-CH = CH2 (H'a), and in the intermediate that can be obtained in this way, oxidizing the terminal ethenyl group in the customary manner, for example by means of sodium iodate / ruthenium oxide. The aldehydes of the formula IX wherein one of the radicals Ra and R2a is a group R5, and the other is formyl, can be obtained starting from a halogen compound VIII, wherein one of the radicals R '". and R '"2 is halogen, such as bromine, and the other is a R5 group, by its reaction with a vinyl-lower trialkyl-stannane, such as vinyl tributyl-stannane, preferably in the presence of bis chloride. (triphenylphosphine) palladium (II) and lithium chloride, to form a corresponding compound of formula VIII wherein one of the radicals R '"j and R'" is vinyl, and the other is a group R5, and its oxidation, by example with ozone / oxygen, from -80 ° C to -40 ° C, and its subsequent reaction with triphenylphosphine. An alternative process for the preparation of compounds of formula IX, wherein Rla is formyl, is hydrogen or nitro, and Ra and R4 are hydrogen, comprises treating a compound of formula VIII, wherein R '"j is a group of the formula -alq-Y, where Yj is halogen, and R '", R3, and R4 are hydrogen, with 2-nitropropane in a lower alkanol, from 40 ° C to 100 ° C, and in the presence of a alkali metal lower alkanolate, for example in boiling sodium methanol / methanolate, and if desired, nitrate the resulting product, preferably by treatment with nitric acid, sulfuric acid, and trifluoroacetic acid anhydride in trifluoroacetic acid. The ketones of formula IX, wherein one of the radicals Rla and R2a is a group R5, and the other is lower alkanoyl, for example acetyl, can be obtained starting from halogen compound VIII, wherein one of the radicals R '"and R'" 2 is halogen, such as bromine, and the other is a group R5, in the presence of a palladium catalyst, such as bis (triphenylphosphine) palladium (II) chloride and lithium chloride, preferably in dimethyl formamide, with heating, with a lower 1-lower alkoxy-lower alkenyl-lower trialkyl-stannane, the corresponding compounds of the formula IX being obtained by acid work, wherein one of the radicals R a and R2a is lower alkanoyl, and the other is a group R5. The halogen compounds of the formula VIII, wherein one of the radicals R '"j and R'" 2 is a group of the formula -alq-Yj, and the other is a group R5, wherein Y is halogen, are used as starting materials also in a convenient process for the preparation of the compounds of the formula II, wherein one of the radicals R'j and R'2 is a group R5, and the other is a group of the formula alq-N (R'g) -X-R'7 (He), where R'7 is a radical R7"and R, 8 is hydrogen. According to that process, the halogen compound of the formula VIII is converted in the customary manner, for example, by its treatment with an alkali metal alkanolate, such as sodium methanolate, in the corresponding compound of the formula VIII, in wherein one of the radicals R '"and R'" is formyl, and that compound is further reacted under reducing conditions, for example in the presence of sodium borohydride, with a compound of the formula HN (R'8) - X-R'7 (HIVb). For the preparation of the compounds of the formula II, wherein one of the radicals R'j and R'2 is a group R5, and the other is a group of the formula -alq-N (R'g) -X- R'7 (He) wherein R'7 is a radical R7 other than hydrogen, X has an oxo group at position a, and is, for example, lower oxo-alkylene or carbonyl, and Rg is hydrogen, a compound of the formula VIII wherein one of the radicals R '"and R'" 2 is a group of the formula -alq-Yj, and the other is a group R5, wherein Yj is halogen, the halogen Yj becomes in azide in the customary manner, for example, by its reaction with an alkali metal azide or ammonium azide, such as sodium azide, preferably in dimethyl formamide, the azido group is reduced to amino in the customary manner, for example by treating it with triphenylphosphine in water, and the resulting compound of formula VIII, wherein one of the radicals R '"j and R'" 2 is a group of the formula -alq-Yj, and the other is a group or R5, wherein Yj is amino, is reacted with an acid of the formula HO-X-R7 (VIIle) or a reactive derivative thereof, such as an acid halide, for example, of the formula Hal-X- R7 (HIVe), an anhydride, for example of the formula R7-X-0-X-R7 (VIIIe2) / a sulfonic acid anhydride, such as methanesulfonic acid anhydride, an aromatic or araliphatic isocyanate, for example of the formula ONC-R7 (VIIIß3) 'an aliphatic dicarboxylic acid anhydride, for example succinic acid anhydride. Starting from the amine compounds of formula VIII, wherein one of the radicals R '"j and R'" 2 is a group of the formula -alq-Yj, and the other is a group Rg and Yj is amino, it is also possible to prepare compounds of the formula II wherein one of the radicals R'j and R 'is a group R5, and the other is a group of the formula -alk-N (R' g) -XR '7 (He ) wherein R'7 is esterified phosphonate R7, such as dialkyl lower phosphono, X is methylene, and Rg is hydrogen, by first treating it with formaldehyde, for example in ethanol with a solution of formalin, and the reaction of the trimeric intermediate resulting in the presence of a halosilane, such as an inferior-chlorosilane trialkyl, with a diester of phosphorous acid, such as a lower dialkyl phosphite. For the preparation of the compounds of the formula II, wherein one of the radicals R'j and R'2 is a gxupo R5, and the other is a group of the formula -alq-0-X-R'7 (He ), in a preparation method alternative to the previous one, in the same way the compounds of formula VIII are used as starting materials, wherein one of the radicals R '"j and R'" 2 is a group of the formula - alq-Yj, and the other is a group R5 and Yj is halogen, and the -alk-Yj group thereof is hydrolyzed in the corresponding group -alk-OH, and the reaction product is reacted with a compound of the formula Hal-X-R'7 (HIVg) wherein Hal is halogen and R'7 is a R7 group, protected carboxy, or protected carbamoyl. The compounds of formula II, wherein one of the radicals R'j and R'2 / especially R'j, is a group of the formula -alq-N (Rg) -XR '7 (He), where alq is lower alkylidene, Rg is hydrogen, and X and R'7 are as defined, and the other is a radical R5, can also be prepared by the reaction of a corresponding compound of formula VIII, wherein one of the radicals R '"j and R'" 2 is halogen, such as bromine, and the other is a group Rg, in the presence of a palladium catalyst, preferably in dimethyl formamide, with heating, with 1-lower alkoxy-lower alkenyl-lower trialkyl-stannane, preferably in the presence of a palladium catalyst, such as bis (triphenylphosphine) palladium (II) chloride and lithium chloride, obtaining, with an acid work, a corresponding compound of the formula VIII, wherein one of the radicals R '" j and R '"2 is lower alkanoyl, and the other is a group R5; that compound is condensed with a compound of the formula NX-R'-y, and in a resulting compound of the formula HIV, wherein one of the radicals R '"and R'" 2 is a group of the formula -alk '= NX-R'7, and the other is a group R5, where alq' is lower alkenylidene, the extracyclic double bond is reduced to a single bond in the customary manner, for example, by means of sodium borohydride. This variant of the process is especially suitable for the preparation of compounds of the formula II wherein one of the radicals R'j and '2' especially R'j, is a group of the formula -alq-N (R'g) - X-R'7 (He) wherein alk is ethylidene, X is lower alkylene or lower alkylidene or a direct bond, and R'g is hydrogen, and the other is a radical R5, said compounds of the formula HIV being reacted with 1-ethoxyvinyl-tributyl-stannane, to form the corresponding compounds of the formula HIV, wherein one of the radicals R '"j and R'" 2 is acetyl, and the other is a group R5. In an analogous manner, compounds of the formula II can also be obtained in which one of the radicals R 'and R'2, especially R'j, is a group of the formula -alq-N (R'g) -X- R'7 (He) or -alq-0-X-R'7 (le), alq is ethylene, and R'g is hydrogen, and R'7 and X are as defined, by the reaction of the halogen compound HIV defined above, wherein one of the radicals R '"and'" is halogen, such as bromine, and the other is an Rg group, with a vinyl-lower-trialkyl-stannane, such as vinyl-tributyl-stannane, preferably in the presence of bis (triphenylphosphine) palladium (II) chloride and lithium chloride, to form the corresponding compound of formula VIII, wherein one of the radicals R '"j and R'" 2 is vinyl, and the other is a group Rg; this compound is converted by customary boring and the subsequent oxidation to the corresponding compound of formula VIII, wherein one of the radicals R '"j and R'" 2 is hydroxyethyl, and the other is a group Rg, and if desired, the 2-hydroxyethyl group is converted to 2-aminoethyl by the reaction first with methanesulfonyl chloride, then with an alkali metal azide, and finally with triphenylphosphine, and if desired, the amino group is substituted by reduced amination, by a group of the formula -N (R '8) -XR' 7. Unless indicated otherwise, the above reactions of the compounds of the formula VIII are carried out in the customary manner, preferably in an inert organic solvent, such such as tetrahydrofuran, dioxane, or dimethyl formamide, or in a two phase system, such as benzene / water or toluene / water, if necessary in the presence of a basic condensation agent, such as a tertiary aliphatic amine, such as triethyl amine, or a tertiary aromatic nitrogen base, such as pyridine, an aliphatic or araliphatic quaternary ammonium salt, such as tetramethyl ammonium acid sulfate, or a metal base, such as an alkali metal hydroxide, a metal carbonate alkali, or an alkali metal amide, for example sodium or potassium hydroxide, sodium or potassium carbonate, or sodium or potassium amide, and also optionally other excipients, carbodiimide hydrochloride N- (3-dimethylaminopropyl) ) -N'-ethyl / 1-hydroxybenzotriazole, if necessary with heating, for example, on a temperature scale of about 25 ° C to 120 ° C, preferably 50 ° C to 120 ° C. The groups that can be removed to form a bond according to Process Variant b) are, for example, reactive esterified hydroxy groups, such as hydroxy groups esterified by a mineral acid or a sulfonic acid, especially halogen atoms, for example chlorine, bromine, or iodine, or hydroxy groups esterified by an aliphatic sulfonic acid, or unsubstituted or substituted aromatic, for example, lower alkane sulphonyloxy, such as methanesulfonyloxy, or unsubstituted or substituted benzenesulfonyloxy, such as benzenesul-fonyloxy, bromobenzenesulfonyloxy, or toluenesulfonyloxy, in the reaction of the compounds of the formula III, wherein Yj is a group HN (Rg) -, or hydroxy, with of-carbonyl compounds of the formula IV, wherein X has an oxo group in the position of in relation to Y2, also free or etherified hydroxy groups, such as hydroxy, lower alkoxy, benzyloxy, optionally nitrated phenyloxy, or groups of the formula -0-X-R'7, such as Y2 groups derived from starting from carboxylic acid anhydride or sulfonic acid anhydrides. The compounds of the formula IV containing these groups are, for example, carboxylic acids of the formula HOOC-X-R7 (IVa), wherein X is lower alkylene, lower alkenylene, lower alkylidene, carbonyl, lower aminoalkylidene, lower carbamoylalkylidene, or lower alkoxycarbonylalkylidene, carboxylic acid halides of the formula Hal-C (= 0) -X-R'7 wherein X is lower alkylene, lower alkylidene, carbonyl, or a carboxylic acid anhydride, the formula R'7-XC (= 0) -0-C (= 0) -X-R7 (IVc) wherein X is lower alkylene, lower alkylidene, or a bond, sulfonyl halides of the formula Hal-S ( 02) -X-R7 (IVd), sulfonic acid anhydrides of the formula R7-S (02) -0-S (02) -R7 (IVe), and also dicarboxylic acid anhydrides, such as succinic acid anhydride. The reaction of the compounds of formulas III and IV according to Process Variant b). it is carried out in the customary manner, preferably in an inert organic solvent, such as tetrahydrofuran, dioxane, or dimethyl formamide, or a two-phase system, such as benzene / water or toluene / water, if necessary in the presence of a basic condensation agent, such as tertiary aliphatic amine, such as triethyl amine, or a tertiary aromatic nitrogen base, such as pyridine, an aliphatic or araliphatic quaternary ammonium salt, such as tetramethyl ammonium acid sulfate, or a base of metal, such as an alkali metal hydroxide, an alkali metal carbonate, or an alkali metal amide, for example sodium or potassium hydroxide, sodium or potassium carbonate, or sodium or potassium amide, and also optionally other excipients, carbodiimide hydrochloride N- (3-dimethylaminopropyl) -N'-ethyl / 1-hydroxybenzotriazole, if necessary with heating, for example, on a temperature scale from about 25 ° C to 12 ° C 0 ° C, preferably 50 ° C to 120 ° C. In a preferred embodiment of the invention, for example, a compound of formula III wherein Yj is hydroxy, is reacted in the presence of a quaternary aliphatic ammonium salt, such as tetraethyl ammonium acid sulfate, in a two-system phases, such as benzene / water, with a compound of formula IV wherein Y 2 is halogen, such as bromine. In a further preferred embodiment of the invention, for example, a compound of formula III wherein Yj is amino, is reacted in the presence of a tertiary aliphatic amine, such as triethyl amine, carbodiimide hydrochloride N- (3 -dimethylaminopropyl) -N'-ethyl, and 1-hydroxybenzotria-zol, with a compound of the formula HOOC-X-R7 (IVa), wherein the group -C (0) -X- is lower-oxoalkylene,? α-oxo-lower alkylene, or α-aza-a-oxo-lower alkylene, or with a carboxylic acid anhydride of the formula R'7-XC (= 0) -0-C (= 0) - X-R7 (IVc) wherein X is lower alkylene, lower alkylidene, or a bond. The starting materials of the formula III can be prepared in a manner known per se, for example, by the halogenation of a compound of the formula VIII: in the side chain, with a halogenating agent that introduces halogen Yj, such as N-bromosuccinimide, in the presence of azoisobutyronitrile, to form a corresponding compound of formula VIII wherein one of the radicals R '"j and R'" is a group of the formula -alq-Yj, and the other is a group Rg, where Yj is halogen, especially bromine, and R 'and R "are hydroxy protecting groups, and removing the hydroxy protecting groups R1 and R", or if desired, convert the resulting compound of the formula VIII to one of the radicals R '"[and R'" is a group of the formula -alq-Yj, and the other is a group Rg, where Y is halogen, in the customary manner, for example by basic hydrolysis, for example, in the presence of potassium carbonate, in the corresponding compound of formula III wherein Yj is hydroxy, or by reaction with an alkali metal azide, such as sodium azide, in dimethyl formamide, and then with triphenylphosphine in tetrahyd ofurano, and in each case, the hydroxy protecting groups R 'and R "are removed in the corresponding compounds of the formula III wherein Yj is amino. The protected amino groups R'g in the compounds of the formula II, wherein one of the radicals R "and R" 2 is a group Rg, and the other is a group of the formula -alq-C (R'7) (R'6) -R'7 (Ha '), according to Process Variant c), are, for example, amino-protected by one of the amino protecting groups mentioned under Process Variant a), by for example, lower-amino-alkanoyl or lower-alkoxy-carbonylate ino. The protected carboxy groups R'7 are, for example, esterified carboxy groups, such as lower alkoxycarbonyl, or lower trialkyl-silyloxycarbonyl groups, and also unsubstituted or substituted phenyl-lower coxycarbonyl or phenyloxycarbonyl groups. In the acid treatment, the R '7 protected carboxy groups are hydrolyzed to carboxy, one of them is decarboxylated, and the amino protecting group R, 6' and when it is. present, the hydroxy protecting groups R 'and / or R "are removed.The starting materials for Process Variant c) can be prepared, for example, by the reaction of a compound of formula III, wherein one of the radicals R "jy R "2 is -alk-Yj and Y is reactive esterified hydroxy, such as halogen, or one of the sulfonyloxy groups mentioned, in the customary manner, with an aminomalonic acid derivative of the formula HC (R ') (R'7 ) -R'7 The compounds that can be obtained according to the process, can be converted in the customary manner into compounds other than formula I. For example, aliphatic, araliphatic, or cycloaliphatic radicals, such as lower alkyl, or acyl derived from aliphatic or araliphatic carboxylic acids, from aliphatic or araliphatic semi-esters, or from aliphatic, araliphatic, or aromatic semibasters of carbonic acid or aromatic sulfonic acid, or from phosphoric acid, or from of an ester of phosphonic acid, such as lower alkanoyl, lower alkane-sulfonyl, or the acyl radical of a lower alkane-, lower alkene-, or lower alkyne-dicarboxylic acid, for example lower alkyl fumaroyl, can be introduced in the customary manner, for example, by its reaction with a lower alkylating agent, such as a lower alkyl halide, or a reactive lower alkanoic acid derivative, such as lower alkanoic acid chloride or nitrile of lower alkanoic acid, lower alkane sulphonic acid anhydride or lower alkane sulphonic acid chloride, or a lower dialkyl ester of lower alkane-, lower alkene-, or lower alkydocarboxylic acid, for example a lower alkyl ester of fumaric acid, if necessary in the presence of a customary basic condensation agent. In particular, in the compounds of the formula I wherein one of the radicals Rj and R2 is a group of the formula, and Rg is hydrogen, a radical other than hydrogen can be introduced. In addition, in a compound of the formula I wherein one of the radicals Rj and R is a group of the formula Le, Id, or If, where X is a bond, and R7 and / or R8 are hydrogen, an atom of Hydrogen R7 and / or R8 can be replaced in the customary manner by a radical R7 and / or R different from hydrogen. In addition, compounds of formula I containing esterified or amidated carboxy groups can be hydrolyzed in the customary manner to form the corresponding carboxylic acids, and compounds of formula I containing free carboxy can be esterified or amidated from the customary way In addition, in the resulting compounds of formula I, cyano can be converted to tetrazolyl in the customary manner, for example by reaction with hydrazoic acid. The resulting salts can be converted into the free compounds in a manner known per se, for example, by treatment with a base, such as an alkali metal hydroxide, a metal carbonate, or an acid metal carbonate, or other salt-forming base mentioned at the outset, or with an acid, such as a mineral acid, for example with hydrochloric acid, or another salt-forming acid mentioned at the beginning. The resulting salts can be converted into different salts in a manner known per se; the acid addition salts, for example, by treatment with a suitable metal salt, such as a sodium, barium, or silver salt, of a different acid, in a suitable solvent in which an inorganic salt is insoluble. it is being formed, and consequently eliminated from the equilibrium of the reaction, and basic salts by the liberation of the free acid and conversion into a salt again. The compounds of formula I, including their salts, may also be obtained in the form of hydrates, or may include the solvent used for crystallization. In view of the close relationship between the novel compounds in free form and in the form of their salts, hereinafter and hereinafter, any reference to the free compounds and their salts, should be understood to also include the salts and corresponding free compounds, respectively, as appropriate and convenient. The resulting diastereoisomeric mixtures and mixtures of racemates can be separated into the pure diastereomers or racemates in a known manner, based on the physicochemical differences between the constituents, for example by chromatography and / or fractional crystallization.

The resulting racemates can also be resolved in the optical antipodes according to known methods, for example by recrystallization from an optically active solvent, with the aid of microorganisms, or by reaction of the diastereoisomeric mixture or the resulting racemate with a optically active auxiliary compound, for example, depending on acid, basic, or functionally modifiable groups present in the compounds of formula I, with an optically active acid, a base, or an optically active alcohol, to form mixtures of salts diastereoisomers or functional derivatives, such as esters, and their separation into the diastereoisomers from which the desired enantiomer can be released in the usual customary manner. The bases, acids, and alcohols suitable for this purpose are, for example, optically active alkaloid bases, such as strychnine, cinchonine, or brucine, or D- or L- (1-phenyl) -ethyl amine, 3 - pipecoline, ephedrine, amphetamine, and bases that can be obtained synthetically similar, optically active carboxylic or sulfonic acids, such as quinic acid or D- or L-tartaric acid, D- or L-di-o-toluyltartaric acid, D-acid or L-malic, D- or L-mandelic acid, or D- or L-camphorsulfonic acid, and optically active alcohols, such as borneol or D- or L- (l-phenyl) ethanol. The invention also relates to the process forms according to which a compound that can be obtained as an intermediate at any stage of the process is used as the starting material, and the remaining steps are performed, or a starting material is used in the form of a salt, or especially it is formed under the conditions of the reaction. The invention also relates to novel starting materials, which have been developed especially for the preparation of the compounds according to the invention, especially those starting materials that result in the compounds of the formula I described as preferred. at the beginning, to processes for their preparation, and to the use of them as intermediaries. This applies in particular to the compounds of the formula IX: wherein: The radicals R 'and R "are identical or different hydroxy protecting groups, one of the radicals R a and R a is a group R g, and the other is lower alkanoyl, such as especially formyl or acetyl, or a group of the formula -CH (R'g) -alk-R7 (Ha) -alk-CH (R'g) -R'7 (IIb), -alk-N (R'8) -X-R'7 (Hc ), -alq-N + (R'g) (R9) -XR »7 A '(IId), -alq-0-X-R'7 (IIe) or -alq-SX-R'7 (Illa), or -alq-Yj (Illa) endonde Y is hydroxy, reactive hydroxy esterified, mercapto, or a group of the formula -N (R'8) -H, R'7 is a group R7 other than hydrogen, or is protected carboxy or protected carbamoyl, and R'g is an Rg group or an amino protecting group, wherein R3, R4, R5, Rg, R7, Rg, alk and X are as defined for the compounds of the formula I, especially the preferred groups of compounds of the formula I, with the proviso that, in the compounds of the formula I wherein Rja is lower alkanoyl or a group of the formula He, He, or Illa, when R2a and R3 are each independently of the other fluorine, chlorine, bromine, methyl, ethyl, or trifluoromethyl, and R4 is hydrogen, the lower alkanoyl Rla is different from formyl, or the He group is different from a 5-membered mono-, di-, tri-, or tetra-azaheteroaryl radical which is linked by of a nitrogen atom, and which is optionally benzocondensate and / or substituted by alkyl having up to and including 6 carb atoms ono, or substituted in the position? by a group of the formula -N (Ra) -Rj, wherein Ra and Rj are each independently of the other hydrogen, alkyl, cycloalkyl, phenylalkyl, or pyridylalkyl, or together with the nitrogen atom which binds them , form a pyrrolidino, piperidino, piperazino, N'-lower alkyl-piperazino, morpholino, or azepino group, or the group He or Illa is different from hydroxymethyl, l-hydroxyethyl, and 1-hydroxypropyl, or the Illa group is different from halomethyl, 1-haloethyl, and 1-halopropyl, and their salts. The invention preferably relates to the compounds of the formula IX wherein: the radicals R 'and R "are identical or different hydroxy protecting groups, one of the radicals Rla and R2a is a group R5, and the other is lower alkanoyl , such as especially formyl or acetyl, or a group of the formula -alk-N (R'g) -X-R'7 (He), -alk-N + (R'g) (R9) -X-R ' 7 A '(IId), -alq-0-X-R'7 (He), -alq-SX-R'7 (Hf), or -alq-Yj (Illa), and is hydroxy, halogen, lower alkane sulphonyloxy, sulphonyloxy, or a group of the formula -N (R'8) -H, R'7 is a group R7, protected carboxy or protected carbamoyl, and R'8 is a group R8 or an amino protecting group, Ra is a group R5, R3 R4 # and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, cyano, or nitro, Rg is amino , R7 is carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl; C 1 -C 4 -carbonyl phenylalkoxy which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, such as methyl, C 1 -C 4 alkoxy, hydroxy, halogen having an atomic number of up to and including 35, and / or by trifluoromethyl; carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, hydroxy, halogen having an atomic number of up to and including 35, nitro, carboxy, alkoxy of 1 to 4 carbon atoms carbon-carbonyl, phenyl, phenyloxy, and / or trifluoromethyl; tetrazolyl or phosphono, R is hydrogen, or together with X and the nitrogen atom linking R8 and X, forms a radical of pyrrolidinylene, piperidinylene, or piperazinylene, alk is alkylene of 1 to 4 carbon atoms and X is carbonyl, alkylene from 1 to 4 carbon atoms, alkylidene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, or, with the group N (R8),? -aza-cü -oxo-alkylene of 3 to 5 carbon atoms, or? -aza-a-oxo-alkenylene of 3 to 5 carbon atoms, each linked via the carbon atom a, phenylalkylidene of 1 to 4 carbon atoms, such as 2-phenylethi-1idene, or in the formula le, together with R8 and the nitrogen atom linking R8 and X, forms a radical of pyrrolidinylene, piperidinylene or piperazinylene, and salts thereof. The invention preferably relates to the compounds of the formula IX wherein: the radicals R 'and R "are identical or different lower alkyl groups, Rla is a group of the formula (Illa), wherein Yj is hydroxy, halogen, or a group of the formula -N (R'8) -H wherein R'g is a group Rg, R2a is a group Rg, R3 R4 »and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, cyano or nitro, and alk is alkylene of 1 to 4 carbon atoms, and salts thereof The invention also relates to pharmaceutical compositions comprising the compounds according to the invention, or pharmaceutically acceptable salts thereof, as active ingredients, and processes for their preparation, The pharmaceutical compositions according to the invention, which comprise the compounds according to the invention, or pharmaceutically acceptable salts. of the same, are for enteral, such as oral, and also rectal, and parenteral, administration to (a) warm-blooded animals, the compositions comprising the pharmacological active ingredient alone or together with a pharmaceutically acceptable carrier. The daily dose of the active ingredient depends on the age and the individual condition, and on the mode of administration.

The novel pharmaceutical compositions comprise, example, from about 10 percent to about 80 percent, preferably from about 20 percent to about 60 percent active ingredient. The pharmaceutical compositions according to the invention enteral or parenteral administration are, example, those which are in unit dosage s, such as dragees, tablets, capsules, or suppositories, and also ampoules. They are prepared in a manner known per se, example, by means of conventional mixing, granulating, confectioning, dissolving, or lyophilizing processes. example, pharmaceutical compositions oral administration can be obtained by combining the active ingredient with solid carriers, optionally granulating a resultant mixture, and processing the mixture with the granules, if desired or necessary, after administration. addition of suitable excipients, to tablets or dragee cores. Suitable carriers are especially fillers, such as sugars, example lactose, sucrose, mannitol, or sorbitol; cellulose preparations and / or calcium phosphates, example calcium triphosphate or calcium acid phosphate, and also binders, such as starch pastes, using, example, corn starch, wheat starch, rice starch or potato starch, gelatin, tragacanth, methyl cellulose, and / or polyvinyl pyrrolidone, if desired disintegrants, such as the above-mentioned starches, and also carboxymethyl starch, cross-linked polyvinyl pyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. The excipients are especially flow agents, flow conditioners, and lubricants, example silicic acid, talc, stearic acid or salts thereof, such as magnesium or calcium stearate, and / or polyethylene glycol. Dragee cores are provided with suitable, optionally enteric coatings, using, among others, concentrated sugar solutions, which may contain, gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol, and / or titanium dioxide, or solutions of coating in suitable organic solvents or solvent mixtures, or, the preparation of enteric coatings, solutions of suitable cellulose preparations, such as acetyl cellulose phthalate or hydroxypropylmethyl cellulose phthalate. Dyes or pigments may be added to tablets or dragee coatings, example, identification purposes, or to indicate different doses of the active ingredient. Other pharmaceutical compositions that can be administered orally, are hard gelatin capsules, and also soft sealed capsules consisting of gelatin and a plasticizer, such as glycerol or sorbitol. Hard gelatine capsules may comprise the active ingredient in the of granules, example mixed with fillers, such as lactose, binders, such as starches and / or brighteners, such as talc or magnesium stearate, and if desired stabilizers. In soft capsules, the active ingredient is preferably dissolved or suspended in suitable liquids, such as fatty oils, paraffin oil, or liquid polyethylene glycols, it being possible in the same manner to add stabilizers. Suitable rectally administrable pharmaceutical compositions are, example, suppositories which consist of a combination of the active ingredient with a suppository base material. Suitable suppository base materials are, example, natural or synthetic triglycerides, paraffinic hydrocarbons, polyethylene glycols or higher alkanols. It is also possible to use rectal gelatin capsules, which comprise a combination of the active ingredient with a base material. Suitable base materials are, example, liquid triglycerides, polyethylene glycols, or paraffinic hydrocarbons. For parenteral administration, aqueous solutions of an active ingredient in a water-soluble form, for example in the form of a water-soluble salt, and also suspensions of the active ingredient, such as the corresponding oily suspensions for injection, are especially suitable. suitable solvents or lipophilic vehicles, such as fatty oils, for example sesame oil, or synthetic fatty acid esters, for example ethyl oleate, or triglycerides, or aqueous suspensions for injection comprising viscosity-increasing substances, for example, sodium carboxymethyl cellulose, sorbitol and / or dextran, and optionally also stabilizers. The dose of the active ingredient depends on the species of warm-blooded animal, age, and individual condition, and also on the mode of administration. In a normal case, the approximate daily dose for oral administration to a patient weighing approximately 75 kilograms is estimated to be from about 10 milligrams to about 500 milligrams. The following Examples serve to illustrate the invention; temperatures are given in degrees Celsius, and pressures in mbar.

Example 1; N- (7-bromo-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -glycine bromide 380 milligrams (0.921 mmol) of tertiary butyl ester - (7-bromo-2, 3 -dimetoxiquinoxalin-5-ylmethyl) -glycine are dissolved in 6 milliliters of a solution to about 25 percent hydrogen bromide in acetic acid, and the solution is stirred for 2 hours at 70 ° C. The mixture is cooled to 20 ° C, and diluted with diethyl ether. The solid is filtered and washed with diethyl ether. After drying under a high vacuum, the title compound is obtained in the form of a white powder.

^ -RMN (250 MHz, SODM-Dg + 5% D20) d = 7.42, 7.37 (2d, 2H), 4.32 (s, 2H), 3.91 (s, 2H) MS: 328.2 (M + H) +. p.f. = 281 ° C (decomposition).

The starting material can be prepared, for example, as follows: to 5-bromo-2,3-diamino-toluene A solution of 15 grams (64.9 millimoles) of 4-bromo-2-methyl-6-nitro-aniline in 300 milliliters of ethanol, is hydrogenated in the presence of 1.5 grams of nickel from Raney for 4 hours at approximately 27 ° C. Then the reaction mixture is filtered and concentrated by evaporation. The title compound is obtained in the form of a chestnut oil.

^ -NMR (250 MHz, CDCl 3) d = 6.76, 6.73 (2d, 2H), 3.22 (s, 2NH2), 2.14 (S, Me). b) 7-bromo-5-methyl-1,4-dihydroquinoxaline-2,3-dione 13.05 grams (64.9 millimoles) of 5-bromo-2,3-diamino-toluene, and 6.42 grams (1.1 equivalents) of oxalic acid are stirred under reflux for 16 hours in 2N hydrochloric acid. The mixture is cooled, and the solid is filtered and washed with water. The title compound is obtained in the form of a chestnut solid.

* H-NMR (250 MHz, SODM) d = 11.98, 11.32 (2s, 2NH), 7.13 (S, 2H), 2.33 (S, Me). c) 7-bromo-2,3-dichloro-5-methyl-quinoxaline 17 grams (66.6 millimoles) of 7-bromo-5-methyl-1,4-dihydroquinoxaline-2,3-dione are stirred in 80 milliliters of oxychloride of phosphorous for 5 hours at reflux, and for 40 hours at 20 ° C. The mixture is concentrated by evaporation, and dried under a high vacuum. A saturated solution of potassium carbonate is carefully added to the residue, and the solid is filtered and washed with water. The title compound is obtained in the form of a chestnut solid.

H-NMR (250 MHz, SODM) d = 8.16, 7.99 (2d, 2H), 2.63 (s, Me) dj_ 7-bromo-5-methyl-2,3-dimethoxyquinolaline 2.97 grams (129.5 millimoles) of sodium are dissolved in 100 milliliters of methanol. The solution is added to 18.9 grams (64.7 mmol) of 7-bromo-5-methyl-2, 3-dichloroquinoxaline in 60 milliliters of methanol, and the mixture is refluxed for 20 hours. The mixture is cooled, and 15 milliliters of water are added. The solid is filtered and washed with methanol and water. The title compound is obtained in the form of a beige solid.

H-NMR (250 MHz, SODM) d = 7.73, 7.58 (2d, 2H), 4.05, 4.03 (2s, 2Me), 2.58 (s, Me). 7-bromo-5-bromomethyl-2, 3-dimethoxy-quinhoxaline 15 grams (53 mmol) of 7-bromo-5-methyl-2, 3-dimethoxy-quinotoxaline, 9.9 grams (1.05 equivalents) of N-bromo-succinimide, and 0.87 grams (0.1 equivalents) of azoisobutyronitrile, dissolved in 100 milliliters of carbon tetrachloride, and the solution is stirred at reflux for 24 hours. The solid is filtered, and the filtrate is diluted with dichloromethane, then washed once with each of water and brine. The organic phase is dried over magnesium sulfate and concentrated by evaporation. The residue is recrystallized from ethyl acetate and hexane. The title compound is obtained in the form of light orange crystals.

H-NMR (250 MHz, CDC13) d = 7.90, 7.68 (2d, 2H), 4.95 (s, 2H), 4.20, 4.13 (2s, 2Me). f) Tertiary butyl ester of N- (7-bromo-2,3-dimethoxy-quinanoal-5-ylmethyl) -glycine 850 milligrams (2.35 millimoles) of 7-bromo-5-bromo-methyl-2, 3-dimethoxy-quinotoxaline, 0.982 milliliters of triethyl amine, and 719 milligrams of glycine tertiary butyl ester hydrochloride, are dissolved in 15 milliliters of acetonitrile, and the solution is stirred at reflux for 18 hours. The mixture is concentrated by evaporation, and the residue is dissolved in diethyl ether, and washed with an aqueous 5% sodium carbonate solution, and brine. The organic phases are combined, dried over magnesium sulfate, and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate and petroleum ether (1: 2). The title compound is obtained in the form of a yellow oil.

H-NMR (250 MHz, CDCl 3) d = 7.88, 7.57 (2d, 2H), 4.20 (s, 2H), 4.15, 4.12 (2s, 2Me), 3.32 (s, 2H), 1.42 (s, 9H) .

Example 2; The following compounds are also prepared in a manner analogous to that described in Example 1: N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahi-droquinoxalin-5-ylmethyl) -hydrochloride ß-alanine, pf = 271 ° C (decomposition); N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -glutamic acid bromide, m.p. = 220 ° C (decomposition); N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroxy-5-ylmethyl) - (L) -phenylalanine bromide, p.f. = 249 ° C (decomposition); O-N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -lysine dibromhydrate, m.p. = 256 ° C (decomposition), - N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-2-carboxylic acid ethyl ester bromide. pf. = 240 ° C (decomposition); N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid ethyl bromide p.f. = > 250 ° C; N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid ethyl bromide p.f. = > 260 ° C; Example 3; The following compounds are prepared in a manner analogous to that described in Example 1, but starting from 7-bromo-5-bromomethyl-2,3-dimethoxy-8-nitroquinoxaline, instead of 7-bromo-5-bromomethyl -2, 3-dimethoxyquinolutin: 7-bromo-5- (5-nitro-benzimidazol-l-ylmethyl) -1,4-dihydro-quinoxalin-2,3-dione bromide, mp = 246 ° C (decomposition), - 7-Bromo-5- (6-nitro-benzimidazol-1-ylmethyl) -1,4-dihydro-quinoxalin-2,3-dione Bromhydrate, m.p. = 278 ° C (decomposition); N- (7-bromo-2,3-dioxo-8-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-dimethylaminopiperidine dibromhydrate, m.p. = 209 ° C (decomposition); N- (7-bromo-2,3-dioxo-8-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-tetrahydroquinoline, p.f. = 213 ° C (decomposition), - N- (7-bromo-2,3-dioxo-8-nitro-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -jS-alanine bromide, m.p. = 254 ° C (decomposition), - QÍ-N- (7-bromo-2,3-dioxo-8-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -lysine hydrobromide. , pf = 180 ° C (decomposition); N- (7-bromo-2,3-dioxo-8-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -phenylalanine Bromhydrate, m.p. = 218 ° C (decomposition), - N- (7-Bromo-2,3-dioxo-8-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -glycine Bromhydrate, m.p. = 238 ° C (decomposition), - N- (7-bromo-2,3-dioxo-8-nitro-1,2,4,5-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ethyl ester hydrobromide. -carboxylic, pf = 260 ° C (decomposition); The starting material can be prepared, for example, as follows: a) 7-bromo-5-bromomethyl-2,3-dimethoxy-8-nitro-quinoxaline 20 milliliters of sulfuric acid are cooled to 0 ° C, and then 5 grams (13.8 millimoles) of 7-bromo-5-bromomethyl-2, 3-dimethoxy-quinotoxaline. After another 15 minutes, 1.46 grams (1.05 equivalents) of potassium nitrate are added, and the mixture is stirred for 15 hours at 20 ° C. The mixture is poured onto ice, and the solid is filtered and washed with water. The title compound is obtained in the form of a beige solid.

^ -RMN (250 MHz, SODM-Dg) d = 8.14 (s, H), 5.09 (s, 2H), 4. 12, 3.99 (2s, 2Me).

Example 4; The following compounds are also prepared in a manner analogous to that described in Example 1, but starting from 5-bromomethyl-2,3-dimethoxy-7-nitro-quinoxaline instead of 7-bromo-5-bromomethyl-2. , 3-dimethoxyquinoline: N- (2, 3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid ethyl ester bromide, mp. 287 ° C (decomposition); N- (2,3-dioxo-7-nitro-l, 2, 3,4-tetrahi-droquinoxalin-5-ylmethyl) -0-alanine bromide, m.p. 241 ° C (decomposition); A-N- (2, 3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) - (D) -lysine dibromhydrate, m.p. 185 ° C (decomposition), - N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -glycine Bromhydrate, m.p. 271 ° C (decomposition); N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -glutamic acid bromide, m.p. 143 ° C (decomposition), - N- (2,3-dioxo-7-nitro-l, 2, 3,4-tetrahi-droquinoxalin-5-ylmethyl) - (L) -phenylalanine Bromhydrate, m.p. 204 ° C (decomposition), - a-N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -lysine dibromhydrate, m.p. 150 ° C (decomposition), - The starting material, 5-bromomethyl-2, 3-dimethoxy-7-nitro-quinoxaline, can be prepared, for example, as follows: -Bromomethyl-2,3-dimethoxy-quinotoxaline The title compound may be prepared in a manner analogous to that described in Examples 1, 1, 1, and 1, starting from 5-methyl-2,3-l, 2, 3, 4-tetrahydroquinoxaline (CAS registry number 61875-33-0).

Bl 5-bromomethyl-2,3-dimethoxy-7-nitro-quinoxaline 25 milliliters of sulfuric acid are cooled to 0 ° C, and then 9.5 grams (33.55 mmol) of 5-bromomethyl-2,3-dimethoxy-quinotoxaline are added. After a further 10 minutes, 3.39 milliliters (one equivalent) of isopropyl nitrate are added, and the mixture is stirred at 0 ° C for 1 hour. The mixture is poured onto ice, and the solid is filtered and washed with water. The title compound is obtained in the form of a beige solid.

^ -RMN (250 MHz, SODM-Dg) d 8.62, 8.40 (2d, 2H), 5.02 (S, 2H), 4.27, 4.19 (2s, 2Me).

-Bromomethyl-2,3-dimethoxy-7-nitro-quinoxaline can also be prepared as follows: a2) 5-methyl-7-nitro-quinoxalin-2, 3-dione A mixture of 9.3 grams (55.63 mmol) of 2,3-diamino-5-nitro-toluene and 14 grams of oxalic acid in 93 milliliters of 6N HCl , it is refluxed for 30 minutes, and then it is stirred at room temperature overnight until the reaction is complete. The suspension is filtered and then washed with water, recovered in 250 milliliters of 2N NaOH, and heated to reflux until a homogeneous solution is formed. After cooling, the mixture is acidified to a pH of 3, and the resultant 5-methyl-7-nitro-quinoxalin-2,3-dione is filtered. b2) 2, 3-dichloro-5-methyl-7-nitro-quinoxaline 62 milliliters of P0C13 are added to the 5-methyl-7-nitro-quinoxalin-2,3-dione obtained according to a2), and the mixture heat to reflux for 18 hours. Excess POCI3 is removed under reduced pressure. The residue is neutralized with a 10 percent aqueous sodium carbonate solution, filtered, and dried. c2) 2,3-dimethoxy-5-methyl-7-nitro-quinoxaline The crude 2,3-dichloro-5-methyl-7-nitro-quinoxaline obtained according to A) is recovered in a solution of 1.24 grams (27 millimoles) ) of sodium in 140 milliliters of methanol, and heated to the boiling point for 4 hours. After cooling, the mixture is concentrated using a rotary evaporator, neutralized with 2N HCl, extracted with ethyl acetate, dried over sodium sulfate, filtered and concentrated by rotary evaporation. Filtration over silica gel using methylene chloride as eluent afforded the title compound in the form of yellowish crystals, m.p .: 167-168 ° C Thin Layer Chromatography: hexane / ethyl acetate 9/1: Rf = 0.40. d2) 5-bromomethyl-2,3-dimethoxy-7-nitro-quinoxaline A suspension of 0.249 grams (1.0 millimoles) of 2,3-dimethoxy-5-methyl-7-nitro-quinoxaline, 0.178 grams (1 millimole) of N- bromosuccinimide, and 0.016 grams (0.1 millimoles) of azoisobutyronitrile in 3 milliliters of CC14, is heated at reflux for 20 hours. The reaction mixture is washed with water and brine, and concentrated using a rotary evaporator. Crystallization from ethyl acetate yields the title compound. Thin Layer Chromatography: hexane / ethyl acetate, 6/1: Rf = 0.63, ^ -RM (CDCI3): d 8.64 (d, J = 3, 1H), 8.41 (d, J = 3, 1H), 5.02 (s, 2H), 4.27 (s, 3H), 4.20 (s, 3H).

Example 5: The following compounds are also prepared in a manner analogous to that described in Example 1, but starting from 6-methyl-7-nitro-l, 4-dihydroquinoxalin-2,3-dione, instead of 7 -bromo-5-methyl-l, 4-dihydroquinoxalin-2, 3-dione: N- (2,3-dioxo-7-nitro-l, 2, 3, 4 -tetrahi-droquinoxalin-6-ylmethyl) -hydrochloride -β-alanine, pf = 305 ° C (decomposition); A-N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-6-ylmethyl) - (L) -lysine dibromhydrate, m.p. = 230 ° C (decomposition); N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydro-6-ylmethyl) - (L) -phenylalanine bromide, p.f. = 228 ° C (decomposition); N- (2,3-dioxo-7-nitro-1,2,3-tetrahydroquinoxalin-6-ylmethyl) - (L) -glutamic acid bromide, m.p. = 235C (decomposition); N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydro-5-ylmethyl) -glycine bromide, p.f. = 270 ° C (decomposition); N- (2,3-dioxo-7-nitro-1,2,3-tetrahydroquinoxalin-6-ylmethyl) -piperidine-4-carboxylic acid hydrochloride, m.p. = 255 ° C (decomposition), - N- (2,3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-6-ylmethyl) -piperidine-4-carboxylic acid ethyl ester, m.p. = 288-289 ° C (decomposition); Example 6: AcidoN- (7-bromo-2,3-dioxo-1.2,3.4-tetrahidrosui- noxalin-5-ylmethyl) -piperidine-4-carboxylic acid 1.28 grams (3.12 mmol) of hydrobromide acid ethyl ester N- ( 7-bromo-2, 3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid (Example 2), is stirred at 20 ° C for 16 hours in 12 milliliters of a solution of 2N sodium hydroxide. The mixture is acidified with 2N hydrochloric acid, and the resulting solid is filtered and washed with water and diethyl ether. The title compound is obtained in the form of a white solid.

JH-NMR (250 MHz, SODM-Dg + 10% D20) d 7.45, 7.38 (2d, 2H), 4.46 (s, 2H), 3.4 (m, 2H), 3.0 (m, 2H), 2.05 (m, 2H), 1.9 (m, H), 1.7 (m, H). MS: 381 (M1). p.f. > 300 ° C.

Example 7: N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin - * = - i ~ »™» »tyl) -piperidine-4-carboxylic acid amide 382 milligrams (1 millimole) of acid N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-carboxylic acid (Example 6), 186 milligrams (2 equivalents) of aniline, 480 milligrams ( 2.5 equivalents) carbodi-imide hydrochloride N- (3-dimethylaminopropyl) -N' -etílica, and 384 mg (2.5 equivalents) 1-hydroxybenzotriazole, stirred at 20 ° C in formamide dimetílica dry for 48 hours. The mixture is poured into water, and extracted three times with 100 milliliters of dichloromethane. The organic phases are combined and concentrated by evaporation. The residue is dissolved in 30 milliliters of dichloromethane, and the solution is stirred for 30 minutes. The white solid is filtered, washed with dichloromethane, and dried.

? H-RM (250 MHz, SODM-Dg) 12.0, 11.8 (2s, 2NH), 9.9 (s, NH), 7.6 (d, 2H), 7.30-7.15 (m, 4H), 7.01 (t, H) , 3.77 (s, 2H), 2. 38 (m, 1H), 2.05 (m, 2H), 1.85-1.60 (m, 4H). MS: 456 (M1). P.f. > 250 ° C.

Example 8: The following compounds are also prepared in a manner analogous to that described in Examples 6 and 7: N- (7-bromo-2,3-dioxo-8-nitro-1,2,3-chlorohydrate, 4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-carboxylic acid, mp = 278 ° C (decomposition). N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-carboxylic acid hydrochloride, m.p. = 294 ° C (decomposition). N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-2-carboxylic acid hydrochloride, m.p. = 225-240 ° C (decomposition). N- (7-Bromo-2,3-dioxo-1,2,3,4-tetrahydroquin-xalin-5-ylmethyl) -piperidine-3-carboxylic acid, m.p. > 250 ° C. N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid hydride, p.f. > 260 ° C. Phenylic acid N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-2-carboxylic acid.

Example 9: 5-aminomethyl-7-bromo-2,3-dioxo-1,2,3,4-tetrahydrosuinoxaline hydrochloride 150 milligrams (0.5 millimoles) of 5-aminomethyl-7-bromo-2,3-dimethoxy-1 , 2, 3, 4-tetrahydroquinoxaline, are dissolved in 3 milliliters of acetic acid and 3 milliliters of a solution of 48% hydrogen bromide with acetic acid. After 18 hours at 20 ° C, the mixture is diluted with diethyl ether, and the solid is filtered and washed with diethyl ether.

XH-NMR (250 MHz, SODM-D d 12-15, 11.75 (2s, 2NH), 8.10 (br, NH2), 7.42, 7.35 (2d, 2H), 4.28, 4.20 (m, 2H) .Pf > . 250 ° C The starting material can be prepared, for example, as follows: a) 5 -azidometil-7-bromo-2.3-dimethoxy-1.2.3.4-droquinoxalina tetrahi 743 mg (2 equivalents) of azide are added sodium at 20 ° C, at 2.07 grams (5.72 millimoles) of 7-bromo-5-bromomethyl-2,3-dimethoxy-quinotoxaline in 25 milliliters of dimethyl formamide. After 3 hours, the mixture is poured into water, extracted with diethyl ether, washed with water and brine, and dried with magnesium sulfate. The solvent is concentrated by evaporation.

H-NMR (250 MHz, CDCl 3) d 7.92, 7.58 (2d, 2H), 4.80 (s, 2H), 4.18, 4.13 (2s, 2Me). b) 5-Aminomethyl-7-bromo-2,3-dimethoxy-l.2.3, 4-tetrahi-droquinoxaline 4.47 grams (13.8 millimoles) of 5-azidomethyl-7-bromo-2,3-dimethoxy-1,2,4-tetrahydroquinoxaline are dissolved in 35 milliliters of tetrahydrofuran, and 3.98 grams are added (1.1 equivalents) of triphenylphosphine. The mixture is stirred at 20 ° C for 4 hours. 746 milligrams of water are added, and the mixture is stirred for another three hours. The solid is filtered, and the filtrate is extracted with ethyl acetate and a sodium carbonate solution. The organic phases are combined, washed with brine, dried over magnesium sulfate, and concentrated by evaporation. The residue is chromatographed on silica gel with ethyl acetate / petroleum ether, 1: 1.

H-NMR (250 MHz, CDCl 3) d 7.85, 7.53 (2d, 2H), 4.22 (s, 2H), 4.12 (S, 2Me).

Example 10: Ethyl 3- [(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -acrylic acid ethyl ester 351 milligrams (1 millimole) of 5-aminome-tyl-7-bromo-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxaline hydrochloride, 217 milligrams (1.5 equivalents) of fumaric acid monoethyl ester, 0.210 milliliters of triethyl amine, 383 milligrams (2 equivalents) of N- (3-dimethylaminopropyl) -N'-ethyl carbodiimide hydrochloride, and 270 milligrams (2 equivalents) of 1-hydroxybenzotriazole, are stirred at 20 ° C in formamide dimethyl is dry for 18 hours. The mixture is poured into 700 milliliters of water and 3 milliliters of IN hydrochloric acid, and stirred for 15 minutes. The solid is filtered, washed with water, and dried.

^ -RMN (250 MHz, SODM-Dg) d 12.0, 11.4 (2s, 2NH), 9.18 (t, NH), 7.23, 7.18 (2d, 2H), 7.05, 6.64 (2d, 2H), 4.50 (d, 2H), 4.18 (q, 2H), 1.24 (t, 3H), MS: 395 (M + ). P.f. = 288-293 ° C Example 11: 3- F (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroouinoxalin-5-ylmethyl) -carbamoi-acrylic acid 144 milligrams (0.36 millimoles) of 3- [(7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -acrylic acid ethyl ester and 76 milligrams of lithium hydroxide hydrate are dissolve in 18 milliliters of tetrahydrofuran / water, 2: 1, and the solution is stirred for 18 hours. 50 milliliters of water are added, the tetrahydrofuran is concentrated by evaporation, and the solution is acidified with IN hydrochloric acid. The solid is filtered, washed with water, and dried. l-NMR (250 MHz, SODM-Dg) d 12.9 (COOH), 12.05, 11.38 (2s, 2NH), 9.17 (t, NH), 7.24, 7.18 (2d, 2H), 6.98, 6.60 (2d, 2H) , 4.50 (d, 2H). MS: 367 (M +). P.f. > 250 ° C.

Example 12: Phenolic amide of 3- [(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethi) -carbamoyl-acrylic acid The title compound is prepared in a manner analogous to that described in Example 7, but starting from 3- [(7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -acrylic acid, instead of hydrobromide N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid. P.f. > 250 ° C.

Example 13: The following compounds are also prepared in a manner analogous to that described in Examples 9 to 12: Amide N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquin-xalin-5) -ylmethyl) -2- (3-phenyl-ureido) -acetic, mp > 300 ° C; Tertiary butyl ester of acid. { [(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -methyl} -carbámico p.f. 238-242 ° C (decomposition); Acid benzyl ester. { [(7-bromo-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -methyl} -carbámico p.f. 225-230 ° C (decomposition); Example 14: 7-Bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid 1.14 grams (3.81 mmol) of 7-bromo-5-hydroxymethyl-2,3-dimethoxyquinolutin, 840 milliliters (1.5 equivalents) of tertiary butyl bromoacetic acid ester, and 65 milligrams (0.05 equivalents) of tetrabutyl ammonium acid sulfate, are stirred in 40 milliliters of benzene and 4 milliliters of a 50 percent sodium hydroxide solution for 18 hours. 100 milliliters of water and 100 milliliters of diethyl ether are added to the mixture, the organic phase is separated, and the aqueous phase is extracted once more with diethyl ether. The organic phases are combined, washed with brine, dried over magnesium sulfate, and concentrated by evaporation. The residue is dissolved in 30 milliliters of acetic acid, and 10 milliliters of 2N hydrochloric acid, heated to reflux for 2 hours, and cooled to 20 ° C. 20 milliliters of water are added, and the solid is filtered, washed with water, and dried.

* H-NMR (250 MHz, SODM-Dg) 12.0, 11.45 (2s, 2NH), 7.30, 7. 28 (2d, 2H), 4.62 (s, 2H), 4.19 (s, 2H). MS: 328 (M +). P.f. > 250 ° C.

The starting material can be prepared, for example, as follows: a) 7-bromo-5-hydroxymethyl-2,3-dimethoxy-quinhoxaline 11.5 grams (31.85 millimoles) of 7-bromo-5-bromomethyl-2,3-dimethoxy-quinotoxaline, are suspended at 20 ° C, in 100 milliliters of dioxane. Then 16.4 grams (164 millimoles) of calcium carbonate in 100 milliliters of water are added, and the mixture is heated at reflux for 24 hours. The dioxane is concentrated by evaporation, and 300 milliliters of dichloromethane are added. The salt is filtered, the organic phase is washed with brine and concentrated by evaporation, and the residue is chromatographed on silica gel with ethyl acetate and hexane (1: 1).

^ -RMN (250 MHz, SODM-Dg) 7.78, 7.68 (2d, 2H), 5.40 (t, OH), 4.96 (d, 2H), 4.02 (S, 2Me). g-< Mw go > 15 • 7-bromo-2,3-dioxo-5-hydroxymethyl-1,2, 3,4-tetrahydroquinoxaline 450 milligrams (1.5 millimoles) of 7-bromo-5-hydroxy-methyl-2,3-dimethoxy-quinotoxaline, are dissolved in 30 milliliters of acetic acid and 10 milliliters of 2N hydrochloric acid, and the solution is heated at reflux for 2 hours, and cooled to ° C. The solid is filtered, washed with water, and dried.

* H-NMR (250 MHz, SODM-Dg) 7.28, 7.19 (2d, 2H), 5.5 (br.OH), 4.62 (S, 2H). MS: 270 (M +). P.f. > 250 ° C.

Example 16: 7-Bromo-2,3-dioxo-l.2.3.4-tetrahydroquinoxalin-5-ylmethoxyacetic acid ethyl ester 450 milligrams (1.37 millimoles) of 7-bromo-2,3-dioxo-1,2 acid, 3-tetrahydroquinoxalin-5-ylmethoxyacetic acid is suspended in 20 milliliters of ethanol. 0.5 milliliters of sulfuric acid are added, and the mixture is heated under reflux, under nitrogen, for 2 hours. After cooling to 20 ° C, 80 milliliters of diethyl ether are added, and the solid is filtered, washed with diethyl ether and dried.

^ -RN (250 MHz, SODM-Dg) 12.0, 11.1 (2s, 2NH), 7.28, 7.26 (2d, 2H), 4.63 (s, 2H), 4.23 (s, 2H), 4.20 (q, 2H), 1.22 (t, 3H), MS: 356 (M +). P.f. = 250-252 ° C g- om ip 171 Amide (7-Bromo-2,3-dioxo-1.2.3.4-tetrahydroquinoxalin-5-ylmethoxy) -N-phenylacetic acid The title compound is prepared in a manner analogous to that described in Example 7, but starting from 7-bromo-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid, instead of N- (7-bromo-2) hydrobromide. 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid. P.f. > 250 ° C. ta-j «» w? i tq «7-Bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylsulfanylacetic acid ethyl ester 1.5 milliliters (4 millimoles) of a 21 percent solution of sodium ethanolate in ethanol are diluted with 10 milliliters of ethanol under nitrogen. 601 milligrams (5 millimoles) of thioglycolic acid ethyl ester are added at 0 ° C, and the mixture is heated to 20 ° C. After one hour, 1.09 grams (3 millimoles) of 7-bromo-bromomethyl-2, 3-dimethoxy-quinoxaline, 10 milliliters of ethanol, and 10 milliliters of tetrahydrofuran are added. The mixture is stirred for 18 hours, acidified with 2 milliliters of 2N hydrochloric acid and concentrated by evaporation. The residue is extracted with ethyl acetate and 0.1N hydrochloric acid, and the combined organic phases are washed with a 10 percent sodium carbonate solution and brine, dried over magnesium sulfate and concentrated by evaporation. The residue is dissolved in 20 milliliters of a 120 (FAB): 356 (M + H +). P.f. > 280 ° C.

The starting material can be prepared, for example, as follows: a) 2-amino- (7-bromo-2,3-dimethoxy-quinotoxal-5-yl) -propionic acid ethyl ester hemi-oxalate 2.49 grams (18 mmol) of potassium carbonate, and 1.6 grams (6 millimoles) of N-benzhydrylidene glycine ethyl ester are added at room temperature under nitrogen to a suspension of 1.81 grams (5 millimoles) of 7-bromo-bromomethyl-2,3-dimethoxyquinolaline and 193 milligrams (0.6 equivalents) of normal tetrabutyl ammonium bromide in 10 milliliters of acetonitrile. The reaction mixture is stirred under reflux for 20 hours, and then cooled to room temperature. The solid is filtered and washed with acetonitrile, the solvent is concentrated by evaporation, and the residue is dissolved with 1.35 grams (15 millimoles) of oxalic acid in 25 milliliters of acetone and 1 milliliter of water. The solution is stirred at room temperature for 18 hours, and the solid is filtered, washed with acetone, suspended in 100 milliliters of water and stirred for 10 minutes. The solid is filtered again, washed with water and acetone and dried. ^ -RM (S0DM-D6) d = 7.87, 7.58 (2d, 2H), 4.33 (t, 1H), 4.08, 4.03 (2s, 2Me), 3.98 (q, 2H), 3.61, 3.47 (2dd, 2H) 0.94 (t, 3H). 121 g-jompin 22; 2-amino-3- (7-bromo-2) hydrochloride, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) -propionic 368 milligrams (5 equivalents) of lithium hydroxide hydrate are added to 767 milligrams (1.75 millimoles) of ethyl ester hydrobromide 2 -amino-3- (7-bromo-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-yl) -propionic in 60 milliliters of tetrahydrofuran / water (2: 1). The reaction mixture is stirred at room temperature for 72 hours. The tetrahydrofuran is concentrated by evaporation, and the solution is acidified with IN hydrochloric acid. The solid is filtered, washed with water and dried. ^ -RMN (D20 + NaOD) d = 6.88, 6.66 (2d, 2H), 3.19, 2.92, 2.45 (3dd, 3H); MS (FD): 327 (M +). P.f. > 250 ° C.

Tüj «» tn in 23 »Ethyl ester of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethi-** 1fin-i 254 milligrams (0.79 mmol) of ethyl ester of N-acid (7-Bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) -oxamic acid are dissolved in 6 milliliters of a solution of about 25 percent hydrogen bromide in acetic acid, and the solution is stirred at room temperature for 16 hours. The mixture is diluted with diethyl ether, and the solid is filtered and washed with diethyl ether.After drying under a high vacuum, the title compound is obtained in the form of a beige solid.

(FAB): 356 (M + H +). P.f. > 280 ° C.

The starting material can be prepared, for example, as follows: a) 2-amino- (7-bromo-2,3-dimethoxy-quinotoxal-5-yl) -propionic acid ethyl ester hemi-oxalate 2.49 grams (18 mmol) of potassium carbonate, and 1.6 grams (6 millimoles) of N-benzhydrylidene glycine ethyl ester are added at room temperature under nitrogen to a suspension of 1.81 grams (5 millimoles) of 7-bromo-bromomethyl-2,3-dimethoxyquinolaline and 193 milligrams (0.6 equivalents) of normal tetrabutyl ammonium bromide in 10 milliliters of acetonitrile. The reaction mixture is stirred under reflux for 20 hours, and then cooled to room temperature. The solid is filtered and washed with acetonitrile, the solvent is concentrated by evaporation, and the residue is dissolved with 1.35 grams (15 millimoles) of oxalic acid in 25 milliliters of acetone and 1 milliliter of water. The solution is stirred at room temperature for 18 hours, and the solid is filtered, washed with acetone, suspended in 100 milliliters of water and stirred for 10 minutes. The solid is filtered again, washed with water and acetone and dried. i-NMR (S0DM-D6) d = 7.87, 7.58 (2d, 2H), 4.33 (t, 1H), 4.08, 4.03 (2s, 2Me), 3.98 (q, 2H), 3.61, 3.47 (2dd, 2H) 0.94 (t, 3H).

Example 22: 2-Amino-3- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) -propionic acid hydrochloride 368 milligrams (5 equivalents) of lithium hydroxide hydrate are added at 767 milligrams (1.75 millimoles) of 2-amino-3- (7-bromo-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-yl) -propionic acid ethyl ester hydrobromide in 60 milliliters of tetrahydrofuran / water (2: 1). The reaction mixture is stirred at room temperature for 72 hours. The tetrahydrofuran is concentrated by evaporation, and the solution is acidified with IN hydrochloric acid. The solid is filtered, washed with water and dried. ^ -NMR (D20 + NaOD) d = 6.88, 6.66 (2d, 2H), 3.19, 2.92, 2.45 (3dd, 3H); MS (FD): 327 (M +). P.f. > 250 ° C.

B? «Am io 23; Ethyl ester of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - ** 1μm 9r > 254 milligrams (0.79 millimoles) of N- (7-bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) -oxamic acid ethyl ester are dissolved in 6 milliliters of a solution at about 25 percent hydrogen bromide in acid acetic acid, and the solution is stirred at room temperature for 16 hours. The mixture is diluted with diethyl ether, and the solid is filtered and washed with diethyl ether. After drying under a high vacuum, the title compound is obtained in the form of a beige solid.

^ -RMN (250 MHz, SODM-Dg) + 5% D20) d 7.24, 7.19 (2d, 2H), 4.40 (S, 2H), 4.23 (q, 2H), 1.27 (t, 3H). P.f. = 192 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) N- (7-Bromo-2,3-dimethoxy-quinoxalin-5-ylmethyl) -oxamic acid ethyl ester 300 milligrams (1 millimole) of 5-aminomethyl-7-bromo-2,3-dimethoxy-quinotoxaline hydrochloride are suspended in 10 milliliters of tetrahydrofuran and the suspension is cooled to 0 ° C. 0.183 milliliters (1.3 equivalents) of triethyl amine are added, and then 0.123 milliliters (1.1 equivalents) of oxalic acid monoethyl ester chloride are added dropwise over the course of 30 minutes. The mixture is stirred at 0 ° C for 2 hours, then at 20 ° C for 16 hours, and concentrated by evaporation. The residue is stirred with diethyl ether, and the solid is filtered, washed with water and diethyl ether, and dried. XH-NMR (250 MHz, CDC13) d = 8.12 (t, NH), 7.90, 7.58 (2d, 2H), 4.81 (d, 2H), 4.32 (q, 2H), 4.19, 4.14 (2s, 2Me), 1.38 (t, 3H).

Example 24: N- (7-bromo-2,3-dioxo-1.2.3.4-etrahydrosuinoxalin-5-ylmethyl) -malonamic acid methyl ester The title compound is prepared in a manner analogous to that described in Example 23. Pf > 300 ° C.

Example 25; N- (7-bromo-2,3-dioxo-1, 2, 3, 4- te rahidroquinoxalin-5-ylmethyl) -oxalamic acid The title compound is prepared in a manner analogous to that described in Example 21, starting from of N-7-bromo-2, 3-dimethoxy-quinotoxalin-5-ylmethyl) -oxalamic acid. P.f. 265 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) N- (7-Bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl-oxalmic acid 276 milligrams of N- (7-bromo-2,3-ethyl) ethyl ester -dimetoxiquinoxalin-5-ylmethyl) -oxamic acid and 150 milligrams of potassium carbonate are suspended in 2 milliliters of water and 5 milliliters of methanol.The mixture is stirred for 20 hours and acidified with IN HCl, and the solid is filtered and wash with methanol and diethyl ether, mp> 300 ° C.

Example 26: N- (7-bromo-2,3-dioxo-l, 2.3.4-tetrahydroquinoxalin-5-ylmethi) -malonamic acid The title compound is prepared in a manner analogous to that described in Example 25. P.f. > 300 ° C.

Example 27: Amide (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) of furan-2-carboxylic acid 310 milligrams (0.79 mmol) of amide (7-bromine) -2, 3-dimethoxyquinolalin-5-ylmethyl) of furan-2-carboxylic acid are dissolved in 6 milliliters of a solution to about 25 percent hydrogen bromide in acetic acid, and the solution is stirred at room temperature for 16 hours. The mixture is diluted with diethyl ether, and the solid is filtered and washed with diethyl ether. After drying under a high vacuum, the title compound is obtained in the form of a beige solid. ^ -RN (250 MHz, SODM-Dg) d = 12.01, 11.42 (2s, 2NH), 9.12 (t, NH), 7.91 (d, 1H), 7.22 (m, 3H), 6.68 (t, 1H), 4.50 (d, 2H). MS (FAB): 364 (M +). P.f. = 216 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) Amide (7-bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) of furan-2-carboxylic acid 300 milligrams (1 millimole) of 5-aminomethyl-7-bromo-2,3-dimethoxy-quinotoxaline hydrochloride, 124 milligrams (1.1 equivalents) of furan-2-carboxylic acid, 212 milligrams (1.1 equivalents) of N- (3-dimethylaminopropyl) -N'-ethyl carbodiimide hydrochloride, and 12.2 milligrams (0.1 equivalents) of 4-dimethyl aminopyridine are stirred in Dry tetrahydrofuran at 20 ° C for 20 hours. The mixture is poured into water, and the solid is filtered and washed with water and diethyl ether. After drying under a high vacuum, the title compound is obtained in the form of a beige solid. 1 H-NMR (250 MHz, CDC13) d = 7.89 (d, 1H), 7.62 (d, 1H), 7.40 (d, 1H), 7.29 (t, NH), 7.13 (d, 1H), 6.49 (t, 1H), 5.01 (d, 2H), 4.20, 4.14 (2s, 2Me).

Example 28: The following compounds are also prepared in a manner analogous to that described in Example 23 or 27: amide (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) of cyclopropanecarboxylic acid, mp = 250 ° C (decomposition), 2-amino-N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -acetic amide hydrobromide, m.p. = 293 ° C (decomposition), - amide N- (7-bromo-2, -dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3,5-bistrifluoromethylbenzene, m.p. = 300 ° C; amide N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -benzene, m.p. = 210 ° C (decomposition).

Example 29: Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) 50 milligrams (0.19 mmol) of 5-aminomethyl-7-bromo-2, 3- hydrochloride dioxo-l, 2, 3, 4-tetrahydroquinoxaline are suspended in 4 milliliters of N, N-dimethyl formamide and stirred at 20 ° C for 24 hours with 0.02 milliliters (1.2 equivalents) of acetic anhydride and 0.059 milliliters (2.2 equivalents) of triethyl amine. The solvent is concentrated by evaporation, and the solid is suspended in diethyl ether, filtered and washed with methanol and diethyl ether. After drying under a high vacuum, the title compound is obtained in the form of a white solid. ! H-NMR (250 MHz, SODM-Dg) d = 12.02, 11.48 (2NH), 8.65 (t, NH), 7.22, 7.18 (2d, 2H), 4.35 (d, 2H), 1.93 (s, Me). KS (ESP) 310 (M + -l). P.f. > 300 ° C.

Example 30: The following compound is also prepared in a manner analogous to that described in Example 29 Amide N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroqui-noxalin-5-ylmethyl) -trifluoroacetic, pf > 300 ° C.

Example 31: The following compounds can also be prepared in a manner analogous to that described in Examples 1 to 29: N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5 hydrobromide. -ylmethyl) - (L) -tyrosine, mp = 264 ° C (decomposition); N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -leucine tertiary hydrobromide, m.p. = 208 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -proline hydrobromide, m.p. = 279 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -alanine hydrobromide, m.p. = 229 ° C (decomposition), N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (D) -alanine hydrobromide, m.p. = 228 ° C (decomposition); N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -sarcosine hydrobromide, m.p. = 280 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -valin hydrobromide, m.p. = 226 ° C (decomposition); N- (2, 3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -oxamic acid methyl ester; N- (2, 3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -oxalamic acid; p.f. = 255 ° C (decomposition); 4- [(7-Bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -butyric acid methyl ester, m.p. > 250 ° C (decomposition), N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-benzyl-glycine ethyl ester hydrobromide - and hydrochloride of N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N-benzyl-glycine, mp = 205 ° C (decomposition).

Example 32: Amide N- (2, 3-dioxo-7-nitro-l, 2.3, -tetrahydroquinoxalin-5-ylmethyl) -acetic 103 milligrams (0.34 millimoles) of N- (2,3-dimethoxy-7-nitroquinoxalin amide -5-ylmethyl) -acetic acid is stirred in 3 milliliters of a 25 percent solution of hydrogen bromide in acetic acid for 24 hours at 50 ° C. The reaction mixture is diluted with diethyl ether, and the solid is filtered, washed with diethyl ether and dried. P.f. = 269-272 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) Amide N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -acetic 111 milligrams (0.437 mmol) of 5-aminomethyl-2,3-dimethoxy-7-nitroquinoxaline, which can be obtained in a manner analogous to that described in Example 9, but starting from 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline, are stirred with 0.046 milliliters (1.1 equivalents) of acetic anhydride and 0.073 milliliters (1.2 equivalents) of 5-meryl amine. milliliters of N, N-diethyl formamide at room temperature for 24 hours. The reaction mixture is diluted with diethyl ether, and the solid is filtered, washed with diethyl ether and dried. ^ -NMR (SODM-Dg, 250 MHz) 8.52 (t, NH), 8.42, 8.16 (2d, 2H), 4.79 (d, 2H), 4.15, 4.12 (2s, 2Me), 1.98 (s, Me).

Example 33: The following compounds can also be prepared in a manner analogous to that described in Examples 21 to 32: amide N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin) -5-ylmethyl) -phenylacetic, mp > 250 ° C; amide N- (7 -bromo -2,3-dioxo-1,2, 3,4-tetrahydro-quinoxalin-5-ylmethyl) -phenylpropionic acid, m.p. > 237 ° C; N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -thiophene-2-carboxylic acid amide, m.p. > 250 ° C; amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3-thienylacetic acid, m.p. > 260 ° C; and N- (7-bromo-2, 3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3-methoxyphenylacetic acid amide, m.p. > 250 ° C.

Example 34: N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroguinoxalin-5-ylmethyl) -N-methylbenzyl amine hydrobromide 213 milligrams (0.53 millimoles) of amine N- (2, 3-dimethoxy-7-nitro-quinoxalin-5-ylmethyl) -N-methylbenzyl are dissolved in 4 milliliters of a solution at about 25 percent hydrogen bromide in acetic acid, and the solution is stirred at room temperature for 20 hours. The mixture is diluted with diethyl ether, and then stirred for 10 minutes, and the solid is filtered and washed with diethyl ether and a small amount of water. After drying under a high vacuum, the title compound is obtained in the form of a beige solid. XH-NMR (S0DM-D6, 250 MHz): 12.17, 11.8 (2s, 2NH), 9.7 (br s, NH), 7.52 (m, Ph + H), 7.38 (d, H), 4.8-4.15 (m , 4H), 2.5 (S, Me); MS (EI): 373 (M +). P.f. = 208-212 ° C (decomposition).

Alternatively, the title compound can be prepared as follows: 213 milligrams (0.53 millimoles) of amine are heated N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N-methylbenzyl acid under reflux in 10 milliliters of 2N aqueous hydrochloric acid for 18 hours. The reaction mixture is concentrated by evaporation, and the solid is suspended in diethyl ether and a small amount of water is filtered and dried. The desired compound is obtained in the form of a beige solid.

The starting material can be prepared, for example, as follows: a) N-2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N-methylbenzyl amine 200 milligrams of 5-bromomethyl-2,3-dimethoxy-7 Nitro-quinoxaline and 0.016 milliliters (2.2 equivalents) of N-benzylmethyl amine are dissolved in 10 milliliters of acetonitrile, and the solution is stirred at reflux for 20 hours. The mixture is concentrated by evaporation, and the residue is dissolved in ethyl acetate and washed in a 5 percent aqueous sodium carbonate solution and brine. The organic phase is dried over magnesium sulfate, and the solvent is concentrated by evaporation. ? -NRM (CDClj, 250 MHz): 7.84, 7.78 (2d, 2H), 7.4-7.2 (m, Ph), 4.13, 4.08 (2s, 2Me), 4.03, 3.65 (2s, 2CH2), 2.26 (s, Me) .

Example 35: The following compounds are also prepared in a manner analogous to that described in Example 34: amine hydrobromide N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) ) -furfurílica, pf = 282 ° C (decomposition), amine hydrobromide N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-morpholino-ethyl, m.p. = 228 ° C (decomposition), N- (2, 3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -diethyl amine hydrobromide, m.p. = 290 ° C (decomposition), N- (2, 3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -dimethyl amine hydrobromide, m.p. = 325 ° C (decomposition), - amine dibromhydrate N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2- (2-pyridyl) -ethyl, pf 205 ° C (decomposition), N- (2, 3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -cyclopropyl amine hydrobromide, m.p. = 268 ° C (decomposition); Amine hydrochloride N- (2, 3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-S-ylmethyl) -dietanolic, m.p. = 251 ° C (decomposition), amine hydrobromide N- (2,3-dioxo-7-nitro-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-2-thiazoline, m.p. = 271 ° C (decomposition), - amine dibromhydrate N- (2, 3-dioxo-7-nitro-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -2-aminopyrazine, m.p. = 183 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminothiazole hydrobromide, m.p. = 153 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -aniline hydrobromide, m.p. > 250 ° C; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-fluoroaniline hydrobromide, m.p. = 218 ° C (decomposition); N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-fluoroaniline hydrobromide, m.p. > 250 ° C; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-fluoroaniline hydrobromide, m.p. = 222-235 ° C; [N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid ethyl ester hydrobromide, m.p. = 258 ° C (decomposition); [N- (7-bromo-2, 3- ioxo-1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid ethyl ester hydrobromide, MS (EI) : 438 (M +). g-j «ampio 6; [N- (2,3-Dioxo-7-nitro-1,2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid hydrochloride 80 milligrams (0.2 mmol) of ester hydrobromide Ethyl [N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid is stirred in 2 milliliters of a 2N sodium hydroxide solution at room temperature for 16 hours. The mixture is acidified with 3N HCl, and the resulting solid is filtered and washed with a small amount of water, and 2 x 20 milliliters of diethyl ether. After drying, the title compound is obtained in the form of a yellow solid.

^? - NMR (SODM-D6, 250 MHz): 12.4, 12.3 (2s, 2NH), 9.0 (s, NH), 8.09, 8.02 (2d, 2H), 6.75 (s, H), 4.8 (br s, 2H), 3.7 (s, 2H), - pf = 284 ° C (decomposition).

Example 37: H- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydro-5-ylmethyl) -N- (2-pyridyl-ethyl) -glycine D-hydrobromide 49 milligrams (0.1 mmol) dihydrochloride N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N- (2-pyridylmethyl) -glycine is stirred in 2 milliliters of a 48 percent solution of hydrogen bromide in acetic acid for 18 hours at 70 ° C. The mixture is diluted with diethyl ether, and the solid is filtered, washed with diethyl ether and dried. The title compound is obtained in the form of a yellow solid. ^ -RMN (S0DM-D6, MHz): 12.3 (s, 2NH), 8.8, 8.25, 7.72, 7. 68 (4m, Py), 7.92, 7.89 (2d, 2H), 4.1 (m, 2H), 3.6 (s, 2H), 3.6 (S, 2H); MS (FAB +) 386 (M + H); p.f. > 280 ° C.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N- (2-pyridylmethyl) -glycine ethyl ester 150 milliliters (0.46 millimoles) of 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline , 98 milligrams (1.1 equivalents) of N- (2-pyridylmethyl) -glycine ethyl ester and 0.076 milliliters (1.2 equivalents) of triethyl amine are stirred at reflux in 5 milliliters of acetonitrile for 20 hours. The mixture is concentrated by evaporation and the residue is suspended in diethyl ether and filtered. After drying, the title compound is obtained in the form of a white powder. ^ -NMR (SODM-Dg, 250 MHz): 8.45, 8.37 (2d, 2H), 8.45, 7.72, 7.43, 7.22 (4m, Py), 4.39 (s, 2H), 4.05 (m, 2Me + 2H), 4.0 (S, 2H), 3.53 (S, 2H), 1.18 (t, Me). b) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl-N- (2-pyridylmethyl) -glycine dihydrochloride 80 milligrams (0.186 mmol) N- (2,3-dimethoxy-7-nitroquinoxalin) ethyl ester -5-ylmethyl) -N- (2-pyridylmethyl) -glycine and 51 milligrams (2 equivalents) of potassium carbonate are stirred in 5 milliliters of methanol and 2 milliliters of water for 20 hours at room temperature. it is acidified with 2N HCl and concentrated by evaporation The residue is recrystallized from hot ethyl acetate, filtered, washed with water and diethyl ether and dried.

Example 38: N- (2,3-dioxo-7-ni ro-l.2.3.4- tetrahydroquinoxalin-5-ylmeH i) -aminobenzoic acid bromide 60 milligrams (0.156 millimoles) of N- [2,3-dimethoxy] -7-nitroquinoxalin-5-ylmethyl] -3-aminobenzoic acid is stirred in 4 milliliters of HBr at approximately 24 percent in acetic acid for 20 hours at 20 ° C. The reaction mixture is diluted with diethyl ether and the solid is filtered and washed with diethyl ether. P.f. = 275 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) N- \ 2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl-3-aminobenzoic acid 350 milligrams (1.06 millimoles) of 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline, 153 milligrams (1.05 equivalents) of acid 3-aminobenzoic acid and 0.165 milliliters (1.1 equivalents) of triethyl amine are combined in 10 milliliters of acetonitrile, and heated to the boiling point at reflux for 24 hours. The reaction mixture is concentrated by evaporation, extracted with ethyl acetate and IN HCl, and washed once with brine. The organic phases are combined, dried over magnesium sulfate and concentrated by evaporation. ^? - NMR (CDC13, 250 MHz): 8.50, 8.27 (2d, 2H), 7.32, 7.15, 7.10, 6.75 (4m, 4H), 4.85 (s, 2H), 4.13, 4.12 (2s, 2Me). te-j «mpi f > 3 < ? . N- (2,3-dioxo-7-nitro-1.2.3.4- tetrahydroquinoxalin-5-ylmethyl) -2-methylaziridine hydrobromide 180 milligrams (0.59 millimoles) of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) ) -2-methylaziridine are stirred in a 33 percent solution of hydrogen bromide in acetic acid for 2 hours at 70 ° C. The mixture is diluted with diethyl ether, and the solid is filtered and washed with diethyl ether. After drying, the title compound is obtained in the form of a yellow solid. P.f. = 241 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methylaziridine 200 milligrams (0.61 millimoles) of 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline, 0.086 milliliters (2 equivalents) of propyleneimine and 0.295 milliliters (0.3 equivalents) of an aqueous solution of 40% tetrabutyl ammonium hydroxide are stirred in 8 milliliters of dichloromethane for 20 hours at room temperature. The mixture is concentrated by evaporation, and the residue is extracted with ethyl acetate and a 5 percent sodium carbonate solution. The combined organic phases are washed once with brine, dried over magnesium sulfate and concentrated by evaporation. γ NMR (CDC13, 250 MHz): 8.6 (m, 2H), 4.18 (m, 2Me + H), 3.95 (S, 2H), 3.38 (m, 2H), 1.0 (t, Me). g «* tnpl9 40: N- (2,3-dioxo-7-nitro-1.2.3.4-tetrahydro-uinoxalin-5-ylmethyl) -azetidine-Bromhydrate. p.f. = 265 ° C (decomposition), can be prepared in a manner analogous to that described in Example 39.

Example 41: N- (2,3-dioxo-7-nitro-l.2.3.4- tetrahydrosuinoxalin-5-ylmethyl) -4-methylpjperidine Bromhydrate The title compound can be prepared as described in Example 39, but starting at from N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -4-methylpiperidine, enlugar of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methylaziridine.

P.f. = 296 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-methylmethyl) -4-methylpiperidine 100 milligrams (0.304 mmol) of 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline, 0.04 milliliters (1.1 equivalents) of 4 methyl-piperidine, and 0.05 milliliters (1.2 equivalents) of triethyl amine are stirred at reflux for 20 hours. The mixture is concentrated by evaporation, and the residue is extracted with ethyl acetate and a 5 percent sodium carbonate solution. The combined organic phases are dried over magnesium sulfate and concentrated by evaporation. HL-NMR (CDC13, 250 MHZ): 8.58, 8.43 (m, 2H), 4.19, 4.17 (2s, 2Me), 4.06 (s, 2H), 2.97, 2.15, 1.62, 1.40-1.25 (4m, 9H), 0.93 (d, Me).

Example 42: The following compounds can also be prepared in a manner analogous to that described in Examples 1 to 41: N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N '- (4-methoxyphenyl) -piperazine hydrobromide, m.p. = 241 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -piperidine hydrobromide, m.p. > 300 ° C; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2,6-dimethylpiperidine hydrobromide, m.p. = 277 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -pyrrolidine hydrobromide, m.p. > 300 ° C; N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-piperidone hydrobromide, m.p. = 259 ° C (decomposition) N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -hexamethyleneimine hydrobromide, m.p. = 298 ° C (decomposition); N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-pyrroline hydrobromide, m.p. > 300 ° C; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -thiomorpholine hydrobromide, m.p. = 291 ° C (decomposition); N- (2, -dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -morpholine hydrobromide, m.p. >; 300 ° C; N- (2, -dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -thiazolidine hydrobromide, m.p. = 250 ° C (decomposition), N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-pyrrolidinol hydrobromide, m.p. = 286 ° C (decomposition); N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N-methylpiperazine dibromhydrate, m.p. = 295 ° C (decomposition), N- (2, 3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2- (2-hydroxyethyl) -piperidine hydrochloride, m.p. = 298 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -piperazine dibromhydrate, m.p. > 300 ° C; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-azabicyclo [3.2.2] nonane hydrobromide, p. f. 271 ° C (decomposition), N- (2, 3-dioxo-7-nitroyl, 2,3,4-tetrahydroquinoxalin-5-methylmethyl) -tetrahydropyridine hydrobromide, p. f. = 279 ° C (decomposition), N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -pyrazole hydrobromide, m.p. = 298 ° C (decomposition), N- (2, 3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-ethoxycarbonyl-pyrazole hydrobromide, m.p. = 195 ° C; [1- (2, 3-Dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -lH-indol-3-yl] -acetic acid methyl ether hydrobromide, m.p. = 230 ° C; N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -1,2, 3,4-tetrahydroquinoxaline hydrobromide, m.p. = 212-215 ° C.

Example 43: N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -methanesulfonic acid amide 83 milligrams (0.31 millimoles) of 5-aminomethyl-7-bromo- 2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxaline are suspended in 4 milliliters of dimethyl formamide. 0.063 milliliters (1.6 equivalents) of triethyl amine and 82 milligrams (1.4 equivalents) of methanesulfonic anhydride are added, and the solution is stirred for 18 hours. The solvent is concentrated by evaporation and the residue is suspended in diethyl ether. The solid is filtered, washed with water and diethyl ether and dried. The title compound is obtained in the form of a white powder. P.f. > 300 ° C.

Example 44: Amide (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) of N-methyl-2-phenylacetic acid 2 milliliters of hydrochloric acid (2N in water) are added to a solution of 129 milligrams (0.3 millimoles) of amide (7-bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) of N-methyl-2-phenylacetic acid in 3 milliliters of tetrahydrofuran, and the mixture is heated to the boiling point under reflux for 16 hours. After cooling in an ice bath, the precipitate is filtered and washed with cold water. Colorless crystals are formed from hot dimethyl formamide overnight in a refrigerator, and filtered and dried under a high vacuum. XH-NMR (300 MHz, SODM-Dg): 12.05-11.95 (br.s, 1H), 11.51-11.33 (br.s, 1H), 7.38-7.10 (m, 7H), 4.78 (s, 0.2H) , 4.59 (s, 1.8H), 3.82 (s, 1.8H), 3.62 (s, 0.2H), 2.99 (s, 2.7H), 2.82 (s, 0.3H). MS (FAB): 402 (M +), m.p. > 260 ° C.

The starting material can be prepared, for example, as follows: a) Amide (7-bromo-2,3-dimethoxyquinolalin-5-ylmethyl) of 2-phenylacetic acid can be prepared as described in Example 27. b) Amide (7-bromo-2,3-dimethoxy-quinolalin-5-ylmethyl) of N-methyl-2-phenylacetic acid A solution of 208 milligrams (0.5 mmol) of amide (7-bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) ) of 2-phenylacetic acid in 4 milliliters of tetrahydrofuran (absolute), is added dropwise over the course of 15 minutes to a suspension of 30.5 milligrams (0.7 millimoles) of sodium hydride in 3 milliliters of absolute tetrahydrofuran. After heating to the boiling point under reflux for 90 minutes, the mixture is cooled in an ice bath. After the addition of 85 milligrams (0.6 mmol) of methyl iodide, the suspension is stirred at 0 ° C for 1 hour and at room temperature for another 15 hours. 0.9 grams of silica gel are added, and the suspension is concentrated, dried and purified on a column of silica gel, using dichloromethane / hexane / diethyl ether (8: 4: 1) as eluent. After concentration and drying under a high vacuum, the title compound is obtained in the form of a virtually colorless honey, which consists of the cis / trans isomer mixture in a ratio of about 2: 3. . ^ - NMR (300 MHz, CDC13): 7.87 (d, 1Hz, 0.4H), 7.83 (d, 1Hz, 0.6H), 7.4-7.15 (m, 6H), 5.10 (s, 1.2H), 5.00 ( s, 0.8H), 4.15 (S, 1.2H), 4.12 (s, 1.8H), 4.09 (s, 3H), 3.82 (s, 1.2H), 3.75 (s, 0.8H), 3.03 (s, 1.2 H), 2.98 (s, 1.8H).

Example 45: N- (7-bromo-2,3-dioxo-l.2.3.4-te rahidroquinoxalin-5-ylmethyl) -a-aminophosphine acid Under a nitrogen atmosphere, 255 milligrams (0.607 millimoles) are dissolved N- (7-bromo-2,3-dimethoxy-quinotoxal-5-ylmethyl) -a-aminophosphonic acid dimethyl ester in 5 milliliters of absolute dichloromethane, and 0.33 milliliters (2.55 millimoles) of trimethylsilyl bromide are added at room temperature. After stirring for 3 hours at room temperature, 5 milliliters of ethanol are added, and stirring is continued at room temperature for another 22 hours. Then the mixture is concentrated to dryness. 5 milliliters of HBr (33 percent in glacial acetic acid) are added to the beige foam, and the mixture is stirred at room temperature for 3 hours before being concentrated to dryness again.

The beige residue is recovered in a solution of C? 3 (approximately IN in water). The pH value is adjusted to 6 with dilute hydrochloric acid, and the suspension is filtered while hot. Hot dimethyl formamide is added to the filtrate and then a small amount of ethanol, until the mixture becomes slightly cloudy. The title compound is separated in the form of beige crystals in the course of 3 days. [H NMR (300 MHz, D20): 7.53 (br.s, 1H), 7.47 (br.s, 1H, 4.57 (br.s, 2H), 3.15 (d, 11.8Hz, 2H); 31P-NMR 8 ppm; MS (FABX) 364, 366 [M + H +] +, (FAB +) 362, 364 [M-H +], mp> 270 ° C.

The starting materials can be prepared, for example, as follows: a) Tri-N- (7-bromo-2,3-dimethoxy-quinxoalin-5-ylmethyl) -triazine 2.98 grams (10 mmol) of amine (7-bromo-2,3-dimethoxy-quininoal-5-ylmethyl) are dissolved in 40 milliliters of Ethanol with heating. After cooling to room temperature, 1 milliliter of formalin solution (37 percent in water) is added dropwise to the light yellow solution. When the addition is complete, the product settles in the form of a colorless precipitate. After stirring for 3 hours, the precipitate is filtered. After drying under a high vacuum, the title compound is obtained in the form of a colorless amorphous crystalline mass. hl-NMR (300 MHz, CDC13): 7.83 (d, 2.3Hz, 3H), 7.72 (d, 2.3 Hz, 3H), 4.24 (s, 6H), 4.13 (s, 9H), 4.04 (s, 9H) , 3.69 (br.s, 6H). MS (FAB) :: 930, 932. b) N- (7-bromo-2. -dimethoxy-quinotoxal-5-ylmethyl) -a-aminophosphonic acid dimethyl ester At 0 ° C, under a nitrogen atmosphere, 0.23 milliliters (2.5 mmol) of dimethyl phosphite are dissolved, 0.383 milliliters (2.75 millimoles) of triethyl amine, and 0.476 milliliters (3.75 millimoles) of trimethylsilyl chloride in 25 milliliters of dichloromethane. After stirring for 15 minutes at 0 ° C, a solution of 0.78 grams (0.83 millimoles) of tri-N- (7-bromo-2,3-dimethoxy-quinxoalin-5-ylmethyl) -triazine in 25 milliliters of water is added dropwise. dichloromethane. After stirring for 30 hours at room temperature, the suspension is poured into ice-cold hydrochloric acid (0.1N in water), and 3 parts of ether are added. The organic phase is exhaustively extracted by stirring with 0.1 N aqueous hydrochloric acid. The combined aqueous phases are adjusted to a pH of 12 to 13 with KCÜ3, and extracted 6 times with chloroform. After drying over sodium sulfate and concentrating the organic phase, a yellow oil is obtained, which is purified on a column of silica gel using a mixture of ethyl acetate / dichloromethane / ethanol, 10: 10: 1 as eluent . After concentration and drying under high vacuum, the title compound is obtained in the form of a light yellow oil which solidifies in the form of a crystal. LH-NMR (300 MHz, CDCL3): 7.88 (d, 2.3 Hz, 1H), 7.54 (d, 2. 3Hz, 1H), 4.25 (s, 2H), 4.15 (s, 3H), 4.14 (s, 3H), 3.78 (d, 10Hz, 6H), 2.95 (d, 13.1 Hz, 2H), MS (ES +): 422, 420 (MH +). Example 46: 1- (7-Nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -3- (4-methoxyphenyl) -urea The title compound can be prepared as described in Example 39, but starting from N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -3- (4-methoxyphenyl) -urea, instead of N- (2,3-dimethoxy-) 7-Nitroquinoxalin-5-ylmethyl (-2-methylaziridine, -FAB-MS: M + = 385; Thin layer chromatography: ethyl acetate / methanol (3: 1) Rf = 0.5.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -3- (4-methoxyphenyl) -urea 62 milligrams (0.416 millimoles) of 4-methoxyphenyl isocyanate are added at room temperature to a suspension of 100 milligrams (0.379 mmol) of 5-aminomethyl-2, 3-dimethoxy-7-nitroquinoxaline in 2 milliliters of methyl tertiary butyl ether, and the mixture is stirred for 3 hours. The suspension is then filtered, and the filter residue is washed with tertiary butyl methyl ether, and dried under a high vacuum. The title compound is obtained in the form of a beige solid. 1-NMR (CDC13, 200 MHz): 8.47, 8.26 (2d, 2H), 7.70 (s, NH), 7.22 (d, 2H), 6.74 (d, 2H), 6.15 (m, NH), 4.89 (d, CH2), 4.11, 4.09 (2s, 2Me), 3.70 (s, Me).

Example 47: The following compounds are also prepared in a manner analogous to that described in Example 46: 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3 - (2-methoxyphenyl) -urea, FAB-MS: M + = 385; thin layer chromatography: ethyl acetate / methanol (3: 1) Rf = 0.5; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (2-ethoxycarbonyl) -urea; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (2-carboxyethyl) -urea, FAB-MS:: M + = 351; thin layer chromatography: ethyl acetate / methanol (1: 3) Rf = 0.67; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-phenyl-urea, FAB-MS: M + = 355; thin layer chromatography: ethyl acetate / methanol (3: 1) Rf = 0.70; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (4-trifluoromethylphenyl) -urea, FAB-MS: M + = 439; thin layer chromatography: ethyl acetate / methanol (3: 1) Rf = 0.50. Example 48: N- (7-nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) -valeric acid amide The title compound can be prepared as described in Example 39, but starting from N- (2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -valeric acid amide, instead of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2 -methyl-aziridine; FAB-MS: M + = 320; ! H-NMR (SODM-D6, 200 MHz): 12.23, 11. 82 (2s, 2NH), 8.73 (t, NH), 7.94, 7.89 (2d, 2H), 4.46 (d, CH2), 2.20 (t, CH2), 1.53 (quint., CH2), 1.28 (hex., CH2), 0.87 (t, CH3). Thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.80.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -valeric acid amide 79 microliters (0.567 millimoles) of triethyl amine and 55 microliters (0.454 mmol) of normal valeroyl chloride are added to a suspension 100 milligrams (0.378 millimoles) of 5-aminomethyl-2, 3-dimethoxy-7-nitroquinoxaline in 2 milliliters of methyl tertiary butyl ether, and the mixture is stirred at room temperature for 16 hours. The mixture is then recovered in dichloromethane, washed with IN hydrochloric acid, and with a solution of sodium hydroxide IN, dried over sodium sulfate, and concentrated by evaporation. The title compound is obtained in the form of a yellowish powder.

Example 49: The following compounds are also prepared in a manner analogous to that described in Example 48: N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-acid) amide ilmethyl) -naphthoic, FAB-MS: M + = 390; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.80; amide N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3,3-dimethylbutyric acid, FAB-MS: M + = 334; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.67; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (3-acetoxy) -endene amide; N- (7-nitro-2: 3 -amide; -dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (2-hydroxy) -benzoic acid, ESC1 + -MS: M + H) + = 357; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.33.

Example 50: Amide N- (7-nitro-2,3-dioxo-l, 2.3.4-tetrahydroquinoxalin-5-ylmethyl) -2-methoxyacetic acid The title compound can be prepared as described in Example 39, but starting from from N- (2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methoxyacetic acid amide, in place of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methylaziridine , - FAB-MS: M + = 308. Thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.80.

The starting material can be prepared, for example, as follows: a) Amide N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methoxyacetic acid The title compound can be prepared as described in Example 29 a), but starting from 5-aminomethyl-2,3-dimethoxy-7-nitroquinoxaline and 2-methoxyacetic acid, instead of 5-aminomethyl-7-bromo-2,3-dimethoxy-quinotoxaline hydrochloride and furan-2 -carboxylic Example 51; The following compounds are also prepared in a manner analogous to that described in Example 50: N- (7-n-tro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N ', N '-dimethylglycinamide, APC1 + -MS: (M + H) + = 321; Thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0. 29; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3,4,5-trimethoxybenzamide, ESC1"-MS: (M + H) + = 429; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.30; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5) -ylmethyl) -3,5-dimethoxy-4-hydroxybenzamide, FAB-MS: M + = 416, thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.90; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxal ind-5-methylmethyl) -N'-acetylglycinamide, FAB-MS: M + = 335; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.80; N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-yl ethyl) -N '-carbamoylglycinamide, FAB-MS: M + = 336; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.60; 4- [N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -sulfamoyl] -benzamide, ESC1 + -MS: (M + H) + = 420; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.88; 2-amino -3-methyl-N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyramide, ESC1 + -MS: M + H) + = 336; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.68; 2-amino-3-hydroxy-N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyramide, ESC1 + -MS: M + H) + = 338; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.48; 2-amino-4-carboxy-N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyramide, FAB-MS: M + = 365; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.39; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-acetyltryptophanamide hydrobromide, FAB-MS: M + = 464; Thin layer chromatography: methanol / acetic acid (9: 1) R £ = O 25 2-amino-N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydro-quinoxalin-5 - ilmethyl) -L-serine-amide, ESC1 + -MS: M + H) + = 324; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.50; 2-amino-N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -D-serine-amide, 2-L-amino-3-amide Carbamoyl-N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -propionic acid, FAB-MS: M + = 351; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.90; 2-D-amino-3-carbamoyl-N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -propionic acid amide; LN- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -histidine-amide, - DN- (7-nitro-2,3-dioxo-1,2) 3, 4-tetrahydroquinoxalin-5-ylmethyl) -histidine-amide.

E etnpi «> 2 • N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -succinic acid amide The title compound can be prepared as described in Example 39, but starting from starting from N- (2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -succinic acid amide, in place of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methylaziridine, - FAB-MS: M + = 336; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.48.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -succinic acid amide 55 microlitres (0.397 millimoles) of triethyl amine and 40 milligrams (0.397 millimoles) of succinic anhydride are added to a suspension of 100 milligrams (0.378 mmol) of 5-aminomethyl-2, 3-dimethoxy-7-nitroquinoxaline in 2 milliliters of methyl tertiary butyl ester, and the mixture is stirred for 3 hours at room temperature. The mixture is then filtered, and the residue is washed twice with tertiary butyl methyl ether. The filter residue is chromatographed on silica gel with dichloromethane / methanol / acetic acid (95: 4.5:: 0.5). The title compound is obtained in the form of a beige powder.

Example 53: The following compounds are also prepared in a manner analogous to that described in Example 52 N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) acid amide. -ftalic; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -glutaric acid amide; FAB-MS: M + = 350; thin layer chromatography: ethyl acetate / methanol (1: 1 + 2% acetic acid) Rf = 0.70; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methylsuccinic acid amide, - FAB-MS: M + = 350; thin layer chromatography: methylene chloride / methanol / acetic acid (80: 18: 2) Rf = 0.46. ta-«mpin« >; N- (7-nitro-2,3-dioxoyl, 2,3,4-tetrahydrosuinoxalin-5-ylmethyl) -N- (2-diethylaminoethyl) amine dibromhydrate The title compound can be prepared as described in Example 39 , but starting from amine N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N- (2-diethylaminoethyl), instead of N- (2,3-dimethoxy-7-nitroquinoxalin-). -ylmethyl) -2-methylaziridine, -FAB-MS :: M + = 335; Thin layer chromatography: methanol / water (5: 1) Rf = 0.16.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -N- (2-diethylaminoethyl) amine The title compound can be prepared as described in Example 39 a), ie, from 5 -bromomethyl-2,3-dimethoxy-7-nitroquinoxaline and 2-diethylaminoethyl amine. The title compound is obtained in the form of a colorless oil.

At 55: The following compounds are prepared in a manner analogous to that described in Example 54: amine hydrobromide N- (7-nitro-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-) ilmethyl) -N-methyl; amine hydrobromide N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -N- (1, 1-dioxo-2,3,4,5-tetrahydro- tien-3-yl), FAB-MS; M + = 354; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.69; amine hydrobromide N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl-N- (2-hydroxyethyl); amine hydrobromide N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N- (3,4-methylenedioxybenzyl), APC1 + -MS: (M + H) + = 371; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.70; N-methoxy-amine hydrobromide N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl, ESC1 + -MS: (M + H) + = 281; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.86; amine hydrobromide N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-isopropyl, APC1 + -MS: (M + H) + = 279; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.53; diamine hydrobromide N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -N '-acetylethylene, FAB-MS: M + = 321; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.40; cis-2- [N- (7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -cyclohexane-1-carboxamide hydrobromide, FAB-MS: M + = 359; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.50; N- (7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl taurine hydrobromide, FAB-MS: M + = 357; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.69; cis -3- [N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -cyclohexane-1-carboxylic acid hydrobromide, FAB-MS: M + = 362; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.70; 3- [N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -3-phenylpropionic acid hydrobromide, ESC1 + -MS: (M + H) + = 385; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.34; cis-2- [N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -cyclopentane-carboxylic acid hydrobromide, - N- (7-nitro) -2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -pyrrolidin-2-one, FAB-MS: M + = 304; thin layer chromatography: ethyl acetate / methanol (2: 1 + 2% acetic acid) Rf = 0.60; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrolidin-4- (4-chlorophenyl) -2-one, FAB-MS: M + = 414; thin layer chromatography: methanol / water (10: 1) Rf = 0.78; amine hydrobromide N- (7-nitro-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -N- (l-acetoxy-2-methyl-prop-2-yl), FAB -MS: M + = 350; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.86; amine hydrobromide N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -N-cyclohexyl-N-methyl, FAB-MS: M + = 332; thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.70; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -N- (1, 1-dimethyl-2-hydroxyethyl) amine hydrochloride, ESC1 + -MS: M + H) + = 309; Thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.62.

Ex »mpi» 5fi »cis-2- [N- (7-nitro-2,3-dioxo-1.2.3.4-tetrahydro-uinoxalin-5-ylmethyl) aminol-cyclohexane-1-carboxylic acid hydrochloride The title compound can be prepared as described in Example 39, but starting from cis-2- [N- (2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) amino] -cyclohexane-1-carboxylic acid, instead of N- ( 2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-methylaziridine; p.f. = 249-251 ° C; ESC1-MS: (M-H) + = 361, - thin layer chromatography: methanol / acetic acid (9 :: 1) Rf = 0.1 - 0.45.

The starting material can be prepared, for example, as follows. a) 2.3-Dimetoxisuinoxalin-5-carbaldehyde 17 milliliters (188 millimoles) of 2-nitropropane are added to a solution of 3.7 grams (163 millimoles) of sodium in 700 milliliters of methanol. After stirring for 5 minutes, 35.5 grams (125.4 mmol) of solid 2,3-dimethoxy-5-bromomethylquinoxaline are added. The mixture is refluxed for 1 hour, forming a homogeneous solution. After cooling, the solution is concentrated under reduced pressure. The residue is taken up in ethyl acetate and IN HCl, the phases are separated and the organic phase is washed with water and brine, dried over sodium sulfate and concentrated. The title compound is isolated in the form of white crystals by crystallization from ethyl acetate. P.f. 137-140 ° C; thin layer chromatography (EtOAc / hexane 1: 3): Rf = 0.45 b) 2,3-dimethoxy-7-nitroquinoxaline-5-carbaldehyde 44 milliliters of 100 percent nitric acid, 44 milliliters of 97 percent sulfuric acid, and 44 milliliters of trifluoroacetic anhydride are added in succession to a solution, cooled to 0 ° C, of 22 grams (100.8 millimoles) of 2,3-dimethoxy-5-bromomethyl-quinoxaline in 88 milliliters of trifluoroacetic acid. The mixture is kept at 0 ° C for 2 hours, and then carefully poured onto a mixture of 4N NaOH and ice. The temperature must not exceed 20 ° C. The mixture is extracted with ethyl acetate. The organic phase is washed with an aqueous solution of IN NaOH, water and brine, and dried over sodium sulfate. Crystallization of the crude product gives the title compound in the form of pale yellow crystals. P.f. 147-149 ° C; thin layer chromatography (EtOAc / hexane 1: 3): Rf = 0.25. c) cis-2- [N- (2,3-dimethoxy-7-nitroauinoxalin-5-ylmethyl) aminol-cyclohexane-1-carboxylic acid 105 milligrams (0.588 mmol) of cis-2-amino-cyclohexanecarboxylic acid and 82 microliters (0.588 millimoles) of triethyl amide are added in succession to a solution of 129 milligrams (0.490 millimoles) of 2,3-dimethoxy-7-nitroquinoxaline-5-carbaldehyde in 1 milliliter of dichloromethane and 2 milliliters of ethanol. After stirring for 3 hours at room temperature, 1 gram of anhydrous sodium sulfate is added to the suspension, and the mixture is stirred for another 20 hours at room temperature. The slurry is diluted with 0.5 milliliters of ethanol, and 46 milligrams (1.23 millimoles) of sodium borohydride are added. After stirring for 3 hours, 0.5 milliliters of acetone are added, and 10 minutes later, 0.3 milliliters of acetic acid are added and filtration is carried out. The filter residue is washed with ethanol and dichloromethane. The filtrate is chromatographed on silica gel first with dichloromethane / ethyl acetate (97: 3) and then with dichloromethane / methanol / glacial acetic acid (90: 9: 1). The title compound is obtained in the form of a white powder. Example 57: The following compounds are also prepared in a manner analogous to that described in Example 56: N- (7-nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) hydrobromide) -amino-methane-phosphonic acid; N- (7-nitro-2,3-dioxo-l, 2, 3, -t and rahidroquinoxal ind-5-ylmethyl) -amino- (3-methoxy-en-1) -methanphosphonic acid hydrochloride; FAB-MS: M + = 436; high performance liquid chromatography: CH3CN / H20 + trifluoroacetic acid at 0.1 percent, 20:80, Rt = 4.2 min. (NucelosiLjOO, Cj8, 5 μM, 250 x 4.5 mm); [(7-nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethylamino- (-hydroxyphenyl) -methyl] -phosphonic acid hydrobromide; FAB-MS: M + = 422; yield rise: CH3CN / H20 + 0.1 percent trifluoroacetic acid, 20:80, Rfc = 2.8 min (NucelosiL100, C ^, 5 μM, 250 x 4.6 mm), amine hydrochloride N- (7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -N- [(4-diethyphosphoryl) -benzyl], ESC1 + MS: (MH) + = 421, thin layer chromatography: methylene chloride / methanol / acetic acid (9: 0.5: 0.5), Rf = 0.28; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -3-amino acid hydrobromide. -propane-1-phosphonic acid, N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-ethanesulfonic acid hydrobromide; 7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-2-phenyl-ethanecarboxylic acid, cis-2- hydrobromide [N- (7-nitro -2, 3-dioxo- 1,2,3, 4 -tetrahydro quinoxalin-5-ylmethyl) -amino] -cyclopentane-1-carboxylic acid; trans-2- [N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -cyclopropan-1-phosphonic acid hydrobromide, trans-hydrochloride -2- [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino- (3-pyridyl) -methanphosphonic acid; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-methylmethyl) -3-amino-1-carboxy-propan-1-phosphonic acid hydrobromide, 4- [ N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) amino] -butyric acid, FAB-MS: M + = 322; Thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.30.

E-¡< * tnpin 58: 160 milligrams (0.461 mmol) of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethylaminomethyl) -tetrazole is stirred under reflux for 20 hours in 6 milliliters of 2N aqueous HCl. The reaction mixture is cooled, and the resulting solid is filtered and washed with diethyl ether. P.f. = 230 ° C (decomposition). a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -aminoacetonitrile 300 milligrams (0.914 mmol) of 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline, 338 milligrams (4 equivalents) of aminoacetonitrile hydrochloride , and 0.66 milliliters (4 equivalents) of Hünig's base are stirred at reflux for 20 hours in 10 milliliters of acetonitrile. The reaction mixture is concentrated by evaporation, and the residue is extracted with ethyl acetate and a sodium carbonate solution at about 5 percent. The combined organic phases are washed once with brine, dried over magnesium sulfate and concentrated by evaporation. The resulting brown oil is passed through chromatography on silica gel (ethyl acetate / petroleum ether, 1: 2, and then 1: 1) and the title compound is obtained in the form of a yellowish solid. b) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethylaminomethyl) -tetrazole 140 milligrams (0.461 mmol) of N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -aminoacetonitrile, 50 milligrams (0.43) equivalents) of dibutyl tin oxide, and 0.244 milliliters (4 equivalents) of trimethylsilyl azide are stirred under reflux for 16 hours in 6 milliliters of toluene. The reaction mixture is cooled, and the title compound is filtered in the form of a tan solid.

E-jempirt ^ p. N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl-2-amino-ethanophonic acid bromide 380 milligrams (0.949 mmol) N- (2,3-dimethoxy) dimethyl ester -7-nitroquinoxalin-5-ylmethyl) -2-amino-ethanophosphonic acid and 1.23 milliliters (10 equivalents) of trimethylsilyl bromide are dissolved in 20 milliliters of dichloromethane and the solution is stirred for 90 minutes at room temperature. it is concentrated by evaporation, and the residue is stirred at 40 ° C for 17 hours in 6 milliliters of a solution of hydrogen bromide at about 33 percent in acetic acid.The reaction mixture is diluted with diethyl ether, and the solid it is filtered, washed thoroughly with diethyl ether and dried The title compound is obtained in the form of a yellowish solid, MP = 235 ° C (decomposition).

The starting materials can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -2-aminoethane-phosphonic acid dimethyl ester 0.19 milliliter (1.2 equivalents) of triethyl amine, 0.215 milliliter (1.5 equivalents) of trimethylchlorosilane and 0.104 milliliter of dimethyl phosphite they are dissolved in dichloromethane at 0 ° C and the solution is stirred for 20 minutes. A solution of 329 milligrams (1135 millimoles) of 2,3-dimethoxy-5-ethylidenaminomethyl-7-nitroquinoxaline is added to the reaction mixture, and stirring is carried out at 0 ° C for 5 hours, and then at room temperature for 12 hours. The solution is diluted with water, and extracted three times with dichloromethane. The organic phases are combined, dried over magnesium sulfate and concentrated by evaporation. The title compound is obtained in the form of a yellow solid. b) 2,3-Dimethoxy-5-ethylidenaminomethyl-7-nitroquinoxaline 300 milligrams (1,135 millimoles) of 2,3-dimethoxy-5-aminomethyl-7-nitroquinoxaline, 500 milligrams (3.7 equivalents) of magnesium sulfate, and 200 milligrams (1.28 milligrams) equivalents) of potassium carbonate, are suspended in 20 milliliters of dichloromethane at room temperature. After 15 minutes, 0.13 milliliters of acetic aldehyde are added, and the reaction mixture is stirred at room temperature for 7 hours, then filtered and concentrated by evaporation.

Example 60: 2- (2,3-Dioxo-7-nitro-1.2.3.4-tetrahydroquinoxalin-5-ylmethoxy) -acetic acid 270 milligrams (0.711 mmol) tertiary butyl ester of 2- (2, 3-dimethoxy-7-nitroquinoxalin-5-ylmethoxy) -acetic are dissolved in 6 milliliters of a solution of hydrogen bromide at about 16 percent in acetic acid, and the solution is stirred at room temperature for 20 hours. The reaction mixture is diluted with diethyl ether, and the solid is filtered, washed with diethyl ether and dried. The title compound is obtained in the form of a solid (m.p. >300 ° C).

The starting material can be prepared, for example, as follows: a) 2- (2,3-Dimethoxy-7-nitroquinoxalin-5-ylmethoxy) -acetic acid tertiary butyl ester 300 milligrams (1.13 millimoles) of 2,3-dimethoxy -5-hydroxymethyl-7-nitroquinoxaline are placed in 8 milliliters of tetrahydrofuran, and cooled to 0 ° C. 52 milligrams added (1.05 equivalents) of NaH to about 55 percent in oil, and the mixture is stirred for 30 minutes at 0 ° C. Add to 0. 2 milliliters (1.5 equivalents) of tertiary butyl bromoacetic acid ester, and after 20 minutes the ice bath is removed. The reaction mixture is stirred at room temperature for 20 hours, diluted with water, and extracted with ethyl acetate. The combined organic phases are washed once with brine, dried over magnesium sulfate and concentrated by evaporation. The residue is passed through chromatography (Si02, ethyl acetate / petroleum ether, 1: 3), and the title compound is obtained in the form of a solid (340 milligrams). b) 2,3-Dimethoxy-5-hydroxymethyl-7-nitroquinoxaline The title compound is prepared as described in Example 14a), but starting from 5-bromomethyl-2,3-dimethoxy-7-nitroquinoxaline.

Example 61: 2- (7-Nitro-2,3-dioxo-1.2.3.4-tetrahydroquinoxalin-5-methoxy) -propionic acid The title compound is prepared in a manner analogous to that described in Example 60, but starting from tertiary butyl ester of 2-bromopropionic acid, - pf 268 ° C (decomposition).

Example 62: D-N- (7-nitro-2,3-dioxo-1.2.3.4-tetrahydro-5-ylmethyl) -4- »tnjnopyridinium bromide 212 milligrams (0.5 millimoles) of 4-amino-1- (2, 3) bromide -dimethoxy-7-nitroquinoxalin-5-ylmethyl) -pyridinium is stirred in 3 milliliters of a 48 percent solution of hydrogen bromide in glacial acetic acid for 18 hours at room temperature. The brown reaction mixture is diluted with 7 milliliters of diethyl ether, and then stirred for 10 minutes. The resulting solid is filtered, washed with a small amount of diethyl ether and dried. The title compound is obtained in the form of a yellow solid having a melting point of > 245 ° C (decomposition).

The starting material can be prepared, for example, as follows: a) 4-Amino-l- (2,3-dimethoxy-7-nitroquinoxalin-5-ylmethyl) -pyridinium bromide A solution of 197 milligrams (0.6 mmol) of 5-bromomethyl-2, 3-dimethoxy-7-nitroquinoxaline in 2 milliliters of dichloromethane is added at room temperature to a suspension of 282 milligrams (3 millimoles) of 4-aminopyridine in 1 milliliter of dichloromethane and 3 milliliters of acetonitrile, and then the mixture is stirred for 3.5 hours at room temperature. The resulting precipitate is filtered, and then washed on the filter with a small amount of acetonitrile. The title compound is obtained in the form of a colorless powder.

Example 63: Bromide of N- (7-nitro-2,3-dioxo-l.2.3.4-tetrahydrosuinoxalin-5-ylmethyl) -? - «™ inopyridinium The title compound can be prepared in a manner analogous to that described in Example 62, but starting from 3-aminopyridine; p.f. > 248 ° C (decomposition).

E om i »64: Bromide of N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydrosuinoxalin-5-ylmethi) -3-» minopyridinium The title compound can be prepared in a manner analogous to that described in Example 62, but starting from 2-aminopyridine; p.f. > 350 ° C (decomposition).

Example 65: 3- (7-chloro-2,3-dioxy-quinoxalin-5-yl) propan-l-ol The title compound is obtained in a manner analogous to that described in Example 15, by heating 3- (7-chloro-2,3-dimethoxyquinolalin-5-yl) -propan-1-ol with acetic acid / acid 2N hydrochloric The starting material can be prepared, for example, as follows: a) 5-Iodo-2, 3, 7-trichloroquinoxaline 406.9 grams (1953 moles) of phosphorus pentachloride are added to a mixture of 195.9 grams (0.93 moles) of 7-chloro-5-iodo-quinoxaline-dione in 1, 200 milliliters of phosphorus oxychloride, and the mixture is stirred under reflux for 18 hours. The excess phosphorus oxychloride is distilled from the reaction mixture at a bath temperature of 150 ° C. The residue is poured into 6,000 milliliters of ice water, and the resulting suspension is stirred for 2 hours, filtered with suction and then washed with a large amount of water. The filter residue is dried under vacuum at 60 ° C. 205.89 grams (89.4 percent) of 5-iodo-2,3,7-trichloroquinoxaline are obtained in the form of pale brown, raw crystals, which can be further reacted without further purification. b) 7-Chloro-2,3-dimethoxy-5-iodo-quinoxaline 205 grams (0.828 moles) of 5-iodo-2,3,7-trichloroquinoxaline are placed in 2.255 milliliters of methanol at room temperature, and 463.9 milliliters of an approximately 5.4 molar solution of sodium methanolate in methanol are added. Then the reaction mixture is heated to reflux, and stirred for 18 hours. The reaction mixture is cooled to 0 ° C, and the suspension is filtered with suction. Then the filter residue is washed with methanol and dried under vacuum at 60 ° C, and the crude product is purified by means of continuous extraction with diethyl ether. 96.4 grams (48.8 percent) of 7-chloro-2,3-dimethoxy-5-iodoquinoxaline having a melting point of 94-96 ° C are obtained. c) 3- (7-Chloro-2,3-dimethoxy-quinoxalin-5-yl) -prop-2-in-l-ol 12.9 grams (36.8 mmol) of 7-chloro-2,3-dimethoxy-5-iodo- quinoxaline, 7.6 milliliters (128.4 millimoles) of propargyl alcohol, 2.1 grams (3 millimoles) of bis (triphenylphosphine) -palladium dichloride, 6.6 milliliters (47.4 millimoles) of triethyl amine, and 0.34 grams (1.8 millimoles) of cuprous iodide are placed in 125 milliliters of dimethyl formamide, and heated to a bath temperature of 70 ° C. The reaction mixture is then stirred for 3.5 hours at that temperature, and then cooled to room temperature. Ethyl acetate is added to the reaction mixture, and extraction is carried out with water, IN hydrochloric acid and brine. The aqueous phases are washed with ethyl acetate. The organic phases are combined, dried over sodium sulfate, filtered with suction and concentrated. Chromatography of the crude product on silica gel with hexane / ethyl acetate (3: 1) yields 1.1 grams of 3- (7-chloro-2,3-dimethoxy-quinoxalin-5-yl) -prop-2-in. l-ol in the form of brown crystals that have a melting point of 137-140 ° C. d) 3- (7-Chloro-2,3-dimethoxy-quinoxalin-5-yl) -propan-1-ol 2.05 grams (7.36 mmol) of 3- (7-chloro-2,3-dimethoxy-quinoxalin-5) -il) -prop-2-in-l-ol are hydrogenated at a normal pressure in 20 milliliters of tetrahydrofuran with approximately 0.4 grams of Raney nickel, until twice the molar amount of hydrogen has been absorbed. The hydrogenated mixture is filtered with suction on a glass fiber filter, and the filtrate is concentrated. 2.04 grams (98 percent) of 3- (7-chloro-2,3-dimethoxy-quinoxalin-5-yl) -propan-1-ol are obtained in the form of beige crystals, which have a melting point of 104. -105 ° C.

Example 66: 4- (7-Chloro-2,3-dioxy-1,2,4-tetrahydro-uinoxalin-5-yl) butanol The title compound is obtained in a manner analogous to that described in Example 65, by means of 4- (7-chloro-2,3-dimethoxy-1, 2, 3,4-tetrahydroquinoxalin-5-yl) butanol, using in step c), instead of propargyl alcohol, the corresponding amount of -3-inol.

Example 67: N- [3- (7-chloro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-yl) propyl] -glycine Bromhydrate The title compound is obtained in a manner analogous to that described in Example 1, by the reaction of 5- (3-bromopropyl) -7-chloro-2,3-dimethoxy-quinoxaline with triethyl amine and tertiary glycine butyl ester hydrochloride, and triethyl amine in acetonitrile, followed by hydrolysis.

The starting material can be prepared, for example, as follows: a) 5- (3-Bromopropyl) -7-chloro-2,3-dimethoxy-quinoxaline 0.5 grams (1.77 millimoles) of 3- (7-chloro-2,3-dimethoxy-quininoal-5-yl) propan-1-ol , and 0.287 grams (1.77 millimoles) of 1,1 '-carbonyldi-imidazole are placed in 5 milliliters of acetonitrile under N2. 0.75 milliliters of allyl bromide are added, and then the mixture is stirred at room temperature for 30 minutes, and refluxed for 2 hours. The reaction mixture is cooled to room temperature, diethyl ether is added, and extraction is carried out with water, 0.1N hydrochloric acid, a saturated sodium hydrogen carbonate solution, and brine. The aqueous phases are then washed with diethyl ether. The organic phases are combined, dried over sodium sulfate, filtered over a layer of silica gel and concentrated. 0.438 grams (79.9 percent) of 5- (3-bromopropyl) -7-chloro-2,3-dimethoxy-quinoxaline are obtained in the form of a yellow oil, which is further used without further purification.

Example 68: N- (7-nitro-2,3-dioxy-l.2.3.4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl amine The title compound is obtained in a manner analogous to that described in Example 34 , by treating amine N- (7-nitro-2,3-dimethoxy-1, 2,3,4-tetrahydroquinoxalin-5-ylmethylene) -N-methyl, with a 25 percent solution of hydrogen bromide in acetic acid.

The starting material can be prepared, for example, as follows: a) N- (7-nitro-2,3-dimethoxy-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl amine Amine is reduced N- (7-Nitro-2,3-dimethoxy-1,2,4-tetrahydroquinoxalin-5-ylmethylene) -N-methyl with sodium borohydride in ethanol to form the title compound. b) 7-Bromo-5-formyl-2,3-dimethoxy-suinoxaline 1.38 grams (60 mmol) of sodium are dissolved in portions, at 0 ° C under N2, in 200 milliliters of methanol. At 0 ° C, 5.85 milliliters (65 millimoles) of 2-nitropropane are added dropwise. Then 18.1 grams (50 millimoles) of 5- (bromomethyl) -7-bromo-2, 3-dimethoxy-quinoxaline are added. The beige suspension is heated to reflux, and stirred for 1 hour. The reaction mixture is poured into 600 milliliters of water, and the methanol is distilled. The residue is extracted twice with ethyl acetate, and the organic phases are dried over sodium sulfate and filtered off with suction. The filtrate is concentrated, and the residue is dried under a high vacuum. 7-Bromo-5-formyl-2,3-dimethoxy-quinoxaline is obtained in the form of beige crystals having a melting point of 179-182 ° C. c) Imine N- (7-nitro-2,3-dimethoxy-1,2,4-tetrahydroquinoxalin-5-ylmethylene) -N-methyl The title compound is obtained by a customary condensation of 7-bromo-5- formyl-2,3-dimethoxy-quinoxaline with methyl amine. d) N- (7-Nitro-2,3-dimethoxy-1,2,3,4-tetrahydro-uinoxalin-5-ylmethylene) -N-methyl amine The title compound is obtained by the reduction of imine N- (7) -nitro-2,3-dimethoxy-1,2,3,4-tetrahydroquinoxalin-5-ylmethylene) -N-methyl in the customary manner, for example, by means of sodium borohydride in tetrahydrofuran.

Example 69: N- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroguinoxalin-5-ylmethyl) -N-triethyl-ammonium bromide The title compound can be prepared as described in Example 39, but starting from N- (2,3-dimethoxy-7-nitro-quinoxalin-5-ylmethyl) -N-triethyl-ammonium bromide, instead of N- (2,3-dimethoxy-) 7-nitro-quinoxalin-5-ylmethyl) -2-methylaziridine; ESC1"-MS: (M-H) + = 361; Thin layer chromatography: methanol / acetic acid (9: 1) Rf = 0.1 - 0.45.

The starting material can be prepared, for example, as follows: a) N- (2,3-dimethoxy-7-nitro-quinoxalin-5-ylmethyl) -N-triethyl-ammonium bromide 0.795 grams (3.65 millimoles) of bis-butoxy tertiary-carbonyl amine and 641 microliters (4.58 millimoles) of triethyl amine are added in succession to a solution of 1.0 grams (3.05 millimoles) of 5-bromomethyl-2,3-dimethoxy-7-nitro-quinoxaline in 5 milliliters of dimethyl formamide. After stirring for 4 hours at 50 ° C, 10 milliliters of methyl tertiary butyl ether are added to the suspension, filtration is performed, and the filter residue is washed with tertiary butyl methyl ether. The title compound is obtained as an unexpected by-product in the form of white crystals.

Example 70: 3 - [1- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) -ethylamino] ropionic acid ethyl ester A solution of 0.139 grams (0.5 millimoles) of l- (2,3- dimethoxy-7-nitro-quinoxalin-5-yl) -ethanone, 0.071 grams (0.5 millimoles) of ß-alanine ethyl ester hydrochloride, and 0.082 grams (0.5 millimoles) of sodium acetate in 50 milliliters of toluene, 2 milliliters of water and 20 milliliters of ethanol is concentrated at 250 mbar and 70 ° C. The product is recovered in a toluene / ethanol mixture (3: 1) and concentrated to dryness by evaporation under reduced pressure. The residue is recovered in 3 milliliters of tetrahydrofuran, and 0.023 grams (0.6 millimoles) of sodium boranate and 1 milliliter of methanol are added. After stirring for 18 hours at 25 ° C, the mixture is acidified with IN HCl, and after 15 minutes it is made basic again with an aqueous solution of 10% sodium hydrogen carbonate. The mixture is extracted with ethyl acetate. The organic phase is washed with brine, dried over sodium sulfate and concentrated to dryness by rotary evaporation. Chromatography on silica gel using ethyl acetate / hexane (1: 1) as eluent, affords the title compound in the form of an oil that solidifies immediately. Thin layer chromatography (EtOAc / hexane 1: 1): Rf = 0.20. H-NMR (CDC13): d 8.57 (d, J = 3Hz, 1H); 8.39 (d, J = 3Hz, 1 HOUR); 4.73 (q, J = Hz, 1H); 4.21 (s, 3H); 4.18 (s, 3H); 4.12 (q, J = 7Hz, 2H); 2.86-2.62 (m, 2H); 2.55-2.47 (m, 2H); 2.0-1.7 (br, NH); 1.51 (d, J = 7Hz, 3H); 1.23 (t, J = 7Hz, 3H).

The starting material can be prepared, for example, as follows: a) 5-Bromo-7-nitro-quinoxalin-2,3-dione A solution of Na2S2, prepared by the brief heating of 8.91 grams (40 millimoles) of crystalline sodium sulfide polyhydrate (content of sodium sulphide from 33 to 38 by percent in weight), and 1.28 grams of sulfur (40 millimoles) in a mixture of 40 milliliters of water and 10 milliliters of ethanol under reflux under a nitrogen atmosphere, is added to a stirred suspension of 10.48 grams (40 millimoles) of 2 -bromo-4, 6-dinitroaniline and 2.08 grams (40 millimoles) of ammonium chloride in 70 milliliters of ethanol and 40 milliliters of water. The mixture is stirred for 30 minutes at 65 ° C. Then 40 milliliters of 2N NaOH are added dropwise over the course of 30 minutes, and the mixture is then stirred for another 15 minutes at 65 ° C. After cooling, the reaction mixture is poured into a mixture of 40 milliliters of 2N HCl, 100 grams of ice and 700 milliliters of water, stirred for 15 minutes until the reaction is complete, and extracted twice with ethyl acetate. The combined organic phases are dried over sodium sulfate, treated with 3 grams of animal charcoal with brief heating, and filtered on High-Flow. Concentration using a rotary evaporator produces 3-bromo-5-nitro-l, 2-diamine reddish brown; thin layer chromatography: ethyl acetate / hexane (1: 1): R. = 0.40 Without further purification, the product is heated to 150 ° C (bath temperature) with 17 grams (135 millimoles) of oxalic acid dihydrate and 50 milliliters of oxalic acid diethyl ester in 100 milliliters of toluene. The ethanol and water formed in the course of the reaction are distilled together with the toluene during the reaction, by means of a short Vigreux column. Then the mixture is further heated to 190 ° C, until no more liquid is distilled. The excess oxalic acid diethyl ester is removed in vacuo. The olive green residue is suspended in 100 milliliters of acetic acid and heated to reflux for 3 hours. After cooling, filtration is carried out, and the gray solid is washed with a large amount of acetic acid, water, ethanol and methyl tertiary butyl ether. The title compound is obtained. Thin layer chromatography (EtOAc / HOAc 98: 2): Rf = 0.45. ^ -RMN (SODM-D6): d 12.3 (br, 1H, NH), 11.6 (br, 1H, NH), 8.19 (1H, d, J = 2.5Hz), 7.96 (1H, d, J = 2.5Hz ). b) 2,3-Dimethoxy-5-bromo-7-nitro-quinoxaline In a manner analogous to that described in Examples 4b2) and 4c2), starting from 5-bromo-7-nitro-quinoxaline-2,3-dione , the title compound is obtained in the form of yellow crystals.

P.f. = 171-175 ° C. γ NMR (CDClj): d 8.61 (d, J = 3Hz, 1H), 8.58 (d, J = 3Hz, 1H), 4.28 (S, 3H), 4.20 (s, 3H). c) 1- (2,3-Dimethoxy-7-nitro-quinoxalin-5-yl) -ethanone A mixture of 3.84 grams (12.23 millimoles) of 2,3-dimethoxy-5-bromo-7-nitro-quinoxaline, 4.41 grams ( 12.23 millimoles) of tributyl- (1-ethoxy-vinyl) -stannate, and 0.055 grams (0.244 mmol) of Pd (OAc) 2 in 50 milliliters of dimethyl formamide is stirred for 4 hours at 80 ° C. The majority of the solvent is removed under reduced pressure. The residue is taken up in ethyl acetate, washed with water and brine, dried and concentrated by rotary evaporation. Chromatography on silica gel using methylene chloride / hexane (1: 1) as eluent yields the intermediate vinyl ether in the form of a light yellow solid. This material is stirred for 1 hour in tetrahydrofuran / IN HCl at 25 ° C. The mixture is diluted with ethyl acetate, washed three times with brine, dried over sodium sulfate and concentrated by rotary evaporation. The title compound is isolated (using ethyl acetate / hexane) in the form of light yellow needles. P.f .: 155-157 ° C. Thin layer chromatography (EtOAc / hexane 1: 3): Rf = 0. 25 Example 71: 3- [1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydrocruinoxalin-5-yl) -1-ethylamino] -propionic acid hydrochloride A suspension of 0.13 grams (0.34 millimoles) of ester Ethyl 3- [1- (2, 3-dimethoxy-7-nitro-quinoxalin-5-yl) -ethylamino] propionic acid in 3 milliliters of methanol and 2 milliliters of 2N NaOH, is stirred at 25 ° C. After 1 hour, the mixture is adjusted to a pH of 4 and extracted with chloroform / ethanol. The combined organic phases are extracted, dried over Na 2 SO 4 and concentrated by rotary evaporation. The residue is heated up to the boiling point with 4N HCl for 18 hours. The mixture is concentrated to dryness by rotary evaporation. Crystallization from water yields the title compound in the form of light beige crystals having a melting point of > 300 ° C. LH-NMR (SODM-D6): d 12.4 (s, 2H); 8.32 (d, J = 3Hz, 1H); 8. 02 (d, J = 3Hz, 1H); 5.1-4.95 (br, 1H); 3.2-2.9 (br, 2H); 2.67 (t, J = Hz); 1.57 (d, J = 7Hz, 3H). MS (ES-): 321 (MH). "Example 72: Tertiary butyl ester of 1- [2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroguinoxalin-5-yl) ethyl) -piperidin-4-carboxylic acid The title compound can be prepared in a manner analogous to that described in Example 1, by the reaction of (2,3-dimethoxy-7-nitro-quinoxalin-5-yl methanesulfonate. ) -ethyl with tertiary butyl ester of piperidin-4-carboxylic acid.

The starting material can be prepared, for example, as follows: a) 2, 3-Dimethoxy-7-nitro-5-vinyl-auinoxaline A mixture of 3.14 grams (1 millimole) of 5-bromo-2,3-dimethoxy-7-nitro-quinoxaline, 6.34 grams (2 millimoles) of tributylvinylstannane, 1.26 grams (3 millimoles) of lithium chloride, and 1.4 grams (0.2 millimoles) of bis (triphenylphosphine) -palladium (II) chloride in 20 milliliters of dimethyl formamide, is heated for 2 hours at 100 ° C. The mixture is cooled to room temperature, and concentrated to dryness by evaporation under reduced pressure. Purification by evaporation chromatography using toluene as eluent affords the title compound in the form of a slightly yellowish solid. b) 2- (2,3-Dimethoxy-7-nitro-quinoxalin-5-yl) -ethanol The title compound is obtained by borohydride customary, for example, with the dimethyl sulphide / borane complex. c) 2- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) -ethyl ester methanesulfonate The title compound is obtained by the customary reaction with methanesulfonyl chloride.

Example 73: l-l2- (7-Nitro-2,3-dioxo-1, 2.3.4-tetrahydro-uinoxalin-5-yl) -etill -piperidine-4-carboxylic acid The title compound can be prepared in an analogous manner to that described in Example 6, but starting from tertiary butyl ester of 1- [2- (7-nitro-2, 3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-yl) -ethyl ester ] -piperidine-4-carboxylic acid.

Example 74: 2- [2- (7-Nitro-2,3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-yl) -ethylamino] -propionic acid methyl ester The title compound is obtained analogously to that described in Example 72, but starting from alanine methyl ester.

Example 75: 2- [2- (7-Nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) -ethylamino] -propionic acid The title compound can be prepared in an analogous manner to that described in Example 22, but starting from 2- [2- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-yl) methyl ester hydrochloride - ethylamino] -propionic.

Example 76: 2-amino-3- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydrosuinoxalin-5-yl) -propionic acid A suspension of 0.29 grams (0.62 millimoles) of diethyl ester of 2-Acetylamino-2- (2,3-dimethoxy-7-nitro-quinoxalin-5-ylmethyl) -malonic acid in 6 milliliters of 6N hydrochloric acid, heat to reflux for 24 hours, and then concentrate to dryness under pressure reduced. After boiling the residue with water, centrifugation and drying, the title compound is obtained in the form of a yellow powder. * H-NMR (S0DM-D6): d 12.3-11.9 (br, 2H), 10.3-9.2 (br), 7. 98 (d, J = 3Hz, 1H), 7.90 (d, J = 3Hz, 1H), 3.50-3.45 (m, 1H), 3. 40-3.32 (m, 1H), 3.06-2.98 (m, 1H). (ES +) - MS: [M + Na + NH4] + The starting material can be prepared, for example, as follows: a) 2-Acetylamino-2- (2,3-dimethoxy-7-nitro-quinoxalin-5-ylmethyl) -malonic acid diethyl ester 0.217 grams (1 millimole) of diethylacetamide malonate are added to a solution, stirred under argon , of 0.026 grams (1.2 millimoles) of sodium in 3 milliliters of ethanol. After 5 minutes, 0.328 grams (1 millimole) of 2,3-dimethoxy-5-bromomethyl-7-nitro-quinoxaline are added, and then the mixture is stirred for 18 hours at 25 ° C. The mixture is diluted with ethyl acetate, washed with IN hydrochloric acid, and then with brine, dried over sodium sulfate and concentrated by rotary evaporation. Chromatography on silica gel using ethyl acetate / hexane (1: 2) as eluent, affords the title compound in the form of an oil which soon solidifies. Thin layer chromatography (EtOAc / hexane 1: 2): Rf = 0.35. ^ -RMN (CDC13): d 8.57 (d, J = 3Hz, 1H), 8.01 (d, J = 3Hz, 1H), 6.34 (S, 1H), 4.36-4.24 (m, 4H), 4.25 (s, 3H), 4.18 (s, 3H), 1.85 (S, 3H), 1.31 (t, J = 7Hz, 6H) . g «a pio 77 i 3-Amino-3- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) -propionic acid hydride A solution of 0.15 grams (0.39 mmol) of 3- ( 2, 3-dimethoxy-7-nitro-quinoxalin-5-yl) -3-methoxycarbonylamino-propionic acid in 5 milliliters of HBr / HOAc at 33 percent, is heated for 16 hours at 70 ° C. After cooling, the gray suspension is diluted with tertiary butyl methyl ether, and filtered with suction. The title compound is obtained in the form of a gray powder. XH-NMR (SODM-D6): d 12.41 (s, 1H), 12.4-11.8 (br, 1H), 8.7-8.3 (br, NH3 +), 5.4-5.28 (m, 2H), 3.16-2.96 (m, 2H); FAB-MS: [M + l] + 295.

The starting material can be prepared, for example, as follows: a) methyl f1- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) -but-3-enyl carbamate SV-2560 1.26 milliliters of BF3 «OEt2 are added all at once to a suspension, stirred at 0 ° C, 2.63 grams (10 millimoles) of 2,3-dimethoxy-7-nitro-quinoxaline-5-carbaldehyde, 0.75 grams (10 millimoles) of methyl carbamate, and 1.2 grams (10.5 millimoles) of allyltrimethylsilane in 30 milliliters of acetonitrile. The mixture is stirred for 30 minutes at 25 ° C, and then poured into a 10% aqueous sodium carbonate aqueous solution, and diluted with brine and ethyl acetate. The organic phase is separated, dried, and concentrated by rotary evaporation. Crystallization of the crude product produces the title compound in the form of almost colorless crystals; p.f. = 135-136 ° C. Thin layer chromatography (EtOAc / hexane 1: 3): Rf 0. 17 b) 3- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) -3-methoxycarbonylamino-propionic acid A mixture of 0.31 grams (0.85 millimoles) of [l- (2,3-dimethoxy-7-nitro- quinoxalin-5-yl) -but-3-enyl] methyl carbamate, 0.733 grams (3.42 mmol) of sodium iodate (NalO.), and 0.01 grams of ruthenium oxide (Ru0) in 5 milliliters of acetonitrile, 5 milliliters of carbon tetrachloride and 5 milliliters of water, vigorously stirred for 4 hours at ß 25 ° C. The mixture is then filtered over High-Flow, and then washed with ethyl acetate and water. The organic phase is washed in succession with IN hydrochloric acid and brine, dried over sodium sulfate and concentrated by rotary evaporation.

The residue is mixed again with 0.50 grams of sodium iodate, 0.005 grams of ruthenium oxide in a mixture of 5 milliliters of water, 5 milliliters of acetonitrile, and 5 milliliters of carbon tetrachloride, and stirred vigorously for an additional 1 hour. The mixture is filtered over High-Flow, and then washed with ethyl acetate and water. The organic phase is separated, washed with brine, dried over sodium sulfate and concentrated by rotary evaporation. Crystallization of the crude product from tertiary butyl methyl ether produces the title compound in the form of gray crystals. Thin layer chromatography EtOAc / HOAc 98: 2): Rf = 0.52. ^? - NMR (CDC13): d 8.61 (d, J = 3Hz, 1H), 8.32 (d, J = 3Hz, 1H), 6.36-6.28 (m, 1H), 6.02-5.88 (m, 1H), 4.23 (s, 3H), 4.19 (s, 3H), 3.68 (s, 3H), 3.18-3.09 (m, 2H).Example 78: The following can also be prepared in a manner analogous to that described in Examples 1 to 77: N- (2,3-dioxo-7-nitroyl, 2, 3, 4-tetrahydroquinoxalin-5 hydrobromide. -ylmethyl) -4-trif luorometylpiperidine, p. f. = 273 ° C (decomposition); N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminobenzimidazole hydrobromide, m.p. > 300 ° C; amine hydrobromide N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -di-isopropyl, m.p. = 284 ° C (decomposition); N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-propylonormal-piperidine hydrobromide, m.p. = 286 ° C; N- (2,3-thioxo-7-nitro-1,2, 3,4-tet rahydroquinoxal in-5-ylmethyl) -4-amino-butyl-normal phosphonic acid bromide, MS (ES +): (M + H) + = 373; N- (2,3-dioxo-7-nitro-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl-4-amino-butyl normal -phosphonic acid hydrobromide, MS (ES +): ( M + H) + = 387; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tet rahydroquinoxalin-5-ylmethyl) -N-methyl-12-amino -dodecanoic acid, m.p. = 232-238 ° C (decomposition), - amine N- (7-nitro-2, 3-dioxo-l, 2, 3, 4-te rahydroquinoxalin-5-ylmethyl) -4-hydroxy-3-methoxy-benzyl , pf > 270 ° C; Amide hydrobromide N- [1- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -methanesulfonic acid ester, (ES) -MS: 410 [MH], - N- [1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -acetic amide hydrobromide, ( ES) -MS: 374 [MH]; amide bis- hydrobromide N- [1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -nicotinic acid, (ES) -MS : 437 [MH]; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4- (4-fluorobenzoyl) -piperidine, (AP) -MS: 425 [MH] , - acid hydrobromide. { 3- [(7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -2-oxo-2,3,4,5-tetrahydro-benzo [.b . ] azepin-1-yl} -acetic, (ES +) - MS: 454 [M + H] +; 4- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperazine-2-carboxylic acid, - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (3-chlorophenyl) -sulfonic acid; p.f. > 270 ° C; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) - (3-carboxyphenyl) -sulfonic acid amide; p.f. > 270 ° C; 4- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-methyl-3,5-dioxo-piperazine, (AP) -MS: 346 [MH] , - amide hydrochloride 4- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -methyl) -benzenesulfonic acid, mp. > 270 ° C; amine hydrobromide N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-azepin-3-yl, m.p. > 270 ° C; 4-hydrochloride. { [(7-nitro-2, 3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -methyl} -benzoic acid, m.p. > 270 ° C; 4- [(7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -benzoic acid hydrochloride, m.p. > 270 ° C; 5- [(7-Nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -3H-imidazole-4-carboxylic acid amide, m.p. > 270 ° C; Morpholine hydrobromide N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -3,5-dimethyl, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) -4,4-ethylenedioxy-piperidine hydrochloride, m.p. = 290 ° C (decomposition); N- (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-methyl-piperidine hydrobromide, m.p. > 300 ° C (decomposition), N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxy-piperidine hydrochloride, m.p. = 290 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-hydroxymethyl-pyrrolidine hydrochloride, m.p. = 247 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-acetoxymethyl-pyrrolidine hydrobromide, m.p. = 175 ° C (decomposition), - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxy-pyrrolidine-2-carboxylic acid hydrochloride, pf = 241 ° C (decomposition); N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-hydroxy-piperidine hydrochloride, m.p. > 2- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethylamino) - (L) -butyric acid hydrochloride, m.p. = 238 ° C (decomposition), 2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) - (L) -butyric acid methyl ester hydrobromide, m.p. = 218 ° C (decomposition); 2- (7-Nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethylamino) -isobutyric acid hydrochloride, m.p. > 300 ° C; 2- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -isobutyric acid methyl ester hydrobromide, m.p. = 243 ° C (decomposition); 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -cyclopropane-1-carboxylic acid hydrochloride, m.p. = 254 ° C (decomposition); N- [N- (7-nitro-2, 3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl- (L) -alanine hydrochloride, m.p. = 277 ° C (decomposition), - N- (7-nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -leucine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -treonine hydrobromide, m.p. = 215 ° C (decomposition), N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methyl-d-alanine hydrochloride, m.p. = 238 ° C (decomposition), N- (7-nitro-2,3-dioxo-l, 2, 3, 4-t €? Trahydroquinoxalin-5-ylmethyl) -4-picolylamine dibromhydrate, m.p. = 218 ° C (decomposition); N- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-picolylamine dibromhydrate, m.p. = 229 ° C (decomposition); N- (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -aminoacetonitrile hydrobromide, m.p. = 275 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-benzylidenepiperidine hydrobromide, m.p. = 242 ° C (decomposition); N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-phenylpiperidine 4-carboxylate hydrochloride, m.p. > 280 ° C; N- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4 -carbamoylpiper idine hydrobromide, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-methylmethyl) -3-methyl-β-alanine hydrochloride, m.p. = 298 ° C (decomposition), - N- (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-f-1-4 -me toxy carboni hydrobromide 1-piperidine, mp = 258 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -imidodiacetic acid hydrochloride, m.p. = 257 ° C (decomposition), N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-tetrahydroisoquinoline hydrobromide, m.p. = 300 ° C (decomposition); N- (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminobenzothiazole hydrobromide, m.p. = 272 ° C (decomposition), - 1- (7- nit) -2, 3-dioxo-1, 2,3, 4-heptohydroquinoxalin-5-ylmethylamino) ethanophonic acid, - N- (7-) nitro-2, 3-dioxo-l, 2,3,4-heptohydroquinoxalin-5-ylmethyl) -N-acetyl- (L) -alanine; N- (7-nitro-2,3-dioxo-1, 2, 3, 4 -hydrohydroquinoxalin-5-ylmethyl) -4-phenyl-piperidine hydrobromide, m.p. > 230 ° C; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-qtiinoxalin-5-ylmethyl) -4-hydroxymethyl-piperidine hydrochloride, m.p. = 248 ° C (decomposition); N- (7-nitro-2, 3-dioxo-1,2,4-tetrahydro-quinoxalin-5-ylmethyl) -2-hydroxymethyl-piperidine hydrochloride, m.p. = 286 ° C (decomposition), - N- (7-nitro-2,3-dioxo-1,2,4-tetrahydro-quinoxalin-S-ylmethyl) -4- (1-hydroxyethyl) -piperidine hydrochloride , pf = 238 ° C (decomposition), N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -4-methoxypiperidine hydrochloride, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methylpiperidine, - N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-methoxy-4-methyl-piperidine; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -4,4-dimethoxypiperidine, N- (7-nitro-2,3- hydrochloride) dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (L) -serine, mp = 228 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -O-acetyl- (L) -serine hydrobromide, m.p. = 250 ° C (decomposition), - N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -azepin-2-one, - N- (7 -nitro-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-2-one, -1- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-ethyl-4-methyl-imidazole; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-cpiinoxalin-5-ylmethyl) -4-oxo-pyrrolidine-2-carboxylic acid, N- (7-nitro) hydrobromide -2, 3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -2-amino-5-bromopyrimidine, mp > 274 ° C; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -5-amino-2-methoxypyrimidine hydrobromide, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydro-quinoxalin-5-ylmethyl) -2-aminopyrimidine hydrobromide, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -2-aminopyridine hydrobromide, m.p. > 300 ° C; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3-aminopyridine hydrobromide, m.p. = 213 ° C (decomposition), N- (7-nitro-2,3-dioxo-1,2,4-tetrahydro-quinoxalin-5-ylmethyl) -2-amino-4-methylpyrimidine hydrobromide, m.p. = 200 ° C (decomposition), - N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-amino-5-tertiary butyl-isoxazole, m.p. = 148-150 ° C (decomposition); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4,5-dicyanoimidazole hydrobromide, m.p. > 300 ° C; ammonium bromide N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -N, N, N-triethyl; 1- (7- nitro -2,3-dioxo-1, 2,3,4-tetrahydro-cfuinoxalin-5-ylmethyl) -1,2,4-triazole-3-carboxylic acid 1- (7 - ni tro -2, 3-dioxo- 1, 2,3, 4-tetrahydro-β-piinoxalin-5-ylmethyl) -1,2,4-triazole-5-carboxylic acid, 4- (7-nitro) -2, 3-dioxo-l, 2, 3, 4-tetrahydro-cp? Inoxalin-5-ylmethyl) -1, 2,4-triazole-3-carboxylic acid; 1- (7- nitro -2,3-dioxo-1, 2,3,4-tetrahydro-β [uinoxalin-5-ylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid; 1- (7-nitro-2,3-dioxo-1,2, 3,4-tetrahydro-quinoxalin-S-ylmethyl) -1,2,4-triazole; 1- (7-Nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,4-triazole-5-carboxylic acid ethyl ester 2- (7 - nor ro -2, 3-dioxo- 1, 2,3, 4-tetrahydro-quinoxalin-5-ylmethyl) -1,2,3-triazole-4,5-di-carboxylic acid; 1- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-methylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid dimethyl ester 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -1,2,3-triazole-4-carboxylic acid; 1- (Chloro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -1,2,3-triazole-4-carboxylic acid amide - dimethyl ester of acid 1- (7-nitro-2, 3-dioxo-l, 2,3,4-tet-rahydroquinoxalin-5-methylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid, mp. = 173-175 ° C; 2- (7-nitro-2,3-dioxo-1,2,3-tetrahydro-quinoxalin-5-ylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid, m.p. 290 ° C (decomposition) - acid l- (7-nitro-2, 3 -dioxo- 1, 2,3, 4- tetrahydro-quinoxalin-5-ylmethyl) -imidazole-2, 4, 5-tricarboxylic acid, - P-benzyl- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -methanophosphinic acid; P-methyl- (7-nitro-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-yl) -metanfosfínico, - N- (7-nitro-2, 3 -dioxo- 1 acid, 2,3, 4 - etrahidroquinoxalin-5-yl) -carbamoilmetanfosfónico, - 1- (7-nitro-2, 3-dioxo-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-1, 2-dihydropyridine; 2- (7-nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-tetrahydroisoquinolin-l-one, - 1- (7-nitrous) -2,3-dioxo-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2,3,4,5-tetrahydro-lH-l-benzazepin-2-one, - N- (7-nitro- 2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-3-phenylpiperidine, - N- (7-nitro-2,3-dioxo-l, 2, 3, 4 -tetrahidroquinoxalin-ylmethyl-5) -2-oxo-5-phenylpiperidine, • N- (7-nitro-2, 3-dioxo-1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -5-methylpyrrolidin-2 -one, 4- (2-oxoimidazolidin-1-yl) -N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine; N-. { 2- [N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) amino] ethyl} -pyrrolidin-2-one; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-phenylpyrrolidin-2-one, - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4- (fluorobenzoyl) -piperidine; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -2-oxo-2-phenylacetic acid amide; amide N- (7-bromo-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-propyl-pentanoic - amide N- (7-bromo-2 acid, 3-Dioxo-1,2,3,4-tetrahydro-cn-inoxalin-5-ylmethyl) - (4-methyl-furan) -2-carboxylic acid, N- (7-bromo-2,3-dioxo- 1, 2, 3,4-tetrahydro -? [Uinoxalin-5-ylmethyl) -thiophen-3-carboxylic acid, mp. > 250 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-cpiinoxalin-5-ylmethyl) -imidazole-4-carboxylic acid amide; N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydro-? fuinoxalin-5-ylmethyl) -3- (thien-3-yl) -acrylic acid amide; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-qtuinoxalin-5-ylmethyl) -2-phenyl isobutyric acid amide; N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydro-qruinoxalin-5-ylmethyl) -1-phenylcyclopropanecarboxylic acid amide; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-phenylpropionic acid amide, N- (7-bromo-2, 3-) acid amide dioxo-l, 2, 3, 4-tetrahydro-quinoxalin-5-ylmethyl) -2-feniglicólico, - N- (7-bromo-2, 3-dioxo-l, 2, 3, 4-tetrahydro-quinoxaline 5-ylmethyl) - (3,4-dimethoxyphenyl) -acetic, mp >; 280 ° C; amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (4-chlorophenyl) -acetic acid, - N- (7-bromo-2,3-amide) dioxo-1, 2,3, 4-tetrahydro-quinoxalin-5-ylmethyl) - (3-chlorophenyl) -acetic, -amide N- (7-bromo-2,3-dioxo- 1, 2,3, 4- tetrahydro-quinoxalin-5-ylmethyl) - (2-chlorophenyl) -acetic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - ( 3-methylthiophen) -2-carboxylic, mp > 280 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (5-methylthiophen) -2-carboxylic acid amide, m.p. > 280 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (1-methylpyrrole) -2-carboxylic acid amide, m.p. > 280 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -nicotinic acid amide hydrochloride, m.p. = 272 ° C (decomposition), - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (4-nitrophenyl) acetic amide, m.p. > 270 ° C; N- (7-bromo-2,3-dioxo-1,2,3-tetrahydro-quinoxalin-5-ylmethyl) - (3-nitrophenyl) acetic acid, m.p. > 270 ° C; N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (2-nitrophenyl) acetic amide, m.p. > 270 ° C, - amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) - (3,4-methylenedioxyphenyl) acetic acid, m.p. > 270 ° C; amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) - (3-phenyloxyphenyl) acetic acid, • N- (7-bromo-2) acid amide , 3-dioxo-1,2, 3,4-tetrahydro-fiinoxalin-5-ylmethyl) -picolinic acid, - 7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethylaminomethanephosphonic acid, pf > 270 ° C; 1- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethylamino) ethanephosphonic acid • N- (7-bromo-2,3-dioxo-1,2-acid) , 3,4-tetrahydro-fiinoxalin-5-ylmethyl) -N-benzyloxycarbonyl-amino-methane-phosphonic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -benzyl urethane, - N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-yl ethyl) -phenylurethane, - N- (7-bromo-2,3-dioxo- 1, 2,3, 4-tetrahydro-fiinoxalin-5-ylmethyl) -N-phenylacetylaminomethanephosphonic acid, - N- (7-bromo-2,3-dioxo-1,2,4-tetrahydro-fiinoxalin-5-ylmethyl) ) -N-phenylacetyl-glycine, 3-acetyl-1- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole hydrobromide, mp. = 225 ° C (decomposition), 1- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrro1-3-carboxylic acid ethyl bromide, m.p. = 195 ° C (decomposition); amide N-methyl-N- (7-bromo -2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -phenylacetic, m.p. > 260 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-acetoxypyrrolidine hydrobromide, m.p. = 246 ° C; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-hydroxypyrrolidine hydrochloride, m.p. = 263 ° C; 1- (7-nor ro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-3-carboxylic acid, - 1- (7-nitro-2,3-dioxo) acid - 1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-2-carboxylic acid; tertiary butyl ester of 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-2-carboxylic acid; l- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -indol-3-ylacetic acid, - 1- (7-nitro-2, 3-ethyl) -dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -indol-3-ylacetic acid, 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5) -ylmethyl) -indol-3-ylcarboxylic acid, • tertiary butyl ester of 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -indole-2-carboxylic acid, - 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -indole-2-carboxylic acid; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -imidazole hydrobromide, m.p. > 300 ° C; 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxymethylimidazole; 1- [1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -imidazol-4-yl] acetic acid, 1- (7-nitro-hydrobromide) 2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -4-methyl-imidazole, mp >; 300 ° C; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -2-methyl-imidazole hydrobromide, m.p. > 300 ° C; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-ethyl-imidazole hydrobromide, m.p. > 300 ° C; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -pyrazole hydrobromide, m.p. > 300 ° C; 1- (7-ni ro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -3,5-dimethylpyrazole hydrobromide, m.p. > 300 ° C; 2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -1, 2,4-triazole hydrobromide, m.p. > 250 ° C; 1- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole; 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperazin-3-one, 1- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -oxazolidin-2-one, 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4- methyl-piperazine-3,5-dione; 3- (7-nitro-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2,3,5,6-tetrahydro-4H-1,2-oxazine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -anthranilic acid; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -anthranilic acid methyl ester; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -anthranilic acid ethyl ester; 1- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-benzyl-4-acetylaminopiperidine, 1- (7-nitro-2,3-dioxo- 1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-phenyl-4-acetylaminopiperidine, - acid. { 3- (7-nitro-2, 3-dioxo-1,2,4,4-tetrahydro-quinoxalin-5-ylmethylamino) -2-oxo-l, 2,3,4-tetrahydrobenzo [b] -azepin-1 -il} -acetic; amine N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -N-iopyl-N- (quinolin-4-ylmethyl, -4- (7- nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethylamino) -5-phenyl-pent-1-ene; 2- (7-nitro-2,3-dioxo- 1, 2 , 3,4-tetrahydro-quinoxalin-5-ylmethyl) -N- (4-nitrophenyl) -acetic acid, - N- [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin) -5-ylmethyl) -glycyl] glycine; N- [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -glycyl] -N-methylglycine, - 1- [N- (7-nitro- 2, 3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) glycyl] -pyrrolidine-2-carboxylic acid; N- [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) glycyl] -phenylalanine, 2- (7-nitro-2,3-dioxo) -l, 2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -alanine; 3- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethylamino) -propanol hydrochloride; 3- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -ethanol hydrochloride; amide N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -5-dimethylamino-naphthanesulfonic acid; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-benzyl-aziridine; 2- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-cniinoxalin-5-yl) ethylamino] -acetic acid, 1- [2- (7-nitro-2 , 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] piperidine; 1- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-yl) et il] piperidin-4-one, - 1 - [2 - (7-nitro- 2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidin-3-ol; 1- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-yl) ethyl] piperdin-4-carboxylic acid, 1- [2- (7- nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-yl) ethyl] -4-acetylaminopiperidine, - 1- [2- (7-nitro-2,3-dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidin-2,5-dione, 1- [2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) ethyl) piperidin-2,6-dione, -1- [2- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidine; amine N-. { 2- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-yl) ethyl]} -N- (pyrazin-2-ylica); amine N-. { 2- [2- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) ethyl]} -N- (thiazol-2-yl), - N-acid amide. { 2- [2- (7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-yl) ethyl]} -quinolin-4-carboxylic acid; N- [2- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-yl) ethyl] -methanesulfonic acid amide; N- [2- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-yl) ethyl] -benzenesulfonic acid amide; N- [2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-yl) ethyl] -acetic amide; N- [2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) ethyl] - (4-methoxy) -benzene amide.

No. 79: Tablets may be prepared, each comprising 50 milligrams of active ingredient, for example, 7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid or a salt thereof. same, as follows: Composition (10,000 tablets) active ingredient 500.0 grams lactose 500.0 grams potato starch 352.0 grams gelatin 8.0 grams talcum 60.0 grams magnesium stearate 10.0 grams silicon dioxide (highly dispersed) 20.0 grams ethanol q.s. The active ingredient is mixed with lactose and 292 grams of potato starch, and the mixture is moistened with an ethanolic solution of the gelatin, and is granulated through a sieve. After drying, the rest of the potato starch, magnesium stearate, talc and silicon dioxide are mixed, and the mixture is compressed into tablets, each weighing 145.0 milligrams, and comprising 50.0 milligrams of active ingredient; if desired, the tablets may be provided with notches to break, for a finer adaptation of the dose.

Example 80: A solution of sterile filtered aqueous gelatine, fie comprises 20 percent cyclodextrins as a solubilizer, and fie comprises 3 milligrams of 7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5 acid or a salt, for example, the sodium salt thereof, as an active ingredient, is mixed under aseptic conditions, with heating, with a sterile gelatin solution comprising phenol as a preservative, such that 1.0 milliliter of the solution has the following composition: active ingredient 3 milligrams gelatin 150.0 milligrams phenol 4.7 milligrams distilled water with 20% cyclodextrins as a solubilizer. 1.0 milliliters Example 81: For the preparation of a sterile dry substance for injection, comprising 5 milligrams of 7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid or a salt, for example the sodium salt thereof, 5 milligrams of one of the compounds of Formula I mentioned in the preceding Examples, as active ingredient, are dissolved in 1 milliliter of an aqueous solution comprising 20 milligrams of mannitol, and 20 percent cyclodextrins as solubilizer. The solution is sterile filtered, and is introduced under aseptic conditions in a 2 milliliter vial, deep frozen, and lyophilized. Before use, the lyophilisate is dissolved in 1 milliliter of distilled water, or in 1 milliliter of a physiological saline solution. The solution is administered intramuscularly or intravenously. The formulation can also be introduced in ampoules for double chamber injection.

Example 82: 10,000 film-coated tablets can be prepared, each comprising 100 milligrams of 7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid or a salt, for example, sodium salt thereof, as follows: active ingredient 1000 grams corn starch 680 grams colloidal silicic acid 200 grams magnesium stearate 20 grams stearic acid 50 grams sodium carboxymethyl starch 250 grams water cs A mixture of one of the compounds of Formula I mentioned in the preceding Examples, as an active ingredient, 5C grams of corn starch, and colloidal silicic acid, is processed with starch paste consisting of 250 grams of corn starch and 2.2 grams of corn starch. kilograms of demineralized water to form a moist mass. The wet mass is forced through a sieve having a mesh size of 3 millimeters, and dried at 45 ° C for 30 minutes in a fluidized bed dryer. The dried granules are compressed through a sieve having a mesh size of 1 millimeter, mixed with a previously sieved mixture (1 millimeter sieve) of 330 grams of corn starch, magnesium stearate, stearic acid and the sodium carboxymethyl starch, and compress to form slightly biconvex tablets.

Example 83: In a manner analogous to that described in Examples 79 to 82, it is also possible to prepare pharmaceutical preparations comprising a different compound according to any of Examples 1 to 78.

Claims

1. A 2,3-dioxo-1,2,4,4-tetrahydroquin-xalinyl derivative of the formula I: wherein: one of the radicals R] and R2 is a group R5 and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), -alk-CH (R6) -R7 (Ib) , -alq-N (Rg) -X-R7 (lc), -alq-N + (Rg) (R9) -X-R7 A "(Id), -alq-0-X-R7 (le) or -alq -SX-R7

(If). R3, R4 and R_ are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is unsubstituted amino or lower alkylated and / or lower alkanoylated, - R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; cyano; acyl derived from carbonic acid or a half-ester or half-amide of carbonic acid, sulfuric acid or an aliphatic or aromatic sulfonic acid or of phosphoric acid or of a phosphonic acid ester; amino which is unsubstituted or aliphatic or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl, - or an aromatic or heteroaromatic radical, Rg is hydrogen; an aliphatic or araliphatic radical; or icyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic carboxylic acid half ester, or R7 and Rg, together with X and the nitrogen atom linking Rg and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl unsubstituted or substituted, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7, Rg and R9, together with X and the nitrogen atom linking Rg, R9 and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through a quaternary nitrogen atom, where A "is the bond of a protonic acid, alk is lower alkylene, and X (except that, together with R7 and Rg and the nitrogen atom linking R8 and X or together with the nitrogen atom linking Rg, R9 and X, is part of one of the abovementioned ring systems) is a bivalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, with the proviso that, in the compounds of the formula 1 wherein Rj, R3 and R4 are hydrogen and R2 is a group of the formula Ib, when alq is methylene, Rg is not amino or R7 is not carboxy, with the additional proviso that, in the compounds of the formula I in where R1, R3, and R4 are hydrogen and R2 is a group of the formula le, when alq is methylene, the group -N (Rg) -X-R7 is not 1-imidazolyl, or when alq is ethylene, the group -N (R8) -X-R7 is not amino, dipropylamino, N- (2-phenylethyl) -N-propyl-amino and N '- (2-chlorophenyl) piperazino, and with the final condition that, in the compounds of the formula I wherein Rj is a group of the formula le, R2 and R3 are each independently fluorine, chlorine, bromine, methyl, ethyl or trifluoromethyl and R4 is hydrogen, when alq is methylene, ethylene, or propylidene, the group -N (Rg) -X-R7 is not a 5-membered mono-, di-, tri- or tetra-azaheteroaryl radical linked through a nitrogen atom and is optionally benzocondensated and / or substituted by alkyl that you have up to 6 carbon atoms inclusive, or is it substituted in the position? by a group of the formula -N (Ra) -Rb where Ra and Rb are each independently hydrogen, alkyl, cycloalkyl, phenylalkyl or lower pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino group , piperazino, N 1 - lower alkyl-piperazino, morpholino or azepino; or a salt of them. 2. A compound of the formula I according to claim 1, wherein: one of the radicals R1 and R2 is a group R5, and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), -alk-CH (R6) -R7 (Ib), -alk-N (Rg) -X-R7 (Ic), -alq- N + (Rg) (R9) -X-R7 A- (Id ), -alk-0-X-R7 (Ie) or -alk-SX-R7 (If), R3, R4, and R5 are each independently of the others, hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, R6 is amino, lower alkyl-amino, lower alkanoyl-amino, lower N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R7 is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-lower aminoalkyl, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, lower polyhaloalkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl , or lower polyhaloalkoxy-lower alkyl, 3- to 8-membered cycloalkyl, carboxycycloalkyl, lower alkoxycarbonylcycloalkyl, aminocycloalkyl, or mono- or di-lower alkyl-aminocycloalkyl, pyrrolidino, oxopyrrolidinyl, carboxypyrrolidino, piperidino, carboxypiperidino, lower alkoxy- carbonylpiperidino, morpholino, or thiomorpholino, carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl, cyano, lower alkylcarbamoyl, lower dialkylcarbamoyl, lower alkoxycarbonylalkyl-lower carbamoyl, lower carboxyl-carbamoyl, carbamoylalkyl-carbamoyl, N-carbamoylalkyl-N-lower alkyl-carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, polyhaloalkoxy lower, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; sulfo, lower alkane sulphonyl; benzylsulfonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, carboxy, and / or by lower alkoxycarbonyl; unsubstituted or substituted naphthalenesulfonyl by lower dialkyl amino, phosphono, lower trialkyl phosphono, amino, lower alkyl amino, lower dialkyl amino, lower alkanoyl amino; phenylalkyl-amino, benzoylamino, or naphthoylamino which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl; ureido, amidino; phenyl or naphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, sulphamoyl, lower alkoxycarbonylamino, lower alkanoyl, halogen, and / or by trifluoromethyl; furyl, lower alkyl furyl, thienyl, imidazolyl, oxazolyl, oxazolinyl (dihydrooxazolyl), carboxyalkyl (oxo) oxazolinyl, thiazolyl, thiazolinyl (dihydrothiazole), carboxyalkyl lower-thiazolyl, lower alkoxycarbonylalkyl-thiazolyl, tetrazolyl , pyridyl, pyrazinyl, indolyl, quinolinyl, benzazepinyl, or lower carboxyalkyl-2, 3,4,5-tetrahydro-lH-l-benzazepinyl, Rg is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl- lower aminoalkyl, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, lower polyhaloalkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, polyhaloalkoxy lower-lower alkyl, -phenylalkyl lower that is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy or, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl; lower alkanoyl, lower alkenoyl; lower phenylalkanoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl; lower alkoxycarbonyl, or lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenekoxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl, or R7 and R8 'together with X and the nitrogen atom linking R8 and X, form pyrrolidino, imidazolidino, tetrahydrothiazolyl, piperidino, morpholino, thiomorpholino, piperazino, homopiperidino or 1-azabicyclononyl which is unsubstituted or substituted by lower alkyl, lower hydroxyalkyl, lower phenylalkyl or unsubstituted or substituted phenyl, carboxy, lower alkoxycarbonyl, unsubstituted or substituted phenylcarbamoyl, lower-amino dialkyl, lower-amino alkanoyl, 2-oxoimidazolidino, phosphono, lower-trialkyl-phosphono, tetrazolyl, lower alkanoyl, benzoyl unsubstituted or substituted, hydroxy, oxo, and / or by lower alkoxy, pyrrolyl optionally partially hydrogenated which is unsubstituted or substituted by carboxy, lower alkoxycarbonyl, and / or by lower alkanoyl, - furyl; thienyl; imidazolyl which is unsubstituted or substituted by lower alkyl, lower hydroxyalkyl, carboxy, lower carboxyalkyl, and / or by lower alkoxycarbonylaminoalkyl; optionally partially hydrogenated thiazolyl which is unsubstituted or substituted by lower carboxyalkyl, and / or by lower alkoxycarbonylalkyl lower, pyrazolyl unsubstituted or substituted by lower alkyl, triazolyl, pyridinyl optionally partially hydrogenated, unsubstituted or substituted by oxo; optionally partially hydrogenated pyrimidinyl unsubstituted or substituted by oxo; pyrazinyl; indolyl which is unsubstituted or substituted by carboxy, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower cyanoalkyl, and / or by nitro, -benzofuranyl; benzimidazolyl unsubstituted or substituted by nitro, -tetrahydro-fiinolinyl, -tetrahydroisopinolinyl unsubstituted or substituted by oxo; tetrahydrobenzazepinyl; or phenyl, cyclohexadienyl, naphthyl or tetrahydronaphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, carboxy, lower alkoxycarbonyl, and / or trifluoromethyl; R9 is lower alkyl, lower alkenyl, lower alkynyl, or lower phenylalkyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or R7, R8, and R9, together with X and the nitrogen atom which bind Rg, R9, and X, form a pyridinium radical which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, amino, alkyl of 1 to 4 carbon-amino atoms, or by dialkyl of 1 to 4 atoms carbon-amino, where A "is the anion of a hydrohalic acid, lower alkane sulphonic acid, or unsubstituted benzenesulfonic acid or substituted by lower alkyl or by halogen, alk is lower alkylene, and X (unless, together with R7 and Rg and the nitrogen atom linking Rg and X, or together with the nitrogen atom linking Rg, R9, and X, is part of one of the ring systems mentioned) is lower alkylene, lower alkylidene, lower alkenylene, oxo -lower alkylene including carbonyl, oxo-lower alkylidene, lower dioxo-alkylene, lower oxo-alkenylene, lower hydroxyalkylidene, oxo (hydroxy) lower alkylene, lower aminoalkylene, lower aminoalkylidene, lower carboxyalkylene, lower carboxyalkylidene, lower carbamoylalkylidene, lower alkoxycarbonylalkylidene, alkoxy lower-lower carbonylalkylene,? -aza-a-oxo-lower alkylene, or? -aza-of-oxo-lower alkenylene, 3- to 7-membered cycloalkylidene, or lower phenylalkylidene or lower phenylalkylene unsubstituted or substituted by lower alkyl, lower alkoxy , lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl, or a salt thereof.

3. A compound of the formula I according to claim 1, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -alq-CH (R6) -R7 (Ib ), -alq-N (Rg) -X-R7 (Ic), -alk-0-X-R7 (Ie) or -alk-SX-R7 (If), R3, R4, and R5 are each independently of the others, hydrogen, lower alkyl, halogen, cyano, or nitro, Rg is amino, lower-amino alkyl, lower-amino alkanoyl, lower N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R7 is carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; phosphono, mono-, di-, or tri-lower alkyl-phosphono, or tetrazolyl, R8 is hydrogen, lower alkyl, or together with X and the nitrogen atom linking Rg and X, forms a radical of pyrrolidinylene, piperidinylene, or piperazinylene, alk is lower alkylene, and X is lower alkylene, lower oxo-alkylene, including carbonyl, lower alkylidene, lower aminoalkylidene, lower carboxyalkylidene, lower alkoxy-carbonyl-lower alkylidene, lower carbamoyl alkylene, or, with the group N (Rg) ,? -aza-a-oxo-lower alkylene or? -aza-a-oxo-lower alkenylene linked via the carbon atom, -phenyl-lower alkylidene which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or in the formula le, together with R8 and the nitrogen atom linking Rg and X, forms a pyrrolidinyl, piperidinyl, or piperazinyl radical, or a salt thereof.

4. A compound of the formula I according to claim 1, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -alq-N (Rg) -X-R7 (Ic), R4 / and R5 are each independently of the others, hydrogen, lower alkyl, halogen, cyano, nitro, R7 is a radical of phenyl, naphthyl, furyl, thienyl, pyridyl, or cycloalkyl of 3 to 8 members which is unsubstituted or substituted by lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, unsubstituted lower phenylalkoxycarbonyl or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl, phenyl-bamoyl unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; cyano, nitro, halogen, and / or trifluoromethyl; or is lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-lower aminoalkyl, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, polyhalo lower alkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, or lower polyhaloalkoxy-lower alkyl, R8 is hydrogen or lower alkyl, alk is lower alkylene, and X is lower oxo-alkylene, or a salt thereof.

5. A compound of the formula I according to claim 1, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -CH (R6) -alq-R7 (la), -alq-CH (Rg) -R7 (Ib), -alq- N (R8) -X-R7 (Ic), -alk-N + (Rg) (R9) -X-R7 A "(Id), -alk-OX-R7 (Ie) or -alq-SX-R7 (If ), R3 4 and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, trifluoromethyl, cyano or nitro, R6 is amino, alkyl of 1 to 4 carbon-amino atoms, alkanoyl of 1 to 4 carbon atoms-amino, N-alkyl of 1 to 4 carbon atoms-N-alkanoyl of 1 to 4 carbon-amino atoms, or dialkyl of 4 carbon atoms carbon-amino, R7 is hydrogen, alkyl of 1 to 7 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms, polyhaloalkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 atoms of carbon, cycloalkyl of 3 to 6 members, 3 to 6 membered carboxycycloalkyl, 3 to 6 membered alkocycloalkyl, pyrrolidino, carboxypyrrolidino, oxopyrrolidino, piperidino, carboxypiperidino, morpholino, thiomorpholino, carboxy, alkoxy of 1 to 4 carbon atoms, carbonyl, phenylalkoxy of 1 to 4 carbon atoms -carbonyl, carbamoyl, cyano, alkyl of 1 to 4 carbon atoms-carbamoyl, alkoxy of 1 to 4 carbon atoms-carbonylcarbamoyl, carboxyalkyl of 1 to 4 carbon atoms-carbamoyl, carbamoylalkyl of 1 to 4 carbon atoms-carbamoyl , N-carbamoylalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamoyl, N-carboxyalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamoyl, carbamoylalkyl from 1 to 4 carbon atoms-carbamoyl, phenylalkyl of 1 to 4 carbon atoms-carbamoyl unsubstituted or substituted by carboxy; phenylcarbamoyl which is unsubstituted or substituted by alkoxy of 1 to 4 carbon atoms, nitro, polyhaloalkoxy of 1 to 4 carbon atoms, phenyloxy, and / or by alkoxy of 1 to 4 carbon atoms-carbonyl; sulfo, alkane of 1 to 4 carbon atoms-sulfonyl; benzenesulfonyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, and / or by carboxy; unsubstituted naphthalenesul-fonyl or substituted by dialkyl of 1 to 4 carbon atoms-amino, phosphono, amino, alkyl of 1 to 4 carbon-amino atoms, dialkyl of 1 to 4 carbon-amino atoms, alkanoyl of 1 to 4 atoms carbon-amino, phenylalkyl of 1 to 4 carbon atoms-amino, benzoylamino, naphthoylamino, ureido, amidino; phenyl or naphthyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkylenedioxy of 1 to 4 carbon atoms, alkylidenedio-xi of 1 to 4 carbon atoms, carboxy, sulfamoyl , alkoxy of 1 to 4 carbon atoms-carbonylamino, alkanoyloxy of 1 to 4 carbon atoms, hydroxy, halogen, and / or trifluoromethyl; furyl, C 1 -C 4 alkyl furyl, thienyl, imidazolyl, (oxo) oxazolinyl, thiazolyl, thiazole nyl (dihydrothiazolyl), carboxyalkyl of the 4 carbon atoms-thiazolyl, alkoxy of 1 to 4 carbon atoms- carbonylalkyl of 1 to 4 carbon atoms-thiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, quinolinyl, benzazepinyl, or carboxyalkyl of 1 to 4 carbon atoms-2,3,4,5-tetrahydro-lH-l-benzazepinyl, Rg is hydrogen, alkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, hydroxyalkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, phenylalkyl of 1 to 4 carbon atoms, pyridylalkyl of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, such as acetyl, phenylalkanoyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-carbonyl, or phenylalkoxy of 1 to 4 carbon atoms-carbonyl, or R7 and R8 »together with X and the nitrogen atom linking R8 and X form pyrrolidino, carboxypyrrolidino, hydroxypyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms-pyrrolidino, mono- or di-oxopirrolidino, alkyl of 1 to 4 carbon atoms- (oxo) pyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms (oxo) pyrrolidino, carboxy (oxo) pyrrolidino, 2-oxoimidazolidino, tetrahydrothiazo-lyl, piperidino, alkyl of 1 to 4 carbon atoms-piperidino, dialkyl of 1 to 4 carbon atoms-piperidino , carboxypiperidino, alkoxy of 1 to 4 carbon atoms -carbonylpiperidino, phenylcarbamoylpiperidino, oxopiperidino, dioxopiperidino, oxo (phenylalkyl of 1 to 4 carbon atoms) piperidino, oxo (fe-nil) piperidino, hydroxypiperidino, hydroxy (phenylalkyl of 1 to 4 carbon atoms) piperidino, carboxy (hydroxy) piperidino, dialkyl of 1 to 4 carbon atoms-aminopiperidino, alkanoyl of 1 to 4 carbon atoms-aminopiperidino, alkanoyl of 1 to 4 carbon atoms-amino (phenylalkyl of 1 to 4 atoms carbon) -piperidino, alkanoyl of 1 to 4 carbon atoms-amino (phenyl) piperidino, phenylpiperidino, alkoxy of 1 to 4 carbon atoms-piperidino, alkoxy of 1 to 4 carbon atoms (alkyl of 1 to 4 carbon atoms) carbon) piperidino, dialkoxy of 1 to 4 cairbono-piperidino atoms, dialkoxy of 1 to 4 carbon atoms (phenylalkyl of 1 to 4 carbon atoms) piperidino, alkylenedioxy of 1 to 4 carbon atoms-piperidino, hydroxyalkyl of 1 to 4 carbon atoms-piperidino, unsubstituted or halogenated benzoylpiperidino, alkanoyl of 1 to 4 carbon atoms-piperidino, oxoimidazo-lidinopiperidino, homopiperidino, oxohomopiperidino, azabicyclo-nonyl, piperazino, alkyl of 1 to 4 carbon atoms-piperazi- no, oxopiperazino, dioxopiperazino, unsubstituted phenylpiperazino 0 alkoxylated with 1 to 4 carbon atoms, morpholino, dialkyl 1 to 4 carbon atoms-morpholino, thiomorpholino, phenyl, cyclohexa-1,3-dien-5-yl, hydroxyphenyl, alkoxy of 1 to 4 carbon atoms-phenyl, carboxyphenyl, such as 3-carboxyphenyl, halo- nyl, trifluoromethylphenyl, bistrifluoromethylphenyl, naphthyl, tetrahydronaphthyl, nitrobenzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or tetrahydrobenzazepinyl unsubstituted or substituted by oxo,. R is lower alkyl, or R7 'R8' and R9 'Together with X and the nitrogen atom linking R8, R9, and X, form a pyridinium radical which is unsubstituted or substituted by amino, alkyl of 1 to 4 carbon atoms. carbon-amino, or by dialkyl of 1 to 4 carbon-amino atoms, where A "is the anion of a hydrohalic acid, alk is alkylene of 1 to 4 carbon atoms or alkylidene of 1 to 4 carbon atoms, and X ( unless together with R7 and Rg and the nitrogen atom fie links R8 and X, or together with the nitrogen atom fie links Rg, R9, and X, is part of one of the ring systems mentioned) is a direct link , alkylene of 1 to 4 carbon atoms, alkylidene of 1 to 4 carbon atoms, alkenylene of 1 to 4 carbon atoms, oxoalkylene of 1 to 4 carbon atoms including carbonyl, dioxoalkylene of 1 to 4 carbon atoms including oxalo, oxoalkenylene of 1 to 4 carbon atoms, hydroxyalkylidene of 1 to 4 carbon atoms, oxo (hydroxy) -alkylene of 1 to 4 carbon atoms, aminoalkylene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, ceirboxyalkylene of 1 to 4 carbon atoms, carboxyalkylidene of: 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms -carbaryl-alkylidene of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-carbonylalkylene of 1 to 4 carbon atoms,? -aza-a-oxo-alkylene of 1 to 4 carbon atoms, or? -aza- a-oxo-alkenylene of 1 to 4 carbon atoms, 3 to 7-membered cycloalkylidene, phenylalkylidene of 1 to 4 carbon atoms or phenylalkylene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, or a salt of the same.

6. A compound according to any of claims 1 to 5, wherein: Rj is a group of the formula -CH (Rg) -alq-R7 (Ia), -alk-CH (Rg) -R7 (Ib) , -alq-N (Rg) -X-R7 (Ic), -alq-N + (Rg) (R9) -XR? A "(Id), -alq-0-X-R7 (Ie) or -alq-SX-R7 (If), and R2 is a group R5, wherein R3, R4, R5, Rg, R7, Rg, R9 , alq, and X are as defined in claims 1 to 5, or a salt thereof

7. A compound according to formula I according to claim 1, wherein: Rj is a group of the formula -CH (Rg) -alk-R7 (Ia), -alq- CH (R6) -R7 (Ib), -alk-N (Rg) -X-R7 (Ic), or -alq-N + (Rg) ( R9) -X-R7 A "(Id), and R2 is a group R5, R3 * R4, and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen fie has an atomic number up to and including 35, trifluoromethyl, cyano or nitro, Rg is amino, alkyl of 1 to 4 carbon atoms-amino, alkanoyl of 1 to 4 carbon atoms-amino, N-alkyl of 1 to 4 carbon atoms-N -alkanoyl of the 4 carbon-amino atoms, or dialkyl of 1 to 4 carbon-amino atoms, R7 is hydrogen, hydroxyalkyl alkyl of 1 to 4 carbon atoms, polyhaloalkyl of 1 to 4 carbon atoms, 3- to 6-membered loyal-failo, carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl, phenylalkoxy of 1 to 4 carbon atoms-carbonyl, carbamoyl, phenylcarbamoyl, alkane of 1 to 4 carbon atoms-sulfonyl, amino, morpholino, benzoylamino, -phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, alkanoyloxy of 1 to 4 carbon atoms, halogen, and / or by trifluoromethyl; furyl, thienyl, thiazolyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, alkoxy of 1 to 4 carbon atoms-carbonylalkyl-1 to 4 carbon atoms-thiazolyl, or pyridyl, Rg is hydrogen , alkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms, phenylalkyl of 1 to 4 carbon atoms, or pyridylalkyl of 1 to 4 carbon atoms, or R and Rg, together with X and the nitrogen atom linking Rg and X, form pyrrolidino , carboxypyrrolidino, hydroxypyrrolidiene, tetrahydrothiazolyl, for example tetrahydrothiazol-1-yl, piperidino, alkyl of 1 to 4 carbon atoms-piperidino, dialkyl of 1 to 4 carbon atoms-piperidino, carboxypiperidino, alkoxy of 1 to 4 carbon atoms carbon-carbonylpiperidino, phenylcarbamoylpiperidino, oxopiperidino, dialkyl of 1 to 4 carbon atoms-aminopiperidino, hydroxyalkyl of 1 to 4 carbon atoms-piperidino, homopiperidino, azabiciclononilo, piperazino, alkyl of 1 to 4 carbon atoms-piperazino; unsubstituted or alkoxylated phenylpiperazino, morpholino, thiomorpholino, phenyl, cyclohexa-1,3-di-5-yl, hydroxyphenyl, alkoxy of 1 to 4 carbon atoms-phenyl, carboxy-phenyl, halophenyl, nitrobenzimidazolyl , tetrahydroquinolinyl, such as 1, 2, 3, 4-tetrahydroquin-1-olin-1-yl, or tetrahydroisoqui-nolinyl unsubstituted or substituted by oxo, R 9 is lower alkyl, or R 7, R g, and R 9, together with X and the nitrogen atom that binds Rg, R9, and X, form an unsubstituted pyridinium radical 0 substituted by amino, where A "is the anion of a halohydric acid, alk is alkyl (id) ene of 1 to 4 carbon atoms, such as methylene and X (unless, together with R7 and Rg and the atom of nitrogen that binds R8 and X, or together with the nitrogen atom linking R8, R9, and X, is part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 7 carbon atoms, alkylidene of 1 to 4 carbon atoms, oxoalkylene of 1 to 4 carbon atoms including carbonyl, oxoalkenylene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-carbonylalkylidene of 1 to 4 carbon atoms,? -aza-of-oxo-alkylene of 1 to 4 carbon atoms, or? -aza-a-alkenylene of 1 to 4 carbon atoms, or phenylalkylidene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, or a salt thereof.

8. A compound of formula I according to claim 1, wherein: Rj is a group of the formula -CH (Rg) -alq-R7 (Ia), -alk-CH (R6) -R7 (Ib) , -alq-N (R8) -X-R7 (le), or -alq-N + (R8) (R9) -X-R7 A "(Id), and R2 is a group R5, R3 and R4 are each independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, or nitro, R 5 is hydrogen, R 7 is hydrogen, alkyl, polyhaloalkyl of 1 to 4 carbon atoms, cycloalkyl from 3 to 6 members, azoxacycloalkyl of 3 to 6 members, carboxy, alkoxy of 1 to 4 carbon atoms, phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, halogen and or by trifluoromethyl, furyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, or alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms-thiazolyl, Rg is hydrogen, alkyl of 1 to 4 atoms carbon, or pyridylalkyl of 1 to 4 carbon atoms, or R7 and Rg, together with X and the nitrogen atom linking R8 and X, form pyrrolidino, piperidino, carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonylpiperidino, oxopiperidino, homopiperidino, azabiciclononilo, piperazino, alkyl of 1 to 4 carbon atoms piperazino, phenylpiperazino unsubstituted or alkoxylated with 1 to 4 carbon atoms, morpholino, or thiomorpholino, R9 is alkyl of 1 to 4 carbon atoms, or R7 ' R8 'R9' together with X and the nitrogen atom linking Rg, R9 and X, form a pyridinium radical unsubstituted or substituted by amino, where A "is the anion of a hydrohalic acid, alk is alkyl (id) ene, 1 to 4 carbon atoms, and X (unless, together with R and Rg and the nitrogen atom linking Rg and X, or together with the nitrogen atom linking Rg, R9, and X, is part of one) of the aforementioned ring systems) is a direct bond, alkylene of 1 to 7 carbon atoms, alkylidene from 1 to 4 carbon atoms, oxoalkylene of 1 to 4 carbon atoms including carbonyl, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, or phenylalkylidene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, or a salt thereof.

9. A compound of the formula I according to claim 1, wherein: R1 is a group of the formula -alk-CH (Rg) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-0-X2-R7 (Ie) or -alq-S-X2-R7 (If), R2 is hydrogen, R3 and R4 are each independently of the other, halogen having an atomic number of up to and including 35, or nitro, Rg is amino, R7 is carboxy, phenylalkoxy of 1 to 4 carbon atoms-carbonyl; phenylcarbamoyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, hydroxy, halogen having an atomic number of up to and including 35, nitro, carboxy, alkoxy of 1 to 4 carbon atoms carbon-carbonyl, phenyl, phenyloxy, and / or trifluoromethyl; or tetrazolyl, Rg is hydrogen, or together with X and the nitrogen atom fie bonds R8 and X forms a piperidinylene radical, alq is methylene, X is alkylidene of 1 to 4 carbon atoms, or • formula is carbonyl, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, or with the group N (R8),? -aza-of-oxo-alkylene of 3 to 5 carbon atoms linked by means of the carbon atom a, or together with Rg and the nitrogen atom linking Rg and X, forms a piperidinylene radical, or a salt thereof.

10. A compound of formula I according to claim 1, wherein: R1 is a group of the formula: -CH (R6) -alk-R7 (Ia), -alk- CH (R6) -R7 (Ib) ), -alk-N (R8) -X-R7 (Ic), OR -alk-N + (R8) (R9) -X-R7 A '(Id), and R2 is a group R5, R3 and R4 are each one independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, or nitro, R5 is hydrogen, R7 is hydrogen, alkyl, polyhaloalkyl of 1 to 4 carbon atoms, 3 to 6 membered cycloalkyl, 3 to 6 membered azoxacycloalkyl, carboxy, C 1 -C 4 alkoxycarbonyl; phenyl which is unsubstituted or substituted by carboxy, sulfamoyl, alkoxy of 1 to 4 carbon atoms, halogen, and / or by trifluoromethyl; furyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, or alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms-thiazolyl, R8 is hydrogen, alkyl of 1 to 4 carbon atoms carbon, or pyridylalkyl of 1 to 4 carbon atoms, or R7 and R8 together with X and the nitrogen atom linking Rg and X, form pyrrolidino, piperidino, carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonylpiperidino, oxopiperidino, homopiperidino, azabicyclononyl, piperazino, alkyl of 1 to 4 carbon atoms-piperazino, phenylpiperazino unsubstituted or alkoxylated with 1 to 4 carbon atoms, morpholino, or thiomorpholino, alq is alkyl (id) ene, of 1 to 4 carbon atoms. carbon, such as methylene, and X (unless, together with R7 and Rg and the nitrogen atom linking R8 and X, forms part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 7 carbon atoms, alkylidene of 1 to 4 carbon atoms, oxoalkylene from 1 to 4 carbon atoms including carbonyl, oxoalkylene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylene of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-carbonylalkylidene of 1 to 4 carbon atoms, α-aza-a-oxo-alkylene of 1 to 4 carbon atoms, or α-aza-a-oxo-alkenylene of 1 to 4 carbon atoms, or unsubstituted phenylalkylidene of 1 to 4 carbon atoms or substituted by halogen and / or trifluoromethyl, or a salt thereof.

11. A compound of the formula I according to claim 1, wherein: R? is a group of the formula -alk-N (R8) -X-R7 (Ic), R2 is hydrogen, R3 and R4 are each independently of the other, halogen having an atomic number of up to and including 35, or nitro, Rg is amino, R7 is carboxy, R8 is hydrogen or, together with X and the nitrogen atom linking R8 and X, forms a piperidinylene radical, alq is methylene, and X is alkylidene of 1 to 4 carbon atoms, or , with the group N (R8), form? -aza-a-oxo-alkylene of 3 to 5 carbon atoms, linked by means of the carbon atom CK, O together with R8 and the nitrogen atom linking Rg and X , forms a piperidinylene radical, or a salt thereof.

12. A compound of the formula I according to claim 1, wherein: Rj is a group of the formula -alq-N (Rg) -X-R7 (le), R2, R3, R, and R5 are each one independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen fie has an atomic number of up to and including 35, cyano or nitro, R7 is a radical of phenyl, furyl, thienyl, or pyridyl, fie is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, carboxy, alkoxy of 1 to 4 carbon atoms, carbonyl, carbamoyl, cyano, nitro, halogen, and / or trifluoromethyl, or 3 to 8 membered cycloalkyl, alkyl of 1 to 7 carbon atoms, aminoalkyl of 1 to 4 carbon atoms, or polyhaloalkyl of 1 to 4 carbon atoms, R8 is hydrogen, alk is methylene, and X is carbonyl, or come out of it

13. A compound of formula I according to claim 1, wherein: R2 is a group R5, and Rj is a group of formula -alk-N the (R8) -X-R7 (le) or -alk-N + ( R8) (R9) -X-R7A "(Id), R3 and R4 are each independently of the other, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, or nitro, R5 is hydrogen, R7 is 3-6-membered cycloalkyl, morpholino, carboxy, alkoxy of 1 to 4 carbon atoms, thiazolinyl (dihydrothiazolyl), or alkoxy of 1 to 4 carbon atoms-carbonylalkyl of 1 to 4 carbon atoms. carbon-thiazolyl, R8 is hydrogen or alkyl of 1 to 4 carbon atoms, or R7 and R8, together with X and the nitrogen atom that binds

R8 and X, form pyrrolidino, piperidino, carboxypiperidino, alkoxy of 1 to 4 carbon atoms-carbonylpiperidino, oxopiperidino, or homopiperidino, alq is methylene, and X (unless, together with R7 and Rg and the nitrogen atom that binds R8 and X, being part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 7 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, or carboxyalkylidene of 1 to 4 carbon atoms, or a salt thereof, 14. A 2,3-dioxo-1,2,3,4-tetrahydroquin-xalinyl derivative of the formula I: wherein: R j is a group of the formula -alk-N (R 8) -X-R 7 (le), R 2 and R 4 are hydrogen, R 3 is halogen or nitro, al is methylene, and any of: R 7 is benzyl, furyl , thienyl, thienylmethyl, thiazolyl, 4,5-dihydrothiazolyl, tetrazol-5-yl, pyridyl, N-lower alkyl-imidazolyl, or carboxy, X is carbonyl, lower alkylidene, or a direct bond, "" and R8 is hydrogen; o ~ - - R7 and Rj together with X and the nitrogen atom linking Rg and X, form pyrrolidino, oxopiperidino or carboxipiperidino, or a salt thereof.

15. N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -glycine; N- (7-bromo-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -β-alaniña; N- (7-Bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (L) -glutamic acid; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -phenylalanine, • aN- (7-bromo-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -lysine; Ethyl N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-2-carboxylic acid ethyl ester - N- (7-bromo-) ethyl ester 2, 3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid, - N- (7-bromo-2,3-dioxo-1,2,3-ethyl ester) , 4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid, - (7-bromo-5- (5-nitrobenzoimidazol-1-ylmethyl) -1,4-dihydro-quinoxalin-2,3-dione (7 -bromo- 5- (6-nitrobenzoimidazol-1-ylmethyl) -1,4-dihydro-quinoxalin-2,3-dione; N- (7-bromo-2,3-dioxo-8-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-dimethylaminopiperidine, - N- (7-bromo-2,3-dioxo-8-nitro-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - 1,2,3, 4-tetrahydroquinoline, - N- (7-bromo-2,3-dioxo-8-nitro-l, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -j8-alanine; aN - (7-bromo-2,3-dioxo-8-nitro-l, 2,3,4-tetrahydroquino-xalin-5-ylmethyl) - (L) -lysine; N- (7-bromo-2,3-dioxo-8-nitro-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (L) -phenylalanine; N- (7-bromo-2,3-dioxo-8-nitro-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -glycine; - N- (7-bromo-2) ethyl ester; 3-dioxo-8-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid; Ethyl ester of N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) - / 3-alanine, - aN- (2, 3-dioxo-7-nitro-l, 2 , 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (D) -lysine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -glycine; N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) - (L) -glutamic acid N- (2,3-dioxo-7-nitro-l) acid , 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -phenylalanine; a-N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -lysine; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-6-ylmethyl) -jS-alanine, - aN- (2,3-dioxo-7-nitro-l, 2, 3,4-tetrahydroquinoxalin-6-ylmethyl) - (L) -lysine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-6-ylmethyl) - (L) -phenylalanine; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxa-lin-6-ylmethyl) - (L) -glutamic acid; N- (2,3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -glycine; N- (2, 3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxa-lin-6-ylmethyl) -piperidine-4-carboxylic acid, - N- (2,3-dioxo) ethyl ester -7-nitro-l, 2, 3,4-tetrahydroquinoxalin-6-ylmethyl) -piperidine-4-carboxylic acid; N- (7-Bromo-2,3-dioxo-1,2,4-tetrahydroquinoxa-lin-5-ylmethyl) -piperidine-4-carboxylic acid; Phenylic acid N- (7-bromo-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid, - N- (7-bromo-2, 3- dioxo-8-nitro-1,2,3,4-tetrahydro-fuinoxalin-5-ylmethyl) -piperidine-4-carboxylic acid, - N- (2,3-dioxo-7-nitro-l, 2,3, 4-tetrahydroquinoxa-1in-5-ylmethyl) -piperidine-4-carboxylic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-2 acid -carboxylic; N- (7-bromo-2,3-dioxo-l, 2, S ^ -tetrahydroquinoxa-lin-S-ylmethyl) -piperidine-3-carboxylic acid, - N- (7-bromo-2, phenyl 3-dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine-3-carboxylic acid, - Phenylic acid amide of N- (7-bromo-2,3-dioxo-l, 2, 3,4 -tetrahydroquinoxalin-5-ylmethyl) -piperidine-2-carboxylic acid; 5-aminomethyl-7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxaline; Ethyl 3- [(7-bromo-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -acrylic acid ethyl ester; 3- [(7-Bromo-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -carbamoyl] -acrylic acid; Phenolic amide of 3- [(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -acrylic acid; Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -2- (3-phenyl-ureido) -acetic acid, - Tertiary butyl ester of acid. { [(7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -methyl} -carbamic; Acid benzyl ester. { [(7-Bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -methyl} -carbamic; 7-Bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid, 7-bromo-2,3-dioxo-5-hydroxymethyl-1,2,3,4-tetrahydroquinoxaline acid; Ethyl ester of 7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethoxyacetic acid, - Amide 7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin- 5-ylmethoxy) -N-phenylacetic; Ethyl ester of 7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethylsulfanylacetic acid; 7-Bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl-ethylsulfanylacetic acid, - Amide (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5) -ylmethylsulfanyl) -N-phenylacetic; Ethyl ester of 2-amino-3- (7-bromo-2,3-dioxo-l, r 2, 3,4-tetrahydro-quinoxalin-5-yl) -propionic acid; 2-Amino-3- (7-bromo-2,3-dioxo-1,2, 3,4-tetrahydro-fiinoxalin-5-yl) -propionic acid; Amide (7-bromo-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-ylmethyl) of furan-2-carboxylic acid, - Amide (7-bromo-2,3-dioxo-1,2) , 3,4-tetrahydroquinoxalin-5-ylmethyl) of cyclopropanecarboxylic acid, - Amide 2-amino-N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fuinoxalin-5-ylmethyl) -acetic, - Amide N- (7-bromo-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3,5-bistrifluoromethylbenzene, - Amide N- (7-bromo- 2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -benzene, - Amide N- (7-bromo-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxa-lin- 5-ylmethyl) -acetic; Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -trifluoroacetic acid, - N- (7-bromo-2,3-dioxo-l) ethyl ester , 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -oxalamic; Methyl ester of N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -malonamic acid; N- (7-bromo-2,3-dioxo-1,2,4,4-tetrahydroquinoxa-l-5-ylmethyl) -oxalamic acid; N- (2, 3-dioxo-7-nitro-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -tyrosine; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -leucine tertiary, - N- (2,3-dioxo-7-nitro-1, 2,3 , -tetrahydroquinoxalin-5-ylmethyl) - (L) -proline; N- (2, 3-dioxo-7-nitro-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -alanine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (D) -alanine; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -sarcosine, -N- (2, 3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) - (L) -valin; N- (2,3-dioxo-7-nitro-1,2,2,4-tetrahydroquinoxalin-5-ylmethyl) -oxamic acid methyl ester; N- (2,3-dioxo-7-nitro-l, 2, S-tetrahydroquinoxa-lin-S-ylmethyl) -oxalamic acid; 4- [(7-Bromo-2,3-dioxo-1,2,3,4-t-tetrahydroquinoxalin-5-ylmethyl) -carbamoyl] -butyric acid methyl ester; N- (2, 3-dioxo-7-nitro-1, 2,3,4-tetrahi-droquinoxalin-5-ylmethyl) -N-benzylglycine ethyl ester, - N- (2,3-dioxo-7-nitro) -1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -N-benzylglycine; Amide N- (2, 3-dioxo-7-nitro-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -acetic acid, - Amide N- (7-bromo-2,3-dioxo-l, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -phenylacetic, • Amide N- (7-bromo-2,3-dioxo-1,2, 3,4-tetrahydroquinoxa-1 in-5-ylmethyl) - 3-phenylpropionic, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-β [uinoxalin-5-ylmethyl) -thiophen-2-carboxylic acid amide, - Amide N- (7-bromo-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3-thienylacetic acid, - Amide N- (7-bromo-2,3-dioxo-1,2) , 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3-methoxyphenylacetic acid; Amina N- (2,3-dioxo-7-nitro-1,2, 3,4-tetrahydroquinoxa-1 in-5-ylmethyl) -N-methylbenzyl, - N- (7-bromo-2,3-dioxolamine -l, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -furfuryl, - N- (2,3-dioxo-7-nitro-1, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) amine ) -2-morpholinoethyl; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -diethyl amine, N-amines (2, 3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) -2- (2-pyridyl) ethylmethyl, - N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxa-lin) -5-ylmethyl) -cyclopropyl; N- (2, 3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -dietanolic amine; N- (2,3-dioxo-7-nitro-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-2-thiazoline; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-aminopyrazine, - N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminothiazole; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -aniline; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-fluoroaniline; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-fluoroaniline; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-fluoroaniline; Ethyl ester of [N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid, - Ethyl ester of acid [ N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid; Acid [N- (2, 3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -2-amino-4-thiazolyl] -acetic acid, - N- (2, 3 -dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N- (2-pyridylmethyl) -glycine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-aminobenzoic acid; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methylaziridine, - N- (2,3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -azetidine; N- (2,3-dioxo-7-nitro-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-methylpiperidine; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N 1 - (4-methoxyphenyl) -piperazine; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-methyl) -piperidine; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2,6-dimethylpiperidine; N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-yl ethyl) -pyrrolidine; N- (2,3-dioxo-7-nitro-l, 2,3,4-te rahydroquinoxalin-5-ylmethyl) -4-piperidone, - N- (2,3-dioxo-7-nitro-l, 2 , 3,4-tetrahydroquinoxalin-5-ylmethyl) -hexamethyleneimine N- (2,3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-pyrroline, - N- (2 , 3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -thiomorpholine; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -morpholine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -thiazolidine; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-pyrrolidinol; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-methylpiperazine, - N- (2,3-dioxo-7-nitro-1,2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2- (2-hydroxyethyl) -piperidine; N- (2,3-dioxo-7-nitro-l, 2, 3,4-tetrahi-droquinoxalin-5-ylmethyl) -piperazine dibromohydrate; N- (2,3-dioxo-7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-azabicyclo [3, 2,2] nonane, - N- (2, 3-dioxo- 7-nitro-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -tetrahydropyridine, - N- (2, 3-dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) - pyrazole; N- (2,3-dioxo-7-nitro-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-ethoxycarbonyl-pyrazole; [1- (2, 3-Dioxo-7-nitro-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1H-indol-3-yl] -acetic acid methyl ester; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-tetrahydroquinoline; Amide of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -ensulfenufonic acid, - Amide (7-bromo-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) of N-methyl-2-phenylacetic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-acid) -ylmethyl) -a-aminophosphonic; 1- (7-nitro-2,3-dioxo-1,2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (4-methoxyphenyl) -urea, 1- (7-nitro-2, 3- dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3- (2-methoxyphenyl) -urea; 1- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (2-ethoxycarbonylethyl) -urea, 1- (7-nitro-2, 3- dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -3- (2-carboxyethyl) -urea; 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-phenyl-urea, 1- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3- (4-trifluoromethyloxyphenyl) -urea, - N- (7-nitro-2,3-dioxo-1, 2, 3,4-tetrahydro- fainoxalin-5-ylmethyl) -valeric; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) naphthoic acid amide; Amide N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -3-dimethylbutyric acid, - Amide N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -benzene, - Amide N- (7-nitro-2, 3-dioxo-1,2,4,4-tetrahydroquinoxa-lin-5-ylmethyl) -2 -methoxyacetic; Glycinamide N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -N ', N' -dimethyl; Amide N- (7-nitro-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3,4,5-trimethoxybenzene, - Amide N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3,5-dimethoxy-4-hydroxybenzene, - Glycinamide N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N'-acetyl; Glycinamide N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -N'-carbamoyl, - Amide 4- [N- (7-nitro-2, 3- dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) sulfamoyl] -benzene; Amide 2-amino-3-methyl-N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyric acid, - Amide 2-amino-3-hydroxy-N - (7-nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyric, - Amide 2-amino-4-carboxy-N- (7-nitro-2, 3- dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -butyric acid, - Tryptophanamide N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-cjuinoxalin-5-ylmethyl) -N-acetyl; L-serine-amide 2-amino-N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl); D-serine-amide 2-amino-N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl); Amide of 2-L-amino-3-carbamoyl-N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -propionic acid, - 2-D acid amide -amino-3-carbamoyl-N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -propionic acid; Histidine-amide LN- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahi-droquinoxalin-5-ylmethyl), - Histidine-amide DN- (7-nitro-2,3-dioxo- 1,2,4,4-tetrahydroquinonoxy-5-ylmethyl), N- (7-ni ro-2, 3-dioxo-1,2,4,4-tetrahydro-qt-inoxalin-5-amide) -ylmethyl) -succinic; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-qiiinoxalin-5-ylmethyl) -phthalic acid amide; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) -glutaric acid amide; Amines N- (7-nitro-2,3-dioxo-l, 2, 3, 4-te rahydroquinoxalin-5-ylmethyl) -N- (2-diethylaminoethyl); N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N-methyl amine; N- (7-nitro-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N- (1, 1-dioxo-2, 3,, 5-tetrahydrothien-3-amine -lilic acid), - N- (7-nitro-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N-methyl-N- (2-hydroxyethyl) amine, - amine N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxa-lin-5-ylmethyl) -N- (3,4-methylenedioxybenzyl), - N-methoxyamine N- (7-nitro) 2, 3-dioxo-1, 2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -N-methyl; N- (7-nitro-2,3-dioxo-l, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N-isopropyl amine; Diamine N- (7-nitro-2,3-dioxo-l, 2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N '-acetylethylene; cis-2- [N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) amino] -cyclohexan-1 -carboxamide, - N- (7-nitro) -2, 3-dioxo-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl taurine, - cis-3- [N- (7-nitro-2, 3-dioxo-l, 2 , 3, 4-tetrahydro-quinoxalin-5-ylmethyl) amino] -cyclohexane-1-carboxylic acid, - 3-tN- (7-nitro-2, 3-dioxo-l, 2,3, 4-tetrahydro-quinoxalin - 5 -ylmethyl) amino] -3-phenylpropionic acid; Cis-2- [N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) amino] -cyclopentanecarboxylic acid; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrolidin-2-one, - N- (7-nitro-2,3-dioxo-1) , 2,3, 4 -ethohydroquinoxalin-5-ylmethyl) -4- (4-chlorophenyl) -pyrrolidin-2-one, - N-amine (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) -N- (1-acetoxy-2-methyl-prop-2-yl), - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) 3-N-cyclohexyl-N-methyl, - cis-2- [N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quinoxalin- 5-ylmethyl) amino] -cyclohexane-1-carboxylic acid; N- (7-nitro-2, 3-dioxo-1, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-ethanephosphonic acid, - N- (7-nitro-2,3-dioxo- 1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -aminomethanphosphonic acid - N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -amino acid - (3-methoxyphenyl) -methanphosphonic acid, - N- (7-nitro-2,3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -3-aminopropane-1-phosphonic acid, - N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -2-aminoethanesulfonic acid, - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-2-phenylethanecarboxylic acid, - cis-2- [N- (7-nitro-2, 3-dioxo-1,2,4,4 -tetrahydro-fiinoxalin-5-ylmethyl) amino] -cyclopentan-1-carboxylic acid, - trans-2- [N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-flinoxalin -5-ylmethyl) amino] -cyclopropan-1-phosphonic acid, • N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -amino- (3) acid -pyridyl) -metaphosphonic acid, - N- (7-nitro-2, 3-dioxo-l, 2, 3,4 acid) -tetrahydroquinoxa-lin-5-ylmethyl) -3-amino-l-carboxy-propan-l-phosphonic acid, - N- (7-nitro-2,3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-) ilmethylaminomethyl) -tetrazole; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3,5-dimethylmorpholine; N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -4,4-ethylenedioxy-piperidine; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-methyl-piperidine; N- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxy-piperidine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-hydroxymethyl-pyrrolidine, - N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-acetoxymethyl-pyrrolidine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxypyrrolidine-2-carboxylic acid, - N- (7-nitro-2,3-dioxo) -l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -3-hydroxy-piperidine; 2- (7-Nitro-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethylamino) - (L) -butyric acid, 2- (7-nitro-2) methyl ester , 3-dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethylamino) - (L) -butyric, - 2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin -5-ylmethylamino) -isobutyric; 2- (7-Nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethylamino) -isobutyric acid methyl ester; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -cyclopropane-1-carboxylic acid, - N- [N- (7-nitro-2, 3- dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -N-methyl- (L) -alanine; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -leucine; N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -threonine; N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methyl-j8-alanine, - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-picolylamine, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2- picolila ina; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -aminoacetonitrile; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-benzylidenepiperidine; 4-carboxylic acid N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-phenylpiperidine, - N- (7-nitro-2,3-dioxo- 1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-carbamoylpiperidine, - N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3- methyl-3-alanine, - N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-phenyl-4-methoxycarbonylpiperidine, - N- (7-) acid nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -iminodiacetic acid; N- (7-nitro-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-tetrahydroisoquinoline, - N- (7-nitro-2, 3 - dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminobenzothiazole, - 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5- illmethylamino) -ethanophosphonic acid, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-acetyl- (L) -alanine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-phenylpiperidine, - N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxymethylpiperidine; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-hydroxymethylpiperidine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4- (1-hydroxyethyl) -piperidine; N- (7-nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) -4-methoxy-piperidine; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methyl-piperidine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-methoxy-4-methylpiperidine, - N- (7-nitro-2,3-dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4,4-dimethoxy-piperidine, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) - (L) -serine; N- (7-nitro-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -O-acetyl- (L) -serine; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -azepin-2-one, - N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-2-one; 1- (7-nitro-2, 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-ethyl-4-methyl-imidazole; N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -4-oxo-pyrrolidine-2-carboxylic acid, - N- (7-nitro-2) , 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-5-bromo-pyrimidine, - N- (7-nitro-2,3-dioxo-1,2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -5-amino-2-methoxypyridine, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-aminopyrimidine; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-pyridine, - N- (7-nitro-2,3-dioxo-1, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -3-amino-pyridine, - N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -2- amino-4-methyl-pyrimidine; N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -3-amino-5-tertiary butyl isoxazole; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-amino-4,5-dicyanoimidazole; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -2-aminopyridinium bromide; Bromide of N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -3-aminopyridinium bromide - N- (7-nitro-2, 3-) bromide dioxo-l, 2, 3, 4-tetrahydro-fiinoxalin-5-ylmethyl) -4-aminopyridinium, - Ammonium bromide N- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin- 5-ylmethyl) -N, N, N-triethyl; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,4-triazole-3-carboxylic acid; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-1in-5-ylmethyl) -1,2,4-triazole-5-carboxylic acid; 4- (7-Nitro-2,3-dioxo-1,2,4-tetrahydroquinoxa-lin-5-ylmethyl) -1,2,4-triazole-3-carboxylic acid, - 1- (7-) acid nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3,4-triazole-4,5-dicarboxylic acid; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,4-triazole, - 1- (7-nitro-2) ethyl ester 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,4-triazole-5-carboxylic acid - 2- (7-nitro-2,3-dioxo-1,2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid, - Dimethyl ester of 1- (7-nitro-2,3-dioxo-l, 2,3) , 4-tetrahydroquinoxalin-5-ylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid, - Amide of 1- (7-nitro-2,3-dioxo-1,2,4-tetrahydro) -fiinoxalin-5-ylmethyl) -1, 2, 3-triazole-4-carboxylic acid, 1- (chloro-2,3-dioxo-l, 2, 3,4-tetrahydro-fiinoxalin-5-ylmethyl) amide ) -1,2, 3-triazole-4-carboxylic acid, - Dimethyl ester of 1- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1,2 , 3-triazole-4,5-dicarboxylic acid; 2- (7-Nitro-2,3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -1,2,3-triazole-4,5-dicarboxylic acid; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -imidazole-2,4,5-tricarboxylic acid, - P-benzyl- (7-) acid nitro-2, 3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-yl) -methanphosphinic acid - P-methyl- (7-nitro-2,3-dioxo-1, 2,3, 4-tetrahydro-fiinoxalin-5-yl) -methanphosphinic acid, - N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) -carbamoylmethane-phosphonic acid, - 1- (7 -nitro-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-1,2-dihydropyridine, -2- (7-nitro-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -1, 2, 3,4-tetrahydroisoquinolin-l-one, - 1- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin -5-ylmethyl) -2,3,4, 5-tetrahydro-lH-l-benzazepin-2-one, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin- 5-ylmethyl) -2-oxo-3-phenyl-piperidine, - N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-5- phenyl-piperidine, - N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -5-methyl-pyrrolidin-2-one; 4- (2-oxoimidazolidin-1-yl) -N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -piperidine; N-. { 2 - [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) amino] ethyl} -pyrrolidin-2-one; N- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-phenyl-pyrrolidin-2-one; N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -4- (4-fluorobenzoyl) -piperidine; Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-2-phenylacetic; Amide of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -2-propylpentanoic acid, - N- (7-bromo-2, 3-dioxo-1, 2,3, 4-tetrahydro-fiinoxalin-5-ylmethyl) - (4-methyl-furan) -2-carboxylic acid, - N- (7-bromo-2,3-dioxo-1, acid amide, 2, 3,4-tetrahydro-fiinoxalin-5-ylmethyl) -thiophene-3-carboxylic acid; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -imidazole-4-carboxylic acid amide; N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -3- (thien-3-yl) -acrylic acid amide; Amide of N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydro-fiinoxalin-5-ylmethyl) -2-phenyl isobutyric acid; Amide of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -1-phenylcyclopropanecarboxylic acid, - N- (7-bromo-2, 3-) acid amide dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-phenylpropionic, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-acid) amide ilmethyl) -2-phenylglycolic; Amide N- (7-bromo-2,3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (3,4-dimethoxyphenyl) -acetic acid, - Amide N- (7-bromo- 2, 3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (4-chlorophenyl) acetic acid, - Amide N- (7-bromo-2,3-dioxo-1, 2, 3 , 4-tetrahydroquinoxa-lin-5-ylmethyl) - (3-chlorophenyl) acetic, - Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (2-chlorophenyl) acetic; N- (7-bromo-2,3-dioxo-1,2,4-tetrahydro-quinoxalin-5-ylmethyl) - (3-methylthiophen) -2-carboxylic acid amide; Amide of N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (5-methylthiophen) -2-carboxylic acid, - N- (N-) acid amide ( 7-bromo-2, 3-dioxo-1, 2,3,4-tetrahydro-quinoxalin-5-ylmethyl) - (1-methylpyrrole) -2-carboxylic acid, - N- (7-bromo-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -nicotinic acid; Amide N- (7-bromo-2,3-dioxo-1,2,4-tetrahydroquinoxa-lin-5-ylmethyl) - (4-nitrophenyl) acetic acid, - Amide N- (7-bromo-2, 3 -dioxo-l, 2, 3, 4-tetrahydroquinoxa-lin-5-ylmethyl) - (3-nitrophenyl) acetic, - Amide N- (7-bromo-2,3-dioxo-l, 2, 3, 4- tetrahydroquinoxa-lin-5-ylmethyl) - (2-nitrophenyl) acetic acid, - Amide N- (7-bromo-2,3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (3 , 4-methylenedioxyphenyl) acetic; Amide N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (3-phenyloxyphenyl) -acetic acid, - N- (7-bromo- 2, 3-dioxo-1,2, 3,4-tetrahydro-fiinoxalin-5-ylmethyl) -picolinic acid; 7-Bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylaminomethane-phosphonic acid, - 1- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxa- 1-in-5-ylmethylamino) ethanophonic acid, - N- (7-bromo-2,3-dioxo-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N-benzyloxycarbonyl-aminomethanephosphonic acid; N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -benzylurethane, - N- (7-bromo-2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -phenylurethane, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-phenylacetyl-aminomethanephosphonic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -N-phenylacetyl-glycine, -3-acetyl-1- (7-nitro-2,3-dioxo- 1, 2,3, 4-tetrahydro-quinoxalin-5-ylmethyl) -pyrrole; Ethyl ester of 1- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-3-carboxylic acid, - Amide-N-methyl-N- (7-bromo- 2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -phenylacetic acid, - N- (7-bromo-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) ) -3-acetoxypyrrolidine; N- (7-bromo-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3-hydroxypyrrolidine, - 1- (7-nitro-2,3-dioxo-1,2-acid) , 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -pyrrole-3-carboxylic acid; 1- (7-Nitro-2,3-dioxo-1,2,3-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-2-carboxylic acid - Tertiary butyl ester of 1- (7-nitro-2,3-acid -dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -pyrrole-2-carboxylic acid; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -indol-3-ylacetic acid, - 1- (7-nitro-2,3-ethyl) ethyl ester -dioxo-l, 2, 3,4-tetrahydroquinoxalin-5-ylmethyl) -indol-3-ylacetic acid; 1- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -indol-3-ylcarboxylic acid - Tertiary butyl ester of 1- (7-nitro) 2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -indol-2-carboxylic acid, - 1- (7-nitro-2,3-dioxo-l, 2,3,4- tetrahydroquinoxa-lin-5-ylmethyl) -indol-2-carboxylic acid; 1- (7-nitro-2, 3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -imidazole; 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-hydroxymethylimidazole; 1- [1- (7-Nitro-2, 3-dioxo-1,2,3,4-tetrahydro-quinoxalin-5-ylmethyl) imidazol-4-yl] acetic acid, 1- (7-nitro-2) , 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-methylimidazole; 1- (7-nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-methylimidazole; 1- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -2-ethylimidazole, 1- (7-nitro-2,3-dioxo-1,2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) pyrazole, -1- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -3,5-dimethylpyrazole; 2- (7-nitro-2, 3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -1,2,4-triazole; 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) pyrrole, 1- (7-nitro-2,3-dioxo-1, 2,3,4 -tetrahydroquinoxalin-5-ylmethyl) -piperazin-3-one; 1- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -oxazolidin-2-one; 1- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-methyl-piperazin-3,5-dione; 3- (7-nitro-2, 3-dioxo-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2,3,5, 6-tetrahydro-4H-l, 2-oxazine, - Acid N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -anthranilic acid; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -anthranilic acid methyl ester; Ethyl ester of N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -anthranilic acid; 1- (7-nitro-2, 3-dioxo-1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-benzyl-4-acetylaminopiperidine, - 1- (7-nitro-2, 3 -dioxo- 1, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-phenyl-4-acetylaminopiperidine, - Acid. { 3- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxa-lin-5-ylmethylamino) -2-oxo-l, 2,3,4-tetrahydrobenzo [b] azepin-1- il} -acetic; Amine N- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahidroquinoxa-lin-5-ylmethyl) -N-isopropyl-N- (quinolin-4-ilmetílica) - 4- (7 -nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -5-phenyl-pent-l-ene; Amide 2- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxa-lin-5-ylmethyl) -N- (4-nitrophenyl) -acetic, - N- [N- (7- nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) glycyl] glycine; N- [N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) glycyl] -N-methylglycine, - 1- [N- (7-nitro- 2 , 3-dioxo- 1, 2, 3, 4-tetrahydro-quinoxalin-5-ylmethyl) glycyl] -pyrrolidin-2-carboxylic acid; N- [N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) glycyl] phenylalanine; 2- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethylamino) -alanine; 3- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -propanol; 3- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethylamino) -ethanol; Amide N- (7-nitro-2,3-dioxo-1, 2, 3, 4 -ethohydroquinoxalin-5-ylmethyl) -5-dimethylaminonephthansulfonic acid; N- (7 -nitro- 2, 3 -dioxo- 1, 2,3, 4 -tetrahidroquinoxalin- 5-ylmethyl) -2-bencilaziridina, - 2- [2- (7-nitro-2, 3-dioxo- 1, 2, S ^ -tetrahydro-qiinoxalin-d-yl) ethylamino] -acetic; 1 - [2 - (7-nitro-2,3-dioxo-1, 2,3,4-tet-rahydroquinoxalin-5-yl) ethyl] piperidine; 1- [2- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-yl) ethyl] piperidin-4-one, - 1- [2- (7-nitro-2 , 3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidin-3-ol; 1- [2- (7-Nitro-2,3-dioxo-l, 2,3,4-tetrahydro-quiinoxal-5-yl) ethyl] piperidin-4-carboxylic acid, 1- [2- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) ethyl] -4-acetylaminopiperidine; 1- [2- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidin-2, 5-dione; 1- [2- (7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrolidin-2,6-dione, 1- [2- (7-nitro -2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-yl) ethyl] pyrrole idine; Amina N-. { 2- [2- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroqui-noxalin-5-yl) ethyl]} -N- (pyrazin-2-yl), - N-amine. { 2- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-noxalin-5-yl) ethyl]} -N- (thiazole-2-yl), - N-acid amide. { 2- [2- (7-nitro-2, 3-dioxo-l, 2,3,4-t €; trahidroquinoxalin-5-yl) ethyl]} -quinolin-4-carboxylic acid, - N- [2- (7-nitro-2,3-dioxo-1,2, 3,4-tetrahi-droquinoxalin-5-yl) ethyl] -methanesulfonic acid amide; N- [2- (7-Nitro-2,3-dioxo-1,2,4-tetrahydroxy-5-yl) ethyl] -benzenesulfonic acid amide; Amide N- [2- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydro-noxalin-5-yl) ethyl] -acetic, - Amide N- [2- (7-nitro- 2, 3-dioxo-l, 2, 3, 4-tetrahidroqui-noxalin-S-yl) ethyl] - (4-methoxy) -bencénica, - Amine N- (2, 3-dioxo-7-nitro-l, 2, 3, 4- tet rahydroquinoxalin-5-ylmethyl) -dimethyl; N- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinolalin-5-ylmethyl) - (2-hydroxy) -benzoic acid amide; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-methylmethyl) -N-methyl succinic acid amide; N- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquino-noxalin-5-ylmethyl) -N- (1, 1-dimethyl-2-hydroxyethyl) amine; Acid hydrobromide [(7 -nitro- 2, 3 -dioxo- 1, 2, 3, 4-te-5-ylmethylamino trahidroquinoxalin-) - (3-hydroxyphenyl) -methyl] -phosphonic; Amine hydrochloride N- (7-nitro-2,3-dioxo-l, 2, 3,4-te-trahydroquinoxalin-5-ylmethyl) -N- [(4-diethoxyphosphoryl) -benzyl], - Acid 4- [ N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquino-noxalin-5-ylmethyl) amino) -butyric, - 2- (2,3-dioxo-7-nitro-l) acid , 2, 3, 4 -hydroquinoxalin-5-ylmethyl oxy) -acetic acid; 2- (2,3-Dioxo-7-nitro-1,2, 3,4-tetrahydroqui-noxalin-5-ylmethoxy) -acetic acid, - 2- (7-nitro-2,3-dioxo-1, 2, 3, 4- tetrahydroquinoxa -lin-5-methoxy) -propionic; 4-amino-1- (2,3-dimethoxy-7-nitro-quinoxalin-5-methylmethyl) -pyridinium bromide; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-trifluoromethylpiperidine; N- (2, 3-dioxo-7-nitro-l, 2,3, 4-tetrahydroquinoxalin-5-ylmethyl) -2-aminobenzimidazole; N- (2,3-dioxo-7-nitro-1,2-, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) -di-isopropyl amine; N- (2,3-dioxo-7-nitro-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-propyl normal-piperidine; N- (2, 3-dioxo-7-nitro-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -4-amino-butyl normal-phosphonic acid, - N- (2,3-dioxo-7) acid -nitro-l, 2,3,4-tetrahydroquinoxa-lin-5-ylmethyl) -N-methyl-4-amino-butyl normal-phosphonic, -3- (7-chloro-2,3-dioxy-quinoxalin-5 -il) -propan-1-ol; 4- (7-chloro-2,3-dioxy-1,2,3,4-tetrahydroquinoxalin-5-yl) butanol, - N- [3- (7-chloro-2,3-dioxo-1-Bromhydrate, 2, 3,4, -tetrahydroquinoxalin-5-yl) propyl] -glycine; Ethyl 3- [1- (2, 3-dimethoxy-7-nitro-quinoxalin-5-yl) -ethylamino] propionic acid ethyl ester; This tertiary butyl of 1- [2- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) -ethyl] -piperidine-4-carboxylic acid, - Acid 1- [ 2- (7-nitro-2, 3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-yl) -ethyl] -piperidine-4-carboxylic acid 2- [2- (7-nitro)] -2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-yl) -ethylamino] -propionic acid; 2- [2- (7-Nitro-2,3-dioxo-1,2, 3,4-tetrahydroquin-xalin-5-yl) -ethylamino] -propionic acid; N- (7-nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl-methyl) -4-hydroxy-3-methoxybenzyl amine; Amide hydride N- [1- (7-nitro-2,3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -methanesulfonic acid, - N-amide hydrobromide - [1- (7-nitro-2, 3-dioxo-l, 2, 3, 4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -acetic, - Bis-amide hydrobromide N- [1-] (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperidin-4-ylmethyl] -nicotinic acid. N- (7-nitro-2,3-dioxo-1,2,4,4-tetrahydroquinoxalin-5-ylmethyl) -4- (4-fluorobenzoyl) -piperidine; Acid bromide. { 3- [(7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -2-oxo-2,3,4,5-tetrahydro-benzo [.b . ] azepin-l-il} -acetic, - 4- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -piperazine-2-carboxylic acid, - Amide N- (7-nitro-2, 3-dioxo-1, 2, S ^ -tetrahydroquinoxa-lin-S-ylmethyl) - (3-chlorophenyl) -sulfonic; Amide N- (7-nitro-2, 3-dioxo-1,2, 3,4-tetrahydroquinoxa-lin-5-ylmethyl) - (3-carboxyphenyl) -sulfonic acid; 4- (7-nitro-2,3-dioxo-1, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -4-methyl-3,5-dioxopiperazine; Amide hydrochloride 4-. { [(7-nitro-2, 3-dioxo-1,2,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -methyl} -benzenesulfonic acid, - N- (7-nitro-2,3-dioxo-l, 2,3,4-tetrahydroquinoxalin-5-ylmethyl) -2-oxo-azepin-3-yl amine hydrobromide; Acid chlorohydrate. { [(7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -methyl} -benzoic; 4- [(7-Nitro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-ylmethyl) -amino] -benzoic acid hydrochloride; 5- (7-Nitro-2,3-dioxo-1,2,3,4-tetrahi-droquinoxalin-5-ylmethyl) -amino] -3H-imidazole-4-carboxylic acid amide, - 2-amino acid -3- (7-nitro-2, 3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl) propionic acid; or N- (2, 3-dioxo-7-nitro-1, 2, 3, 4-te rahidroquinoxa-lin-5-ylmethyl) -N-methyl-12-amino-dodecanoic acid normal, according to claim 1 , or in each case a salt of them.

16. A compound according to any of claims 1 to 15, for the treatment of the human or animal body.

17. A pharmaceutical composition comprising a compound according to any of claims 1 to 16, or a pharmaceutically acceptable salt thereof, together with customary excipients and pharmaceutical carriers.

18. A process for the preparation of a 2,3-dioxo-1,2, 3,4-tetrahydroquinoxalinyl derivative of the formula I: wherein: one of the radicals Rj and R2 is a group R5 and the other is a group of the formula: -CH (Rg) -alq-R7 (Ia), -alk-CH (Rg) -R7 (Ib), -alk-N (Rg) -X-R7 (lc), -alk-N + (R8) (R9) -X-R7 A- (Id), -alq-0-X-R7 (Ie) or -alq- SX-R7 (If), R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is amino unsubstituted or lower alkylated and / or lower alkylated; R7 is hydrogen, - an aliphatic, cycloaliphatic or heterocycloaliphatic radical; acyl derived from carbonic acid or a half-ester or half-amide of carbonic acid, cyano, from sulfuric acid or an aliphatic or aromatic sulfonic acid or from phosphoric acid or a phosphonic acid ester; aimino which is unsubstituted or aliphatically or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, Rg is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic carboxylic acid ester, or R7 and Rg, together with X and the nitrogen atom linking Rg and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl unsubstituted or substituted alkyl, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7, Rg and R9, together with X and the nitrogen atom linking Rg, R9 and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through a quaternary nitrogen atom, where A "is the bond of a protonic acid, alk is lower alkylene , and X (except that, together with R7 and R8 and the nitrogen atom linking Rg and X or together with the nitrogen atom linking Rg, R9 and X, is part of one of the menc Ring systems is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, with the proviso that, in the compounds of formula 1 wherein Rj, R3 and R are hydrogen and R2 is a group of the formula Ib, when al is methylene, Rg is not amino or R7 is not carboxy, with the additional proviso that, in the compounds of the formula I wherein Rj, R3, and R4 are hydrogen and R2 is a group? e the formula le, when alk is methylene, the group -N (Rg) -X-R7 is not 1-imidazolyl, or when al is ethylene, the group -N (Rg) -X-? 7 is not amino, dipropylamino, N- ( 2-phenylethyl) -N-propyl-amino and N '- (2-chlorophenyl) piperazino, and with the final condition that, in the compounds of the formula I wherein Rj is a group of the formula le, R2 and R3 are each independently fluorine, chlorine, bromine, methyl, ethyl or trifluoromethyl and R4 is hydrogen, when either methylene, ethylene, or propylidene, the group -N (R8) -X-R7 is not a mono- , gave- , tri- or tetra-azaheteroaryl 5-membered bonded through a nitrogen atom and is optionally benzocondensated and / or substituted by alkyl having up to 6 carbon atoms inclusive, or substituted in the? by a group of the formula -N (Ra) -Rb where Ra and Rb are each independently hydrogen, alkyl, cycloalkyl, phenylalkyl or lower pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino group , piperazino, N "- lower alkyl-piperazino, morpholino or azepino, - or a salt thereof, wherein: a) in a compound of formula II: wherein: the radicals R 'and R "are identical or different hydroxy protecting groups, one of the radicals R'j and R'2 is a group R5, and the other is a group of the formula -CH (R'6) ) -alk-R7 (IIa) -alq-CH (R'g) -R'7 (IIb), -alk-N (R'g) -X-R'7 (IIc), -alk-N + (R '8) (R9) -X-R'7 A' (Hd), -alk-OXR '7 (He) or -alq-SX-R'7 (Hf), wherein R'g is a Rg or protected amino group, R'7 is a R7 group, protected carboxy or protected carbamoyl, and R'g is an Rg group or an amino protecting group, - the hydroxy protecting groups R 'and / or R "and an amino protecting group R'g that may be present, and if present, carboxy or carbamoyl are released from the protected carboxy R'7 or protected carbamoyl R'7, and / ob) for the preparation of the compounds of the formula I, wherein one of the radicals R j and R 2 is a group of the formula le, le or If, and the salts thereof, the compounds of the formulas III and IV : wherein: one of the radicals R "? and R" 2 is a group R5, and the other is a group of the formula -alq-Yj (Illa), one of the radicals Yj and Y2 is hydroxy, mercapto or a group HN (R'g), and the other is a group that can be removed to form a bond, R'7 is a R7 group, protected carboxy or protected carbamoyl, and R'g is an R8 group or an amino protecting group , they condense with one another; an amino protecting group R'g that may be present is removed, and if present, carboxy or carbamoyl is released from the protected carboxy R'7 or protected carbamoyl R * 7, or c) for the preparation of the compounds of the formula I, wherein one of the radicals R j and R 2 is a group R 5, and the other is a group of the formula -alk-CH (R 6) -R 7 (Ib), R 6 is amino, and R 7 is carboxy, a compound of the formula II: wherein: one of the radicals R "j and R" 2 is a group R5, and the other is a group of the formula -alq-C (R'7) (R'6) -R'7 (Ha1), R 'and R' are identical or different hydroxy protecting groups, R'6 is protected amino and the R'7 groups are identical or different protected carboxy groups, is subjected to an acid treatment, and if desired, a resulting compound is converts to a different compound of formula I, a mixture of the isomers that can be obtained according to the process, is separated into the components, and the preferred isomer is isolated, and / or a free compound obtainable according to with the process, it becomes a salt, or a salt that can be obtained according to the process, becomes the corresponding free compound

19. A derivative of 2,3-dioxo-l, 2, 3,4- tetrahydroquin-xalinyl of the formula I: wherein: one of the radicals Rj and R2 is a group R5 and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), -alq-CH (Rg) -R7 (Ib), -alq-N (Rg) -X-R7 (Ic), -alq-N + (R8) (R9) -X-R7 A * (Id), -alq-0-X-R7 (Ie) or -alq- SX-R7 (If), R3, R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is unsubstituted amino or lower alkylated and / or lower alkanoy; R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; acyl derived from carbonic acid or a half-ester or half-amide of carbonic acid, cyano from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino which is unsubstituted or aliphatic or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, R8 is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or an aliphatic or araliphatic carboxylic acid half ester, or R7 and R8, together with X and the nitrogen atom linking R8 and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl -substituted or unsubstituted radical, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted aryl or heteroaryl radical, optionally partially hydrogenated, R9 is an aliphatic or araliphatic radical, or R7, R8 and R9, together with X and the nitrogen atom linking Rg, R9 and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through an atom of quaternary nitrogen, where A "is the union of a protonic acid, alq is lower alkylene, and X (except that, together with R7 and Rg and the nitrogen atom linking Rg and X or together with the nitrogen atom linking Rg. , R9 and X, being part of one of the aforementioned ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, with the proviso that, in the compounds of the formula I where Rj is a group of the formula le, R and R are each independently fluorine, chlorine, bromine, methyl, ethyl or tr: -fluoromethyl and R4 is hydrogen, when al is methylene, ethylidene or propylidene the group -N (Rg) -X- R7 is not a mono-, di-, tri- or tetra-azaheteroa radical 5-membered rile which is optionally benzocondensate and / or substituted by alkyl having up to and including 5 carbon atoms, or substituted at the? by a group of the formula -N (Ra) -Rb wherein Ra and Rb are each independently hydrogen, alkyl, cycloalkyl, phenylalkyl or lower pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino group , piperazino, N1-lower alkyl-piperazino, morpholino or azepino, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of pathological conditions that respond to blockade of AMPA, kainate, and / or binding sites of NMDA receptor glycine.

20. A compound of the formula I according to claim 19, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula: -CH (R6) -alq-R7 (Ia) , -alk-CH (Rg) -R7 (Ib), -alk-N (Rg) -X-R7 (Ic), -alk-N + (R8) (R9) -X-R7 A '(Id), - alq-0-X-R7 (Ie) or -alk-SX-R7 (If),, R4, and R5 are each independently of the others, hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is amino, lower alkyl-amino, lower alkanoyl-amino, lower N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R7 is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-aminoalkyl lower, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, polyhalo lower alkyl, lower alkoxy-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, or lower polyhaloalkoxy-alkylene lower uilo, 3- to 8-membered cycloalkyl, carboxycycloalkyl, lower alkoxycarbonylcycloalkyl, aminocycloalkyl, or mono- or di-lower alkyl-aminocycloalkyl, pyrrolidino, oxopyrrolidinyl, carboxypyrrolidino, piperidino, carboxypiperidino, lower alkoxycarbonylpiperidino, morpholino, or thiomorpholino, carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl, cyano, lower alkyl-carbamoyl, lower dialkyl-carbamoyl, lower alkoxy-carbonylalkyl-lower carbamoyl, lower carboxyl-carbamoyl, carbamoylalkyl-carbamoyl, N-carbamoylalkyl-N-lower alkylaryl-carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, polyhaloalkoxy lower, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; sulfo, lower alkane sulphonyl; benzylsulfonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, trifluoromethyl, carboxy, and / or by lower alkoxycarbonyl; unsubstituted or substituted naphthalenesulfonyl by lower-amino dialkyl, phosphono, lower trialkyl-phosphono, amino, lower-amino-alkyl, lower-dialkyl-amino, lower-amino-alkanoyl, -phenylalkyl-amino, benzoylamino, or naphthoylamino which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or trifluoromethyl; ureido, amidino; phenyl or naphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkydenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, sulphamoyl, lower alkoxycarbonylamino, lower alkanoyl, halogen, and / or by trifluorometho- lime, - furyl, lower alkyl-furyl, thienyl, imidazolyl, oxazolyl, oxazolinyl (dihydro-oxazolyl), carboxyalkyl (oxo) oxazolinyl, thiazolyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl lower-thiazolyl, lower alkoxy-carbonyl-lower alkyl- thiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, quinolinyl, benzazepinyl, or lower carboxyalkyl-2,3,4,5-tetrahydro-1H-1-benzazepinyl, Rg is hydrogen, lower alkyl, lower aminoalkyl, lower alkyl-lower aminoalkyl, lower dialkyl-lower aminoalkyl, lower alkanoyl-lower aminoalkyl, lower hydroxyalkyl, lower alkanoyloxy-lower alkyl, lower polyhaloalkyl, alkoxy in ferior-lower alkyl, lower hydroxyalkoxy-lower alkyl, lower alkoxy-lower alkoxy-lower alkyl, polyhalo-lower alkoxy-lower alkyl; lower phenylalkyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkydenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl; lower alkanoyl, lower alkenoyl; lower phenylalkanoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenedioxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl; lower alkoxycarbonyl, or lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, lower alkylenedioxy, lower alkylidenekoxy, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or by trifluoromethyl, or R7 and R8, together with X and the nitrogen atom that binds R8 and X form pyrrolidino, imidazolidino, tetrahydrothiazolyl, piperidino, morpholino, thiomorpholino, piperazino, homopiperidino or 1-azabicyclonononyl which is unsubstituted or substituted by lower alkyl, hydroxyalkyl, phenylalkyl or unsubstituted or substituted phenyl, carboxy, lower alkoxycarbonyl , unsubstituted or substituted phenylcarbamoyl, lower-amino dialkyl, lower-amino alkanoyl, 2-oxoimidazolidino, phosphono, lower-trialkyl-phosphono, tetrazolyl, lower alkanoyl, unsubstituted or substituted benzoyl, hydroxy, oxo, and / or lower alkoxy, pyrrolyl optionally partially hydrogenated which is unsubstituted or substituted by carboxy, lower alkoxycarbonyl, and / or by lower alkanoyl; Furyl thienyl; imidazolyl which is unsubstituted or substituted by lower alkyl, lower hydroxyalkyl, carboxy, lower carboxyalkyl, and / or lower alkoxycarbonylaminoalkyl; optionally partially hydrogenated thiazolyl which is unsubstituted or substituted by lower carboxyalkyl, and / or by lower alkoxycarbonylalkyl lower, unsubstituted or unsubstituted pyrazole by lower alkyl, triazolyl; pyridinyl optionally partially hydrogenated, unsubstituted or substituted by oxo; optionally partially hydrogenated pyrimidinyl unsubstituted or substituted by oxo; pyrazinyl; indolyl which is unsubstituted or substituted by carboxy, lower carboxyalkyl, lower alkoxycarbonyl, lower alkoxycarbonylalkyl, lower cyanoalkyl, and / or by nitro, -benzofuranyl; benzimidazolyl unsubstituted or substituted by nitro, -tetrahydro-quinolinyl; tetrahydroisoquinolinyl unsubstituted or substituted by oxo; tetrahydrobenzazepinyl, - or phenyl, cyclohexadienyl, naphthyl or tetrahydronaphthyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, carboxy, lower alkoxycarbonyl, and / or trifluoromethyl; R9 is lower alkyl, lower alkenyl, lower alkynyl, or lower phenylalkyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or R7 'R8"and R9" together with X and the nitrogen atom which bind Rg, R, and X, form a pyridinium radical which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, amino, alkyl of 1 to 4 carbon-amino atoms, or by dialkyl of 1 to 4 atoms carbon-amino, where A "is the anion of a hydrohalic acid, lower alkane sulphonic acid, or unsubstituted benzenesulfonic acid or substituted by lower alkyl or by halogen, alk is lower alkylene, and X (unless faithful, together with R7 and Rg and the nitrogen atom linking Rg and X, or together with the nitrogen atom linking Rg, R, and X, is part of one of the ring systems mentioned) is lower alkylene, lower alkylidene, lower alkenylene, oxo -lower alkylene including carbonyl, oxo-lower alkylidene, dioxo-lower alkylene, lower oxo-alkenylene, lower hydroxyalkylidene, lower oxo (hydroxy) alkylene, lower aminoalkylene, lower aminoalkylidene, lower carboxyalkylene, lower carboxyalkylidene, lower carbamoylalkylidene, lower alkoxycarbonylalkylidene, lower alkoxy- lower carbonylalkylene,? -aza-a-oxo-lower alkylene, or? -aza-a-oxo-lower alkenylene, 3- to 7-membered cycloalkylidene, or lower phenylalkylidene or lower phenylalkylene unsubstituted or substituted by lower alkyl, lower alkoxy, alkylenedioxy lower, lower alkylidene-xi, hydroxy, lower alkoxycarbonyl, carboxy, carbamoyl, lower alkanoyl, halogen, and / or trifluoromethyl, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of conditions pathological responses that respond to blockade of AMPA, kainate, and / or glycine binding sites of the NMDA receptor.

21. A compound of the formula I according to claim 19, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -alq-CH (Rg) -R7 (Ib ), -alq-N (Rg) -X-R7 (Ic), -alk-0-X-R7 (Ie) or -alk-SX-R7 (If), R3, R4, and R5 are each independently of the others, hydrogen, lower alkyl, halogen, cyano, or nitro, Rg is amino, lower-amino alkyl, lower-amino alkanoyl, lower N-lower alkyl-N-lower alkanoyl-amino, or lower-amino dialkyl, R7 is carboxy, lower alkoxycarbonyl; lower phenylalkoxycarbonyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, and / or by trifluoromethyl; carbamoyl; phenylcarbamoyl which is unsubstituted or substituted by lower alkyl, lower alkoxy, hydroxy, halogen, nitro, carboxy, lower alkoxycarbonyl, phenyl, phenyloxy, and / or by trifluoromethyl; phosphono, mono-, di-, or lower trialkyl-phosphono, or tetrazolyl, Rg is hydrogen, lower alkyl, or together with X and the nitrogen atom linking Rg and X, forms a radical of pyrrolidinylene, piperidinylene, or piperazinylene, alk is lower alkylene, and X is lower alkylene, carbonyl, lower alkylidene, lower aminoalkylidene, lower carboxyalkylidene, lower alkoxycarbonylalkylidene, lower carbamoylalkylene, or, with the group N (R8),? -aza-a-oxo-alkylene lower or? -za-a-oxo-lower alkenylene linked via the carbon atom a; lower phenylalkylidene which is unsubstituted or substituted by lower alkyl, lower alkoxy, halogen, and / or by trifluoromethyl, or in the formula le, together with R8 and the nitrogen atom linking R8 and X, forms a pyrrolidinyl, piperidinyl radical, or piperazinyl, or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for the treatment of pathological conditions that respond to blockade of AMPA, kainate, and / or glycine binding sites of the NMDA receptor.

22. A compound of the formula I according to claim 19, wherein: one of the radicals Rj and R2 is a group R5, and the other is a group of the formula -CH (R6) -alq-R7 (Ia ), -alk-CH (Rg) -R7 (Ib), -alk-N (R8) -X-R7 (Ic), -alk-N + (R8) (R9) -X-R7 A * (Id), -alk-OX-R7 (Ie) or -alq-SX-R7 (If), R3 »R4 'and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen fie has a number atomic up to and including 35, trifluoromethyl, cyano or nitro, R6 is amino, alkyl of 1 to 4 carbon atoms-amino, alkanoyl of 1 to 4 carbon atoms-amino, N-alkyl of 1 to 4 carbon atoms carbon-N-alkanoyl of 1 to 4 carbon-amino atoms, or dialkyl of 1 to 4 carbon-amino atoms, R7 is hydrogen, alkyl of 1 to 7 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms, polyhaloalkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, cycloalkyl of 3 to 6 members, carboxy 3 to 6 membered cycloalkyl, 3 to 6 membered alkocycloalkyl, pyrrolidino, carboxypyrrolidino, oxopyrrolidino, piperidino, carboxypiperidino, morpholino, thiomorpholino, carboxy, alkoxy of 1 to 4 carbon atoms-carbonyl, phenylalkoxy of 1 to 4 carbon atoms- carbonyl, carbamoyl, cyano, alkyl of 1 to 4 carbon atoms-carbamoyl, alkoxy of 1 to 4 carbon atoms-carbonylcarbamoyl, carboxyalkyl of 1 to 4 carbon atoms-carbamoyl, carbamoylalkyl of 1 to 4 carbon atoms-carbamoyl, N-carbamoylalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamyl, N-carboxyalkyl of 1 to 4 carbon atoms-N-alkyl of 1 to 4 carbon atoms-carbamoyl, carbamoylalkyl of 1 to 4 carbon atoms-carbamoyl, phenylalkyl of 1 to 4 carbon atoms-carbamoyl unsubstituted or substituted by carboxy; phenylcarbamoyl which is unsubstituted or substituted by alkoxy of 1 to 4 carbon atoms, nitro, polyhaloalkoxy of 1 to 4 carbon atoms, phenyloxy, and / or by alkoxy of 1 to 4 carbon atoms-carbonyl; sulfo, alkane of 1 to 4 carbon atoms-sulfonyl; benzenesulfonyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, and / or by carboxy; unsubstituted naphthalenesul-fonyl or substituted by dialkyl of 1 to 4 carbon atoms-amino, phosphono, amino, alkyl of 1 to 4 carbon atoms-amino, dialkyl of 1 to 4 carbon-amino atoms, alkanoyl of 1 to 4 atoms of carbon-amino, phenylalkyl of 1 to 4 carbon atoms-amino, benzoylamino, naphthoylamino, ureido, amidino; phenyl or naphthyl which is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, alkylenedioxy of 1 to 4 carbon atoms, alkylidenedio-xi of 1 to 4 carbon atoms, carboxy, sulfamoyl , alkoxy of 1 to 4 carbon atoms-carbonylamino, alkanoyloxy of 1 to 4 carbon atoms, hydroxy, halogen, and / or trifluoromethyl; furyl, alkyl of 1 to 4 carbon atoms-furyl, thienyl, imidazolyl, (oxo) oxazolinyl, thiazolyl, thiazolinyl (dihydrothiazolyl), carboxyalkyl of 1 to 4 carbon atoms-thiazolyl, alkoxy of 1 to 4 carbon atoms-carbonylalkyl from 1 to 4 carbon atoms-thiazolyl, tetrazolyl, pyridyl, pyrazinyl, indolyl, quinolinyl, benzazepinyl, or carboxyalkyl of 1 to 4 carbon atoms-2,3,4,5-tetrahydro-1H-1-benzazepinyl, R8 is hydrogen, alkyl of 1 to 4 carbon atoms, hydroxyalkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, hydroxyalkoxy of 1 to 4 carbon atoms-alkyl of 1 to 4 carbon atoms, phenylalkyl of 1 to 4 carbon atoms, pyridylalkyl of 1 to 4 carbon atoms, alkanoyl of 1 to 4 carbon atoms, such as acetyl, phenylalkanoyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms - carbonyl, or phenylalkoxy of 1 to 4 carbon atoms - carbonyl, or R7 and R8 'together with X and the nitrogen atom linking Rí; and X forinan pyrrolidino, carboxypyrrolidino, hydroxypyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms-pyrrolidino, mono-od: L-oxopirrolidino, alkyl of 1 to 4 carbon atoms- (oxo) pyrrolidino, hydroxyalkyl of 1 to 4 carbon atoms (oxo) pyrrolidino, carboxy (oxo) pyrrolidino, 2-oxoimidazolidino, tetrahydrothiazo-lilo, piperidino, alkyl of 1 to 4 carbon atoms-piperidino, dialkyl of 1 to 4 carbon atoms-piperidino, carboxypiperidino, alkoxy of 1 to 4 carbon atoms -carbonylpiperidino, phenylcarbamoylpiperidino, oxopiperidino, dioxopiperidino, oxo (phenylalkyl of 1 to 4 carbon atoms) iperidino, oxo (fe-nil) piperidino, hydroxypiperidino, hydroxy (phenylalkyl of 1 to 4 carbon atoms) piperidino, carboxy (hydroxy) piperidino, dialkyl of 1 to 4 carbon atoms-aminopiperidino, alkanoyl of 1 to 4 carbon atoms-aminopiperidino, alkanoyl of 1 to 4 carbon atoms-amino (phenylalkyl of 1 to 4 carbon atoms) -piperidino , alkanoyl of 1 to 4 carbon atoms-amino (phenyl) piperidino, phenylpiperidino, alkoxy of 1 to 4 carbon atoms-piperidino, alkoxy of 1 to 4 carbon atoms (alkyl of 1 to 4 carbon atoms) piperidino, dialkoxy of 1 to 4 carbon-piperidino atoms, dialkoxy of 1 to 4 carbon atoms (phenylalkyl of 1 to 4 carbon atoms) piperidino, alpha-lodenedioxy of 1 to 4 carbon atoms-piperidino, hydroxyalkyl of 1 to 4 carbon atoms-piperidino, unsubstituted or halogenated benzoylpiperidino, C 1 -C 4 alkanoyl-piperidino, oxoimidazo-lidinopiperidino, homopiperidino, oxohomopiperidino, azabicyclo-nonyl, piperazino, alkyl of 1 to 4 carbon atoms-piperazine, oxopiperazino, dioxopiperazino, phenylpiperazino unsubstituted or alkoxylated with 1 to 4 carbon atoms, morpholino, dialkyl of 1 to 4 carbon atoms-morpholino, thiomorpholino, phenyl, cyclohexa-1,3-dien-5-yl, hydroxyphenyl, alkoxy of 1 to 4 atoms carbon-phenyl, carboxyphenyl, such as 3-carboxyphenyl , halo-nyl, trifluoromethylphenyl, bistrifluoromethylphenyl, naphthyl, tetrahydronaphthyl, nitrobenzimidazolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl or tetrahydrobenzazepinyl unsubstituted or substituted by oxo, Rg is lower alkyl, or R7, R8, and R, together with X and the nitrogen atom linking R8, R9, and X, form a pyridinium radical which is unsubstituted or substituted by amino, alkyl of 1 to 4 carbon atoms. carbon-amino, or by dialkyl of 1 to 4 carbon-amino atoms, where A "is the anion of a hydrohalic acid, alk is alkylene of 4 carbon atoms or alkylidene of 1 to 4 carbon atoms, and X (a less than together with R7 and Rg and the nitrogen atom linking Rg and X, or together with the nitrogen atom linking R8, R, and X, is part of one of the ring systems mentioned) is a direct bond, alkylene of 1 to 4 carbon atoms, alkylidene of 1 to 4 carbon atoms, alkenylene of 1 to 4 carbon atoms, oxoalkylene of 1 to 4 carbon atoms including carbonyl, dioxoalkylene of 1 to 4 carbon atoms including oxalo, oxoalkenylene from 1 to 4 carbon atoms, hydroxyalkylidene of 1 to 4 carbon atoms, oxo (hydroxy) -alkylene of 1 to 4 carbon atoms, aminoalkylene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms -carbonylalkylidene of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms-carbonylalkylene of 1 to 4 carbon atoms,? -aza- -oxo-alkylene of 1 to 4 carbon atoms, or? -aza-a -oxo-alkenylene of 1 to 4 carbon atoms, cycloalkylidene of 3 to 7 members, phenylalkylidene of 1 to 4 carbon atoms or phenylalkylene of 1 to 4 carbon atoms unsubstituted or substituted by halogen and / or trifluoromethyl, or a pharmaceutically salt acceptable thereof, for the preparation of a medicament for the treatment of pathological conditions that respond to blockade of AMPA, kainate, and / or glycine binding sites of the NMDA receptor.

23. A compound of formula IX: wherein: the radicals R1 and R "are identical or different hydroxy protecting groups, one of the radicals Rla and R2a is a group R5, and the other is lower alkanoyl, such as especially formyl or acetyl, or a group of the formula -CH (R'6) -alk-R7 (Ha), -alk-CH (R'g) -R'7 (IIb), -alk-N (R'8) -X-R'7 (IIc) , -alk-N + (R'8) (R9) -X-R'7 A "(IId), -alq-0-X-R'7 (He) -alq-SX-R'7 (Illa), or -alq-Yj (Illa) wherein Yj ee hydroxy, esterified reactive hydroxy, mercapto, or a group of the formula -N (R'8) -H, R'7 is a group R7 other than hydrogen, or is carboxy protected or protected carbamoyl, and R'8 is a R8 group or an amino protecting group, and R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, R6 is amino unsubstituted or lower alkylated and / or lower alkanoylated, - R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; acyl derived from carbonic acid or a half-ester or half-amide of carbonic acid, cyano, from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or a phosphonic acid ester, -amino which is unsubstituted or aliphatic or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, Rg is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic half ester of carbonic acid, or R7 and Rg, together with X and the nitrogen atom linking Rg and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl unsubstituted or substituted, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, alk is lower alkylene, and X (unless, together with R7 and Rg and the nitrogen atom linking Rg and X, are part of one of the ring systems mentioned), is a divalent radical aliphatic, cycloaliphatic, or araliphatic, or a direct bond, with the proviso that, in the compounds of the formula I where Rja is lower alkanoyl or a group of the formula He, He, or Illa, when R2a and R3 are each independently of the another, fluorine, chlorine, bromine, methyl, ethyl, or trifluoromethyl, and R4 is hydrogen, lower alkanoyl R1 is different from formyl, or the group He is different from a mono-, di-, tri-, or tetra- radical. 5-membered heteroaryl which is linked by means of a nitrogen atom, and which is optionally benzocondensate and / or substituted by alkyl having up to and including 6 carbon atoms, or substituted at the? by a group of the formula -N (Ra) -Rb, wherein Ra and R are each independently of the other hydrogen, alkyl, cycloalkyl, phenylalkyl, or pyridylalkyl, or together with the nitrogen atom linking them form a pyrrolidino, piperidino, piperazino, N1-lower alkyl-piperazino, morpholino, or azepino group, or the He or Illa group is different from hydroxymethyl, 1-hydroxyethyl, and 1-hydroxypropyl, or the Illa group is different from halomethyl, 1-haloethyl, and 1-halopropyl, or a salt thereof.

24. A compound according to claim 23, wherein: the radicals R 'and R "are identical or different lower alkyl groups, one of the radicals Rla and Ra is a group R5, and the other is lower alkanoyl, such as especially formyl or acetyl, or a group of the formula -alk-N (R ') -X-R'7 (He), alk-N + (R'8) (R9) -A "(lid), -alk- 0-X-R'7 (He), -alk-SX-R'7 (Hf) or -alq-Yj (Illa), wherein Yj is hydroxy, halogen, lower alkane-sulphonyloxy, sulfonyloxy, or a group of the formula -N (R'8) -H, R'7 is a group R7 other than hydrogen, or is protected carboxy or protected carbamoyl, and R'8 is a group R8 or an amino protecting group, R2a is a group R5,, R4, and 5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen fie has an atomic number of up to and including 35, cyano, or nitro, R6 is amino, R7 is carboxy , alkoxy of 1 to 4 carbon atoms-carbonyl; C 1 -C 4 -carbonyl phenylalkoxy h is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, such as methyl, C 1 -C 4 alkoxy, hydroxy, halogen having an atomic number of up to and including -where 35, and / or by trifluoromethyl; carbamoyl; phenylcarbamoyl ie is unsubstituted or substituted by alkyl of 1 to 4 carbon atoms, alkoxy of 1 to 4 carbon atoms, hydroxy, halogen having an atomic number of up to and including 35, nitro, carboxy, alkoxy of 1 to 4 carbon atoms carbon-carbonyl, phenyl, phenyloxy, and / or trifluoromethyl; tetrazolyl or phosphono, R8 is hydrogen, or together with X and the nitrogen atom linking R8 and X, forms a radical of pyrrolidinylene, piperidinylene or piperazinylene, alk is alkylene of 1 to 4 carbon atoms, and X is carbonyl, alkylene from 1 to 4 carbon atoms, alkylidene of 1 to 4 carbon atoms, aminoalkylidene of 1 to 4 carbon atoms, carboxyalkylidene of 1 to 4 carbon atoms, or with the group N (R8),? -aza-of- oxo-alkylene of 3 to 5 carbon atoms, or? -aza-a-oxo-alkenylene of 3 to 5 carbon atoms, each linked via the carbon atom a, phenylalkylidene of 1 to 4 carbon atoms, as 2-phenylethi-1idene, or in the formula le, together with Rg and the nitrogen atom? [ue h binds Rg and X, forms a radical of pyrrolidinylene, piperidi-nylene or piperazinylene, or a salt thereof.

25. A compound according to claim 23, wherein: the radicals R1 and R "are identical or different lower alkyl groups, Rla is a group of the formula (Illa), wherein Yj is hydroxy, halogen, or a group of the formula -N (R'8) -H, wherein R * 8 is a group R8, R2a is a group R5, R3 »R4» and R5 are each independently of the others, hydrogen, alkyl of 1 to 4 carbon atoms, halogen having an atomic number of up to and including 35, cyano or nitro, and alk is 1 to 4 carbon atoms, or a salt thereof,

26. Aminomethyl-7-bromo-2, 3 -dimethoxy-l, 2,3,4-tetrahydroquinhoxaline, 5-aminomethyl-7-bromo-2,3-dimethoxy-1,2,3,4-tetrahydroquinoxaline 5-bromomethyl-2,3-dimethoxy-7 -nitroquinoxaline; 7-Bromo-5-hydroxymethyl-2, 3-dimethoxy-quinotoxaline, 7-bromo-5-hydroxymethyl-2, 3-dimethoxy-quinotoxaline, 5-aminomethyl-7-bromo-2,3-dimethoxy-1, 2, 3, 4-tetrahydro-quinoxaline, -2, 3-dimethoxy-7-nitro-quinoxaline-5-carbaldehyde; 2,3-dimethoxy-quinoxaline-5-carbaldehyde, - 5-aminomethyl-2,3-dimethoxy-7-nitro-quinoxaline, - 1- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) ethanone; 2, 3-dimethoxy-5-hydroxymethyl-7-nitro-quinoxaline, -2- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) ethanol; 2- (2,3-Dimethoxy-7-nitro-quinoxalin-5-yl) ethyl, -3- (7-chloro-2,3-dimethoxy-quinoxalin-5-yl) -propan-l-ol methanesulfonate, • 4- (7-chloro-2,3-dimethoxy-1,2,3,4-tetrahydroquinoxalin-5-yl) butanol; 5- (3-bromopropyl) -7-chloro-2,3-dimethoxy-quinoxalin-2- (2,3-dimethoxy-7-nitro-quinoxalin-5-yl) ethanol or 2- (2,3-) methansulfonate dimethoxy-7-nitro-quinoxalin-5-yl) ethyl, according to claim 23. SUMMARY The 2,3-dioxo-1, 2, 3, 4-tetrahydroquinoxali-nyl derivatives of the formula I: wherein: one of the radicals Rj and R2 is a group R5 and the other is a group of the formula: -CH (R6) -alq-R7 (Ia), -alq-CH (Rg) -R7 (Ib), -alk-N (Rg) -X-R7 (IO, -alk-N + (R8) (R9) -X-R7 A "(Id), -alq-0-X-R7 (le) or -alq-SX -R7 (If), R3, R4 and R5 are each independently of the other hydrogen, lower alkyl, halogen, trifluoromethyl, cyano, or nitro, Rg is unsubstituted amino or lower alkylated and / or lower alkanoy; R7 is hydrogen; an aliphatic, cycloaliphatic or heterocycloaliphatic radical; acyl derived from carbonic acid or a half-ester or half-amide of carbonic acid, cyano from sulfuric acid or from an aliphatic or aromatic sulfonic acid or from phosphoric acid or from a phosphonic acid ester; amino which is unsubstituted or aliphatic or araliphatically substituted and / or substituted by aliphatic, araliphatic or aromatic acyl; or an aromatic or heteroaromatic radical, Rg is hydrogen; an aliphatic or araliphatic radical; or acyl derived from an aliphatic or araliphatic carboxylic acid or from an aliphatic or araliphatic half ester of carbonic acid, or R and Rg, together with X and the nitrogen atom linking Rg and X, form a mono- or diazacycloalkyl, azoxacycloalkyl, azathiacycloalkyl unsubstituted or substituted, or an optionally oxidized tiacycloalkyl radical linked through a nitrogen atom, or an unsubstituted or substituted, optionally partially hydrogenated aryl or heteroaryl radical, R9 is an aliphatic or araliphatic radical, or R7, Rg and R9, together with X and the nitrogen atom linking Rg, R and X, form a substituted or unsubstituted quaternary heteroaryl radical linked through the quaternary nitrogen atom, where A "is the bond of a protonic acid, alk is lower alkylene, and X (except that, together with R7 and Rg and the nitrogen atom which binds Rg and X or together with the nitrogen atom linking Rg, R9 and X, is part of one of the abovementioned all ring systems) is a divalent aliphatic, cycloaliphatic or araliphatic radical or a direct bond, and pharmaceutically acceptable salts thereof, can be used in the preparation of a medicament for the treatment of pathological conditions that respond to AMPA blockade, cainate, and / or the glycine binding sites of the NMDA receptor. * * * * *